{"76350fb3b1b17d425885eced924be457d2c8a547": [["IntroductionIt is common knowledge that Watson-Crick basepair-\" ing is the main folding principle in RNA.", [["RNA", "RNA", 101, 104]]], ["Although a number of different types of tertiary interactions can shape the final three-dimensional (3D) structure, it was only during the last decade that Watson-Crick basepairing was realized to play a role at the level of tertiary structure formation.", [["tertiary interactions", "PROBLEM", 40, 61], ["tertiary interactions", "OBSERVATION", 40, 61], ["tertiary structure", "OBSERVATION", 225, 243]]], ["This involves base-pairing between a loop region in an orthodox secondary structure and a complementary sequence outside that loop.", [["a loop region", "TREATMENT", 35, 48], ["a complementary sequence", "TEST", 88, 112], ["base", "ANATOMY_MODIFIER", 14, 18], ["loop", "OBSERVATION", 37, 41], ["loop", "OBSERVATION", 126, 130]]], ["This type of basepairing leads to what is called a pseudoknot structure.", [["pseudoknot structure", "OBSERVATION", 51, 71]]], ["It is now clear that in many cases the function of an RNA molecule can only be understood in terms of such pseudoknot formation.IntroductionThe simplest form of pseudoknot arises when a stretch of nucleotides from a hairpin loop basepairs with a complementary single-stranded non-loop sequence close to the hairpin.", [["nucleotides", "CHEMICAL", 197, 208], ["RNA molecule", "PROTEIN", 54, 66], ["complementary single-stranded non-loop sequence", "DNA", 246, 293], ["an RNA molecule", "PROBLEM", 51, 66], ["such pseudoknot formation", "PROBLEM", 102, 127], ["pseudoknot arises", "PROBLEM", 161, 178], ["a stretch of nucleotides", "PROBLEM", 184, 208], ["a hairpin loop basepairs", "TREATMENT", 214, 238], ["a complementary single-stranded non-loop sequence", "TREATMENT", 244, 293], ["the hairpin", "TREATMENT", 303, 314], ["clear", "OBSERVATION", 10, 15], ["pseudoknot formation", "OBSERVATION", 107, 127], ["pseudoknot", "OBSERVATION", 161, 171]]], ["Fig. 1 illustrates the four basic elements of a pseudoknot of this type, showing the relative orientation of stems 1 and 2 ($1, S2) and the connecting loops 1 and 2 (L1, L2).", [["stems", "ANATOMY_MODIFIER", 109, 114], ["loops", "ANATOMY_MODIFIER", 151, 156], ["L1", "ANATOMY_MODIFIER", 166, 168], ["L2", "ANATOMY_MODIFIER", 170, 172]]], ["In the case where both stem regions are contiguous, a stacking of the two helices becomes possible (as shown in Fig. 1 ).", [["stem regions", "ANATOMY", 23, 35], ["stem regions", "DNA", 23, 35], ["both", "ANATOMY_MODIFIER", 18, 22], ["stem", "ANATOMY_MODIFIER", 23, 27], ["regions", "ANATOMY_MODIFIER", 28, 35]]], ["In principle, each of the two loops may consist of hundreds of nucleotides, possessing their own secondary structure.", [["nucleotides", "CHEMICAL", 63, 74], ["nucleotides", "TREATMENT", 63, 74], ["loops", "OBSERVATION", 30, 35], ["secondary structure", "OBSERVATION", 97, 116]]], ["There is some debate, however, as to whether pseudoknots formed by long-range basepairing interactions, including stems formed by loop-loop interactions, should be called tertiary interactions, and whether the term pseudoknot should be restricted to the simpler case illustrated in Fig. 1 .", [["pseudoknots", "PROBLEM", 45, 56], ["loop-loop interactions", "TREATMENT", 130, 152], ["the term pseudok", "PROBLEM", 206, 222], ["some", "OBSERVATION_MODIFIER", 9, 13], ["debate", "OBSERVATION", 14, 20]]], ["For a discussion of these aspects of definition and classification see [1] [2] [3] [4] .IntroductionThis review evaluates the current status of our understanding of RNA pseudoknot of structure and function, based on the advances made during the past year.", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 71, 86]]], ["It should be stressed that the number of pseudoknot structures proposed in the literature is rapidly growing, but that often these proposals are not supported by experimental results and/or covariation search, and it is for that reason that these are given less attention here.", [["rapidly", "OBSERVATION_MODIFIER", 93, 100], ["growing", "OBSERVATION_MODIFIER", 101, 108]]], ["(For recent reviews on RNA pseudoknots, covering the period before 1993, see [1, 2, 4] .) of triple interactions between L1 or L2 with the stems S2 and Sl, respectively, remains an open question.", [["Sl", "GENE_OR_GENE_PRODUCT", 152, 154], ["L1", "PROTEIN", 121, 123], ["S2", "PROTEIN", 145, 147], ["Sl", "PROTEIN", 152, 154], ["RNA pseudoknots", "PROBLEM", 23, 38], ["triple interactions between L1", "PROBLEM", 93, 123], ["L1", "ANATOMY", 121, 123], ["L2", "ANATOMY_MODIFIER", 127, 129], ["stems S2", "ANATOMY", 139, 147], ["Sl", "ANATOMY", 152, 154], ["open", "OBSERVATION", 181, 185]]], ["The possibility of such interactions must certainly be envisaged since 'nucleoside triples' have been observed in a structural element of the Group I intron that has certain features in common with pseudoknots [6] .IntroductionThe successful crystallization of a pseudoknot-harbouring RNA fragment further fosters our expectation that the elucidation of the detailed structure of an RNA pseudoknot will only be a matter of time [7\u00b0] .TopologyA recurrent question related to pseudoknot structure is that of the possible existence of real knots in natural RNA (see [1] ).", [["nucleoside", "CHEMICAL", 72, 82], ["nucleoside", "CHEMICAL", 72, 82], ["Group I intron", "DNA", 142, 156], ["pseudoknot-harbouring RNA fragment", "DNA", 263, 297], ["RNA pseudoknot", "RNA", 383, 397], ["such interactions", "PROBLEM", 19, 36], ["nucleoside triples'", "TREATMENT", 72, 91], ["the Group I intron", "TREATMENT", 138, 156], ["The successful crystallization", "TREATMENT", 227, 257], ["a pseudoknot-harbouring RNA fragment", "PROBLEM", 261, 297], ["an RNA pseudoknot", "PROBLEM", 380, 397], ["pseudoknot structure", "PROBLEM", 474, 494], ["real knots in natural RNA", "PROBLEM", 532, 557], ["RNA pseudoknot", "OBSERVATION", 383, 397], ["pseudoknot structure", "OBSERVATION", 474, 494], ["knots", "OBSERVATION", 537, 542], ["natural RNA", "OBSERVATION", 546, 557]]], ["A few papers last year reported topo-logically real knot formation in single-stranded nucleic acids.", [["nucleic acids", "CHEMICAL", 86, 99], ["single-stranded nucleic acids", "SIMPLE_CHEMICAL", 70, 99], ["few", "OBSERVATION_MODIFIER", 2, 5], ["nucleic acids", "OBSERVATION", 86, 99]]], ["Interlocking RNA circles were described by Winter et al. [8] as a product of aberrant splicing in a yeast mitochondrial precursor for the large ribosomal subunit RNA, as a result of an activation of cryptic opening sites in the 5' exon of nmtant precursors.", [["mitochondrial", "ANATOMY", 106, 119], ["mitochondrial", "CELLULAR_COMPONENT", 106, 119], ["large ribosomal subunit RNA", "RNA", 138, 165], ["cryptic opening sites", "DNA", 199, 220], ["5' exon", "DNA", 228, 235], ["nmtant precursors", "CELL_TYPE", 239, 256], ["yeast", "SPECIES", 100, 105], ["yeast", "SPECIES", 100, 105], ["Interlocking RNA circles", "TREATMENT", 0, 24], ["aberrant splicing", "PROBLEM", 77, 94], ["a yeast mitochondrial precursor", "PROBLEM", 98, 129], ["the large ribosomal subunit RNA", "PROBLEM", 134, 165], ["cryptic opening sites", "PROBLEM", 199, 220], ["RNA circles", "OBSERVATION", 13, 24], ["aberrant splicing", "OBSERVATION", 77, 94], ["yeast mitochondrial precursor", "OBSERVATION", 100, 129], ["large", "OBSERVATION_MODIFIER", 138, 143], ["ribosomal subunit RNA", "OBSERVATION", 144, 165], ["cryptic opening", "OBSERVATION", 199, 214]]], ["The first, small circle is derived from part of the 5' exon and the second, large one comprises the intron.", [["5' exon", "DNA", 52, 59], ["intron", "DNA", 100, 106], ["small", "OBSERVATION_MODIFIER", 11, 16], ["circle", "OBSERVATION", 17, 23], ["large", "OBSERVATION_MODIFIER", 76, 81]]], ["The results could be explained by the formation of a pseudoknot structure involving the internal guide sequence (IGS).TopologyKnotting has also been described for chemically synthesized, single-stranded DNA molecules ( [9] , and references therein).", [["DNA", "CELLULAR_COMPONENT", 203, 206], ["internal guide sequence", "DNA", 88, 111], ["IGS", "DNA", 113, 116], ["single-stranded DNA molecules", "PROTEIN", 187, 216], ["a pseudoknot structure", "PROBLEM", 51, 73], ["TopologyKnotting", "TREATMENT", 118, 134], ["single-stranded DNA molecules", "TREATMENT", 187, 216], ["could be explained", "UNCERTAINTY", 12, 30], ["pseudoknot structure", "OBSERVATION", 53, 73], ["internal", "ANATOMY_MODIFIER", 88, 96]]], ["The basepairing schemes in these circular molecules of 70, or more, nucleotides are reminiscent of RNA pseudoknots.", [["nucleotides", "CHEMICAL", 68, 79], ["RNA pseudoknots", "RNA", 99, 114], ["The basepairing schemes", "PROBLEM", 0, 23], ["RNA pseudoknots", "PROBLEM", 99, 114], ["circular", "ANATOMY_MODIFIER", 33, 41], ["RNA pseudoknots", "OBSERVATION", 99, 114]]], ["The ligation of the 3' to the 5' end gives rise to trefoil and figure-eight knots depending on the presence or absence of Z-DNA structure in one of the two helices.", [["trefoil", "GENE_OR_GENE_PRODUCT", 51, 58], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["5' end", "DNA", 30, 36], ["trefoil", "PROTEIN", 51, 58], ["Z-DNA structure", "DNA", 122, 137], ["The ligation", "TREATMENT", 0, 12], ["trefoil and figure-eight knots", "TREATMENT", 51, 81], ["Z-DNA structure", "PROBLEM", 122, 137], ["ligation", "OBSERVATION", 4, 12]]], ["It would be very interesting to see whether similar structures can be fashioned with single-stranded RNAs.", [["single-stranded RNAs", "RNA", 85, 105]]], ["A study of such RNA real knots may likewise reveal flexibility constraints that could be useful for understanding pseudoknot structures.Plant virusesThe RNA pseudoknots, as we know them today, were first discovered in the tRNA-like structure of some plant viral RNAs.", [["Plant viruses", "ORGANISM", 136, 149], ["RNA pseudoknots", "RNA", 153, 168], ["plant viral RNAs", "RNA", 250, 266], ["A study of such RNA real knots", "TEST", 0, 30], ["flexibility constraints", "PROBLEM", 51, 74], ["Plant viruses", "PROBLEM", 136, 149], ["The RNA pseudoknots", "PROBLEM", 149, 168], ["some plant viral RNAs", "PROBLEM", 245, 266], ["viruses", "OBSERVATION", 142, 149], ["RNA pseudoknots", "OBSERVATION", 153, 168], ["some plant", "OBSERVATION", 245, 255], ["viral RNAs", "OBSERVATION", 256, 266]]], ["Although aminoacylation at the 3' end of turnip yellow mosaic virus (TYMV) RNA takes place in vivo, probably as a necessary step in the multiplication of the virus [10] , it is still not known why a pseudoknot is specifically used for the proper folding of the tRNA-like structure.", [["3' end", "CELLULAR_COMPONENT", 31, 37], ["turnip yellow mosaic virus", "ORGANISM", 41, 67], ["3' end", "DNA", 31, 37], ["turnip yellow mosaic virus (TYMV) RNA", "RNA", 41, 78], ["tRNA-like structure", "PROTEIN", 261, 280], ["turnip yellow mosaic virus", "SPECIES", 41, 67], ["turnip yellow mosaic virus", "SPECIES", 41, 67], ["TYMV", "SPECIES", 69, 73], ["aminoacylation", "TREATMENT", 9, 23], ["turnip yellow mosaic virus (TYMV) RNA", "TREATMENT", 41, 78], ["mosaic virus", "OBSERVATION", 55, 67], ["pseudoknot", "OBSERVATION", 199, 209], ["tRNA", "ANATOMY", 261, 265]]], ["This problem received a new twist with the observation by Haenni and coworkers [11] that a 3' terminal fragment of TYMV RNA of as few as 38 nucleotides, harbouring just one pseudoknot, is sufficient for specific initiation of minus-strand synthesis.", [["nucleotides", "CHEMICAL", 140, 151], ["TYMV", "GENE_OR_GENE_PRODUCT", 115, 119], ["3' terminal fragment", "DNA", 91, 111], ["TYMV RNA", "RNA", 115, 123], ["a 3' terminal fragment of TYMV RNA", "TREATMENT", 89, 123], ["strand synthesis", "PROBLEM", 232, 248], ["strand synthesis", "OBSERVATION", 232, 248]]], ["If this is indeed the case, it would be interesting to know which part of this pseudoknot is responsible for the recognition of the viral replicase.Plant virusesIt has been difficult to understand the resemblance of the tRNAqike structure of brome mosaic virus (BMV), encompassing some 170 nucleotides, to the canonical elongator tRNATy r.", [["nucleotides", "CHEMICAL", 290, 301], ["Plant viruses", "ORGANISM", 148, 161], ["tRNAqike", "GENE_OR_GENE_PRODUCT", 220, 228], ["brome mosaic virus", "ORGANISM", 242, 260], ["BMV", "ORGANISM", 262, 265], ["viral replicase", "PROTEIN", 132, 147], ["tRNAqike structure", "PROTEIN", 220, 238], ["canonical elongator tRNATy", "PROTEIN", 310, 336], ["brome mosaic virus", "SPECIES", 242, 260], ["brome mosaic virus", "SPECIES", 242, 260], ["BMV", "SPECIES", 262, 265], ["this pseudoknot", "PROBLEM", 74, 89], ["the viral replicase", "PROBLEM", 128, 147], ["Plant viruses", "PROBLEM", 148, 161], ["brome mosaic virus", "PROBLEM", 242, 260], ["viral replicase", "OBSERVATION", 132, 147], ["viruses", "OBSERVATION", 154, 161], ["brome mosaic virus", "OBSERVATION", 242, 260]]], ["A recent, careful and extensive study by Felden et al. [12\u00b0], using chemical modification, enzymatic digestion and computer modeling has led to an improved and more detailed structure.", [["extensive study", "TEST", 22, 37], ["chemical modification", "TREATMENT", 68, 89], ["enzymatic digestion", "TREATMENT", 91, 110], ["computer modeling", "TEST", 115, 132], ["improved", "OBSERVATION_MODIFIER", 147, 155]]], ["Moreover, this Strasbourg group obtained experimental evidence for a pseudoknot just upstream of the tRNA-like structure, as predicted earlier in my laboratory.Plant virusesThese conserved pseudoknots just downstream of the stop codon in the 3' untranslated region (UTR) are a recurrent motif in many non-polyadenylated plant viral RNAs.", [["Plant viruses", "ORGANISM", 160, 173], ["3' untranslated region", "CELLULAR_COMPONENT", 242, 264], ["tRNA", "DNA", 101, 105], ["stop codon", "DNA", 224, 234], ["3' untranslated region", "DNA", 242, 264], ["UTR", "DNA", 266, 269], ["non-polyadenylated plant viral RNAs", "RNA", 301, 336], ["a pseudok", "PROBLEM", 67, 76], ["Plant viruses", "PROBLEM", 160, 173], ["These conserved pseudoknots", "PROBLEM", 173, 200], ["a recurrent motif in many non-polyadenylated plant viral RNAs", "PROBLEM", 275, 336], ["tRNA", "ANATOMY", 101, 105], ["viruses", "OBSERVATION", 166, 173], ["pseudoknots", "OBSERVATION", 189, 200], ["stop codon", "OBSERVATION", 224, 234], ["many", "OBSERVATION_MODIFIER", 296, 300], ["non-polyadenylated plant", "OBSERVATION", 301, 325], ["viral RNAs", "OBSERVATION", 326, 336]]], ["In some cases only one pseudoknot is present, as reported recently for TYMV RNA [13] .", [["TYMV RNA", "RNA", 71, 79], ["TYMV", "SPECIES", 71, 75], ["pseudoknot", "OBSERVATION", 23, 33]]], ["Other viral RNAs usually harbour more pseudoknots, even up to eleven in a row like in some tobamoviruses (A Gultyaev, C Pleij, unpublished data).Plant virusesTwo papers that appeared in 1993 dealt with the function of these 3' UTR-pseudoknots [14\u00b0%15] .", [["viral RNAs", "RNA", 6, 16], ["UTR", "DNA", 227, 230], ["Other viral RNAs", "PROBLEM", 0, 16], ["pseudoknots", "TEST", 231, 242], ["viral RNAs", "OBSERVATION", 6, 16], ["harbour more", "OBSERVATION_MODIFIER", 25, 37], ["pseudoknots", "OBSERVATION", 38, 49], ["viruses", "OBSERVATION", 151, 158]]], ["A few years ago Gallie and coworkers [14 \u00b0\u00b0] found that the three consecutive pseudoknots PKI-PK 3 in tobacco mosaic virus RNA (Fig. 2 ) promote efficient translation of the viral RNA in conjunction with the 5' leader.", [["PKI", "CHEMICAL", 90, 93], ["PKI-PK 3", "GENE_OR_GENE_PRODUCT", 90, 98], ["tobacco mosaic virus", "ORGANISM", 102, 122], ["tobacco mosaic virus RNA", "RNA", 102, 126], ["viral RNA", "RNA", 174, 183], ["5' leader", "DNA", 208, 217], ["tobacco mosaic virus", "SPECIES", 102, 122], ["tobacco mosaic virus", "SPECIES", 102, 122], ["PKI", "TEST", 90, 93], ["PK", "TEST", 94, 96], ["tobacco mosaic virus RNA", "PROBLEM", 102, 126], ["the viral RNA", "PROBLEM", 170, 183], ["mosaic virus", "OBSERVATION", 110, 122], ["viral RNA", "OBSERVATION", 174, 183]]], ["As such, they mimic the function of the polyA tail in cellular mRNAs.", [["cellular", "ANATOMY", 54, 62], ["polyA tail", "GENE_OR_GENE_PRODUCT", 40, 50], ["cellular", "CELL", 54, 62], ["polyA tail", "PROTEIN", 40, 50], ["cellular mRNAs", "RNA", 54, 68], ["tail", "OBSERVATION_MODIFIER", 46, 50], ["cellular mRNAs", "OBSERVATION", 54, 68]]], ["In a very extensive nmtagenesis analysis, Gallie and coworkers [14\" ] have pinpointed which part of the 72 base stalk, or upstream pseudoknot domain (UPD), mediates this regulation; it turned out that both the higher order structure of PK 2 and PK 3 and their conserved sequences, especially in the 3' proximal PK3, are essential for translation.", [["PK 2", "GENE_OR_GENE_PRODUCT", 236, 240], ["PK 3", "GENE_OR_GENE_PRODUCT", 245, 249], ["PK3", "GENE_OR_GENE_PRODUCT", 311, 314], ["upstream pseudoknot domain", "PROTEIN", 122, 148], ["PK 2", "PROTEIN", 236, 240], ["PK 3", "PROTEIN", 245, 249], ["PK3", "PROTEIN", 311, 314], ["PK", "TEST", 236, 238], ["PK", "TEST", 245, 247]]], ["Using band shift analysis they also demonstrated that this upstream pseudoknot domain is specifically recognised by proteins from wheat germ or carrot extracts.", [["germ", "ANATOMY", 136, 140], ["extracts", "ANATOMY", 151, 159], ["wheat germ", "ORGANISM_SUBSTANCE", 130, 140], ["carrot extracts", "ORGANISM_SUBSTANCE", 144, 159], ["upstream pseudoknot domain", "DNA", 59, 85], ["wheat", "SPECIES", 130, 135], ["carrot", "SPECIES", 144, 150], ["wheat", "SPECIES", 130, 135], ["carrot", "SPECIES", 144, 150], ["band shift analysis", "TEST", 6, 25], ["this upstream pseudoknot domain", "PROBLEM", 54, 85]]], ["These proteins also recognise the 5' leader, thereby parallellingo the properties of polyA-binding proteins.Picorna virusesIt has been proposed that pseudoknots are present in the 5' UTR of picornaviral RNAs, such as foot and mouth disease virus (FMDV), encephalomyocarditis virus (EMCV) or hepatitis A virus (HAV).", [["foot and mouth disease", "DISEASE", 217, 239], ["encephalomyocarditis virus (EMCV) or hepatitis A", "DISEASE", 254, 302], ["HAV", "DISEASE", 310, 313], ["polyA-binding proteins", "GENE_OR_GENE_PRODUCT", 85, 107], ["Picorna viruses", "ORGANISM", 108, 123], ["foot and mouth disease virus", "ORGANISM", 217, 245], ["FMDV", "ORGANISM", 247, 251], ["encephalomyocarditis virus", "ORGANISM", 254, 280], ["EMCV", "ORGANISM", 282, 286], ["hepatitis A virus", "ORGANISM", 291, 308], ["HAV", "ORGANISM", 310, 313], ["5' leader", "DNA", 34, 43], ["polyA", "DNA", 85, 90], ["5' UTR", "DNA", 180, 186], ["picornaviral RNAs", "RNA", 190, 207], ["foot and mouth disease virus", "SPECIES", 217, 245], ["FMDV", "SPECIES", 247, 251], ["encephalomyocarditis virus", "SPECIES", 254, 280], ["hepatitis A virus", "SPECIES", 291, 308], ["Picorna viruses", "SPECIES", 108, 123], ["foot and mouth disease virus", "SPECIES", 217, 245], ["FMDV", "SPECIES", 247, 251], ["encephalomyocarditis virus", "SPECIES", 254, 280], ["EMCV", "SPECIES", 282, 286], ["hepatitis A virus", "SPECIES", 291, 308], ["HAV", "SPECIES", 310, 313], ["polyA-binding proteins", "PROBLEM", 85, 107], ["Picorna viruses", "PROBLEM", 108, 123], ["pseudoknots", "PROBLEM", 149, 160], ["picornaviral RNAs", "PROBLEM", 190, 207], ["foot and mouth disease virus (FMDV", "PROBLEM", 217, 251], ["encephalomyocarditis virus", "PROBLEM", 254, 280], ["EMCV", "PROBLEM", 282, 286], ["hepatitis A virus", "PROBLEM", 291, 308], ["polyA-binding proteins", "OBSERVATION", 85, 107], ["viruses", "OBSERVATION", 116, 123], ["pseudoknots", "OBSERVATION", 149, 160], ["picornaviral RNAs", "OBSERVATION", 190, 207], ["foot", "ANATOMY", 217, 221], ["mouth", "ANATOMY", 226, 231]]], ["These pseudoknots of the simple type (as shown in Fig. 1 ) are located upstream of the 'ribosomal landing pad' and border long single-stranded regions [16, 17] .", [["ribosomal", "ANATOMY", 88, 97], ["ribosomal", "CELLULAR_COMPONENT", 88, 97], ["border long single-stranded regions", "DNA", 115, 150], ["the 'ribosomal landing pad'", "TREATMENT", 83, 110], ["pseudoknots", "OBSERVATION", 6, 17], ["simple type", "OBSERVATION_MODIFIER", 25, 36], ["ribosomal", "OBSERVATION", 88, 97], ["landing pad", "OBSERVATION", 98, 109], ["border", "OBSERVATION_MODIFIER", 115, 121], ["long", "OBSERVATION_MODIFIER", 122, 126], ["stranded", "OBSERVATION_MODIFIER", 134, 142]]], ["No functional role for these pseudoknots has been reported as yet.Picorna virusesThe 'ribosome landing pad' (RLP) itself has also been described as containing a few pseudoknots, both in the human enterovirus and rhinovirus RNAs [18] , and in the cardiovirus, hepatitis A and aphtovirus RNAs [17] .", [["ribosome", "ANATOMY", 86, 94], ["hepatitis A", "DISEASE", 259, 270], ["Picorna viruses", "ORGANISM", 66, 81], ["human", "ORGANISM", 190, 195], ["enterovirus", "ORGANISM", 196, 207], ["rhinovirus", "ORGANISM", 212, 222], ["cardiovirus", "GENE_OR_GENE_PRODUCT", 246, 257], ["hepatitis A", "ORGANISM", 259, 270], ["human enterovirus and rhinovirus RNAs", "RNA", 190, 227], ["cardiovirus, hepatitis A and aphtovirus RNAs", "RNA", 246, 290], ["human", "SPECIES", 190, 195], ["Picorna viruses", "SPECIES", 66, 81], ["human enterovirus", "SPECIES", 190, 207], ["hepatitis A", "SPECIES", 259, 270], ["these pseudoknots", "PROBLEM", 23, 40], ["Picorna viruses", "PROBLEM", 66, 81], ["The 'ribosome landing pad' (RLP", "TREATMENT", 81, 112], ["a few pseudoknots", "PROBLEM", 159, 176], ["the human enterovirus", "PROBLEM", 186, 207], ["rhinovirus RNAs", "PROBLEM", 212, 227], ["hepatitis A and aphtovirus RNAs", "PROBLEM", 259, 290], ["viruses", "OBSERVATION", 74, 81], ["ribosome landing", "OBSERVATION", 86, 102], ["few", "OBSERVATION_MODIFIER", 161, 164], ["pseudoknots", "OBSERVATION", 165, 176], ["hepatitis", "OBSERVATION", 259, 268]]], ["However, some of these pseudoknots, proposed on the basis of sequence comparisons and computer prediction, clearly need experimental verification because the predictions are either not supported by covariations, or actually show contra-indicators in related sequences.", [["computer prediction", "TEST", 86, 105], ["experimental verification", "TEST", 120, 145], ["pseudoknots", "OBSERVATION", 23, 34]]], ["If present, the role of these pseudoknots in the cap-independent initiation of protein synthesis remains to be established.Picorna virusesTwo different models for 3' UTR folding of the poliovirus genome were recently proposed.", [["Picorna viruses", "ORGANISM", 123, 138], ["poliovirus", "ORGANISM", 185, 195], ["poliovirus genome", "DNA", 185, 202], ["Picorna viruses", "SPECIES", 123, 138], ["these pseudoknots", "PROBLEM", 24, 41], ["the cap-independent initiation of protein synthesis", "TREATMENT", 45, 96], ["Picorna viruses", "PROBLEM", 123, 138], ["3' UTR folding", "TREATMENT", 163, 177], ["the poliovirus genome", "PROBLEM", 181, 202], ["pseudoknots", "OBSERVATION", 30, 41], ["viruses", "OBSERVATION", 131, 138], ["poliovirus genome", "OBSERVATION", 185, 202]]], ["Both models contain a pseudoknot structure, possibly implicated in viral replication [19\u00b0,20] .", [["a pseudoknot structure", "PROBLEM", 20, 42], ["viral replication", "TREATMENT", 67, 84], ["pseudoknot structure", "OBSERVATION", 22, 42], ["possibly implicated", "UNCERTAINTY", 44, 63], ["viral replication", "OBSERVATION", 67, 84]]], ["The first, presented by Jacob- son et al. ([19\" ], see Fig. 3a ) was supported both by mutational studies and by structure probing, although the phylogenetic evidence is rather weak.", [["mutational studies", "TEST", 87, 105], ["weak", "OBSERVATION", 177, 181]]], ["The proposal has, to my knowledge, the unique feature that a stretch from the coding sequence is needed for pseudoknot formation.", [["coding sequence", "DNA", 78, 93], ["a stretch from the coding sequence", "PROBLEM", 59, 93], ["pseudoknot formation", "PROBLEM", 108, 128]]], ["In the second model, proposed by Pilipenko et al. [20] , the pseudoknot-forn~ng basepairing takes place with the loop of the downstream-located hairpin (Fig. 3b ).", [["downstream-located hairpin", "DNA", 125, 151], ["the pseudoknot-forn~ng basepairing", "PROBLEM", 57, 91], ["hairpin", "OBSERVATION", 144, 151]]], ["An attempt was made to fold the 3' UTR in a tRNA-like structure, including an equivalent of the T-and D-loop interaction of tRNA.", [["3' UTR", "DNA", 32, 38], ["the 3' UTR", "TREATMENT", 28, 38], ["a tRNA", "TREATMENT", 42, 48], ["the T-and D-loop interaction of tRNA", "TREATMENT", 92, 128]]], ["In my view this resemblance is hardly visible, however, and the three-dimensional model could be called, at best, tRNA-like-like.Picorna virusesThese two studies at least show that the spatial folding of the 3\" terminus of the enteroviral RNAs may be rather complicated, or may harbour alternative conformations.Ribosomal RNAOn the basis of phylogenetic comparisons three different pseudoknot structures have been proposed in the small subunit rRNA (see also [4, 21] ).", [["Picorna viruses", "ORGANISM", 129, 144], ["3\" terminus", "PROTEIN", 208, 219], ["enteroviral RNAs", "RNA", 227, 243], ["small subunit rRNA", "DNA", 430, 448], ["Picorna viruses", "SPECIES", 129, 144], ["tRNA", "TEST", 114, 118], ["Picorna viruses", "PROBLEM", 129, 144], ["These two studies", "TEST", 144, 161], ["the enteroviral RNAs", "PROBLEM", 223, 243], ["viruses", "OBSERVATION", 137, 144], ["spatial folding", "OBSERVATION", 185, 200], ["enteroviral RNAs", "OBSERVATION", 227, 243], ["pseudoknot structures", "OBSERVATION", 382, 403], ["small", "OBSERVATION_MODIFIER", 430, 435], ["subunit rRNA", "OBSERVATION", 436, 448]]], ["The nature of two of them (pseudoknots I and III in Fig. 4 ) have now been confirmed by mutagenesis, and a beginning has been made towards understanding their functional role in ribosome a&ivity.", [["ribosome", "ANATOMY", 178, 186], ["pseudoknots", "OBSERVATION", 27, 38], ["ribosome a&ivity", "OBSERVATION", 178, 194]]], ["Powers and Noller [22] obtained evidence for a possible essential function of the pseudoknot involving the 530-1oop (pseudoknot III).", [["530-1oop", "DNA", 107, 115], ["pseudoknot III", "PROTEIN", 117, 131], ["the pseudoknot", "TEST", 78, 92], ["pseudoknot", "OBSERVATION", 82, 92]]], ["A similar in vivo study was performed by Brink et al. [23\" ] on pseudoknot I, using their so-called specialized ribosome system.", [["vivo study", "TEST", 13, 23], ["ribosome system", "OBSERVATION", 112, 127]]], ["From an elegant set of experiments, these authors concluded that mutations disrupting or weakening this tertiary interaction affected the formation of the 70S ribosomal complex.", [["ribosomal", "ANATOMY", 159, 168], ["70S", "CELLULAR_COMPONENT", 155, 158], ["ribosomal", "CELLULAR_COMPONENT", 159, 168], ["70S ribosomal complex", "PROTEIN", 155, 176], ["mutations disrupting", "PROBLEM", 65, 85]]], ["Similar results were obtained by Dan~rnel and Noller [24] who studied a C to U substitution at position 23 in the 5' terminal pseudoknot helix.", [["5' terminal pseudoknot helix", "DNA", 114, 142], ["a C to U substitution at position", "TREATMENT", 70, 103], ["pseudoknot helix", "OBSERVATION", 126, 142]]], ["This mutant, which is cold-sensitive and impaired in assembly, also leads to accumulation of free 30S subunits in the cell.", [["cell", "ANATOMY", 118, 122], ["cell", "CELL", 118, 122], ["30S subunits", "PROTEIN", 98, 110], ["cold", "PROBLEM", 22, 26], ["free 30S subunits in the cell", "PROBLEM", 93, 122], ["impaired", "OBSERVATION", 41, 49], ["free 30S", "OBSERVATION", 93, 101], ["cell", "ANATOMY", 118, 122]]], ["The hypothesis that these strongly conserved pseudoknots play a role as crucial conformational switches still holds.Ribosomal RNAMany potential tertiary interactions have been proposed in the large ribosomal subunit RNA (see [25] ).", [["RNAMany", "GENE_OR_GENE_PRODUCT", 126, 133], ["large ribosomal subunit RNA", "RNA", 192, 219], ["tertiary interactions", "PROBLEM", 144, 165], ["pseudoknots", "OBSERVATION", 45, 56], ["tertiary interactions", "OBSERVATION", 144, 165], ["large", "OBSERVATION_MODIFIER", 192, 197], ["ribosomal subunit RNA", "OBSERVATION", 198, 219]]], ["Kooi et al. [26] obtained evidence that one such interaction in domain III in the 26S rRNA of yeast is essential.", [["26S", "GENE_OR_GENE_PRODUCT", 82, 85], ["domain III", "PROTEIN", 64, 74], ["26S rRNA", "DNA", 82, 90], ["yeast", "SPECIES", 94, 99], ["yeast", "SPECIES", 94, 99], ["yeast", "PROBLEM", 94, 99]]], ["The loop-loop interaction of two base pairs is necessa W for binding of ribosomal L25 as deduced from an in vitro binding assay.Translational regulationThe presence and functional significance of pseudoknots in the 5' leader of prokayotic mRNAs is now a well-documented story.", [["ribosomal", "ANATOMY", 72, 81], ["ribosomal", "CELLULAR_COMPONENT", 72, 81], ["ribosomal L25", "PROTEIN", 72, 85], ["5' leader", "DNA", 215, 224], ["prokayotic mRNAs", "RNA", 228, 244], ["ribosomal L25", "TREATMENT", 72, 85], ["an in vitro binding assay", "TEST", 102, 127], ["Translational regulation", "TEST", 128, 152], ["pseudoknots", "PROBLEM", 196, 207], ["loop", "OBSERVATION_MODIFIER", 4, 8], ["loop", "OBSERVATION_MODIFIER", 9, 13], ["pseudoknots", "OBSERVATION", 196, 207]]], ["In 1993 a few papers appeared that contributed a great deal to our insight into this Wpe of translational regulation.", [["translational regulation", "TREATMENT", 92, 116]]], ["New data have been presented about the pseudoknot-dependent repression mechanisms of ribosomal protein operons in Escherichia coli [27%28,29\u00b0].", [["ribosomal", "ANATOMY", 85, 94], ["ribosomal", "CELLULAR_COMPONENT", 85, 94], ["Escherichia coli", "ORGANISM", 114, 130], ["ribosomal protein operons", "DNA", 85, 110], ["Escherichia coli", "SPECIES", 114, 130], ["Escherichia coli", "SPECIES", 114, 130], ["the pseudoknot-dependent repression mechanisms", "PROBLEM", 35, 81], ["ribosomal protein operons", "PROBLEM", 85, 110], ["Escherichia coli", "PROBLEM", 114, 130], ["ribosomal protein operons", "OBSERVATION", 85, 110], ["Escherichia coli", "OBSERVATION", 114, 130]]], ["In the case of the complex pseudoknot regulating the alpha-operon, Draper and coworkers [27%28] concluded from $4 binding studies and 'toeprint' assays that the repressor protein $4 does not simply 'displace' the ribosome from the mRNA, but rather exerts its activi W by an allosteric effect.", [["ribosome", "CELLULAR_COMPONENT", 213, 221], ["activi W", "GENE_OR_GENE_PRODUCT", 259, 267], ["repressor protein", "PROTEIN", 161, 178], ["mRNA", "RNA", 231, 235], ["activi W", "PROTEIN", 259, 267], ["the repressor protein", "TREATMENT", 157, 178], ["pseudoknot", "OBSERVATION", 27, 37], ["allosteric effect", "OBSERVATION", 274, 291]]], ["The so-called inactive conformation containing the intact pseudoknot structure binds $4 rapidly and tightly.", [["inactive conformation", "OBSERVATION", 14, 35], ["intact", "OBSERVATION_MODIFIER", 51, 57], ["pseudoknot structure", "OBSERVATION", 58, 78]]], ["This complex is still able to bind 30S subunits, but lacks the possibility of forming a proper initiation (or pretemary) complex with tRNAf Met.Translational regulationFollowing a similar experimental approach for ribosomal protein S15, Philippe eta[.", [["ribosomal", "ANATOMY", 214, 223], ["Met", "CHEMICAL", 140, 143], ["30S subunits", "GENE_OR_GENE_PRODUCT", 35, 47], ["tRNAf Met", "GENE_OR_GENE_PRODUCT", 134, 143], ["ribosomal protein S15", "GENE_OR_GENE_PRODUCT", 214, 235], ["Philippe eta", "GENE_OR_GENE_PRODUCT", 237, 249], ["30S subunits", "PROTEIN", 35, 47], ["pretemary) complex", "PROTEIN", 110, 128], ["tRNAf Met", "PROTEIN", 134, 143], ["ribosomal protein S15", "PROTEIN", 214, 235], ["Philippe eta", "PROTEIN", 237, 249], ["ribosomal protein S15", "TREATMENT", 214, 235], ["protein S15", "OBSERVATION", 224, 235]]], ["[29 \u00b0] reached the same conclusion in that the protein, by stabilizing the pseudoknot-containing conformation of the mRNA coding for S15, also blocks the ribosome in a preinitiation complex.", [["ribosome", "ANATOMY", 154, 162], ["S15", "GENE_OR_GENE_PRODUCT", 133, 136], ["ribosome", "CELLULAR_COMPONENT", 154, 162], ["S15", "PROTEIN", 133, 136], ["preinitiation complex", "PROTEIN", 168, 189], ["pseudoknot", "OBSERVATION", 75, 85], ["ribosome", "OBSERVATION_MODIFIER", 154, 162]]], ["The unexpected outcome of these studies is that the pseudoknot structure displays the property of providing determinants for both repressor and ribosome recognition.Translational regulationsame mechanism for expression of overlapping genes in the -1 phase.Translational regulationThe translational repression by the bacteriophage T4 gene 32 protein also requires a pseudoknot structure in the 5' leader, as first shown by Gold and coworkers [30] .", [["ribosome", "ANATOMY", 144, 152], ["ribosome", "CELLULAR_COMPONENT", 144, 152], ["bacteriophage T4", "GENE_OR_GENE_PRODUCT", 316, 332], ["overlapping genes", "DNA", 222, 239], ["bacteriophage T4 gene 32 protein", "PROTEIN", 316, 348], ["5' leader", "DNA", 393, 402], ["these studies", "TEST", 26, 39], ["both repressor", "TREATMENT", 125, 139], ["Translational regulation", "TEST", 256, 280], ["The translational repression", "TREATMENT", 280, 308], ["the bacteriophage T4 gene", "TREATMENT", 312, 337]]], ["The pseudoknot structure is of the classical type (as shown in Fig. 1) , and located at the very 5' end in this case, functions as a nucleation point for cooperative binding of gene 32 protein, which then proceeds in the 3' direction covering the initiation codon.", [["pseudoknot structure", "PROTEIN", 4, 24], ["5' end", "DNA", 97, 103], ["gene 32 protein", "PROTEIN", 177, 192], ["initiation codon", "DNA", 247, 263], ["initiation codon", "OBSERVATION", 247, 263]]], ["This model was confirmed recently and the important pseudoknot structural determinants for binding the protein were determined [31] .", [["binding the protein", "TEST", 91, 110]]], ["How this single strand specific protein binds so tightly to the compact pseudoknot structure remains an intriguing question.Ribosomal frameshfftingOne of the clearest examples of the functional role of pseudoknot structures is found in the case of programmed translational errors like ribosomal frameshifting and translational readthrough.", [["ribosomal", "ANATOMY", 285, 294], ["ribosomal", "CELLULAR_COMPONENT", 285, 294], ["this single strand specific protein binds", "PROBLEM", 4, 45], ["Ribosomal frameshffting", "PROBLEM", 124, 147], ["pseudoknot structures", "PROBLEM", 202, 223], ["programmed translational errors", "PROBLEM", 248, 279], ["ribosomal frameshifting", "PROBLEM", 285, 308], ["translational readthrough", "PROBLEM", 313, 338], ["frameshffting", "OBSERVATION", 134, 147], ["pseudoknot structures", "OBSERVATION", 202, 223], ["translational errors", "OBSERVATION", 259, 279], ["ribosomal frameshifting", "OBSERVATION", 285, 308], ["translational readthrough", "OBSERVATION", 313, 338]]], ["Brierley et al. [32] were the first to convincingly show that the efficiency of-1 franaeshifting in a coronaviral RNA was strongly dependent on a pseudoknot structure downstream of a slippery heptanucleotide sequence.", [["coronaviral RNA", "RNA", 102, 117], ["slippery heptanucleotide sequence", "DNA", 183, 216], ["1 franaeshifting in a coronaviral RNA", "PROBLEM", 80, 117], ["a slippery heptanucleotide sequence", "TREATMENT", 181, 216], ["pseudoknot structure", "OBSERVATION", 146, 166]]], ["Since then a large number of other viral RNAs were shown to use the I will not review here all the new viruses, or virus groups, for which pseudoknots were predicted to play a role in the translation of their overlapping genes, but rather I shall focus on some new aspects and new types of pseudoknots.", [["viral RNAs", "RNA", 35, 45], ["overlapping genes", "DNA", 209, 226], ["other viral RNAs", "PROBLEM", 29, 45], ["pseudoknots", "PROBLEM", 290, 301], ["large", "OBSERVATION_MODIFIER", 13, 18], ["viral RNAs", "OBSERVATION", 35, 45], ["new", "OBSERVATION_MODIFIER", 277, 280], ["pseudoknots", "OBSERVATION", 290, 301]]], ["For a more detailed discussion of pseudoknot-dependent frameshifting and readthrough and other related 'alternative readings of the genetic code', the reader is referred to an excellent review of a recent meeting on this subject [33\u00b0\u00b0].Ribosomal frameshfftingMost of the pseudoknots involved in ribosomal frameshifting are of the classical type, as illustrated in Fig. 1 , though the stems and loops can be relatively large.", [["ribosomal", "ANATOMY", 295, 304], ["stems", "ANATOMY", 384, 389], ["ribosomal", "CELLULAR_COMPONENT", 295, 304], ["stems", "TISSUE", 384, 389], ["pseudoknot-dependent frameshifting", "PROBLEM", 34, 68], ["Ribosomal frameshffting", "PROBLEM", 236, 259], ["the pseudoknots", "PROBLEM", 267, 282], ["ribosomal frameshifting", "PROBLEM", 295, 318], ["dependent frameshifting", "OBSERVATION", 45, 68], ["frameshffting", "OBSERVATION", 246, 259], ["pseudoknots", "OBSERVATION", 271, 282], ["ribosomal frameshifting", "OBSERVATION", 295, 318], ["stems", "OBSERVATION", 384, 389], ["loops", "ANATOMY_MODIFIER", 394, 399], ["relatively", "OBSERVATION_MODIFIER", 407, 417], ["large", "OBSERVATION", 418, 423]]], ["They obtained evidence that a third stem structure, $3, is a necessary component of the hepatitis C virus (HCV) 229E pseudoknot in the overlap of open reading frames la and lb.", [["stem structure", "ANATOMY", 36, 50], ["hepatitis C", "DISEASE", 88, 99], ["hepatitis C virus", "ORGANISM", 88, 105], ["HCV", "ORGANISM", 107, 110], ["open reading frames", "DNA", 146, 165], ["hepatitis C virus", "SPECIES", 88, 105], ["hepatitis C virus", "SPECIES", 88, 105], ["HCV", "SPECIES", 107, 110], ["a third stem structure", "PROBLEM", 28, 50], ["the hepatitis C virus (HCV) 229E pseudoknot", "PROBLEM", 84, 127], ["hepatitis", "OBSERVATION", 88, 97], ["lb", "ANATOMY", 173, 175]]], ["Stem S3 results from basepairing of loop L2 with a region downstream of the classical pseudoknot.", [["loop L2", "PROTEIN", 36, 43], ["Stem S3", "TEST", 0, 7], ["loop L2", "PROBLEM", 36, 43], ["loop", "ANATOMY_MODIFIER", 36, 40], ["L2", "ANATOMY_MODIFIER", 41, 43], ["classical pseudoknot", "OBSERVATION", 76, 96]]], ["This gives rise to a complex or 'elaborated' pseudoknot which is reminiscent of the structure present in the alpha-operon of E. coli (see above).", [["E. coli", "ORGANISM", 125, 132], ["E. coli", "SPECIES", 125, 132], ["E. coli", "SPECIES", 125, 132], ["a complex or 'elaborated' pseudoknot", "PROBLEM", 19, 55], ["E. coli", "PROBLEM", 125, 132], ["pseudoknot", "OBSERVATION", 45, 55], ["E. coli", "OBSERVATION", 125, 132]]], ["Apart from the two possible stacking modes of the three stems, this extra stem may contribute to the stability of the entire pseudoknot structure and thereby increase the pausing time of the ribosome.Ribosomal frameshfftingIt is generally thought that ribosomal pausing caused by the (stable) pseudoknot is a prerequisite for efficient frameshifting.", [["stem", "ANATOMY", 74, 78], ["ribosome", "ANATOMY", 191, 199], ["ribosomal", "ANATOMY", 252, 261], ["ribosome", "CELLULAR_COMPONENT", 191, 199], ["ribosomal", "CELLULAR_COMPONENT", 252, 261], ["pseudoknot structure", "PROTEIN", 125, 145], ["this extra stem", "TREATMENT", 63, 78], ["Ribosomal frameshffting", "PROBLEM", 200, 223], ["ribosomal pausing", "PROBLEM", 252, 269], ["efficient frameshifting", "PROBLEM", 326, 349], ["stacking modes", "OBSERVATION", 28, 42], ["three stems", "ANATOMY_MODIFIER", 50, 61], ["extra stem", "OBSERVATION", 68, 78], ["stability", "OBSERVATION_MODIFIER", 101, 110], ["entire", "OBSERVATION_MODIFIER", 118, 124], ["pseudok", "OBSERVATION", 125, 132], ["increase", "OBSERVATION_MODIFIER", 158, 166], ["frameshffting", "OBSERVATION", 210, 223], ["ribosomal pausing", "OBSERVATION", 252, 269], ["frameshifting", "OBSERVATION", 336, 349]]], ["Heel-printing experiments on the L1 double-stranded RNA virus of Saccharomyces cerevisiae have provided evidence that ribosomes have a decreased rate of movement through a pseudoknot [35] .", [["ribosomes", "ANATOMY", 118, 127], ["Saccharomyces cerevisiae", "ORGANISM", 65, 89], ["ribosomes", "CELLULAR_COMPONENT", 118, 127], ["Saccharomyces cerevisiae", "SPECIES", 65, 89], ["Saccharomyces cerevisiae", "SPECIES", 65, 89], ["Heel-printing experiments", "PROBLEM", 0, 25], ["the L1 double-stranded RNA virus of Saccharomyces cerevisiae", "TREATMENT", 29, 89], ["decreased", "OBSERVATION_MODIFIER", 135, 144]]], ["This ribosomal arrest at the pseudoknot was further substantiated by Somogyi et al. [36 \u00b0] who observed a new translational intermediate when a pseudoknot was inserted at a specific location in an influenza messenger RNA.", [["ribosomal", "ANATOMY", 5, 14], ["ribosomal", "CELLULAR_COMPONENT", 5, 14], ["influenza messenger RNA", "RNA", 197, 220], ["This ribosomal arrest", "PROBLEM", 0, 21], ["a pseudoknot", "PROBLEM", 142, 154], ["an influenza messenger RNA", "PROBLEM", 194, 220], ["ribosomal arrest", "OBSERVATION", 5, 21], ["pseudoknot", "OBSERVATION", 144, 154], ["influenza", "OBSERVATION", 197, 206], ["messenger RNA", "OBSERVATION", 207, 220]]], ["A simple stem-loop structure with the same basepairs as the pseudoknot was less effective in stalling the ribosome, though still more than expected on the basis of its frameshifting efficiency.Ribosomal frameshfftingAlthough -1 frameshifting does occur in prokaryotes, no evidence has so far been reported for the requirement of a pseudoknot structure.", [["ribosome", "ANATOMY", 106, 114], ["ribosome", "CELLULAR_COMPONENT", 106, 114], ["A simple stem-loop structure", "PROBLEM", 0, 28], ["the same basepairs", "PROBLEM", 34, 52], ["its frameshifting efficiency", "PROBLEM", 164, 192], ["Ribosomal frameshffting", "PROBLEM", 193, 216], ["1 frameshifting", "PROBLEM", 226, 241], ["a pseudoknot structure", "PROBLEM", 329, 351], ["simple", "OBSERVATION_MODIFIER", 2, 8], ["stem", "OBSERVATION", 9, 13], ["loop structure", "OBSERVATION", 14, 28], ["pseudoknot", "OBSERVATION", 60, 70], ["less", "OBSERVATION_MODIFIER", 75, 79], ["effective", "OBSERVATION_MODIFIER", 80, 89], ["ribosome", "OBSERVATION_MODIFIER", 106, 114], ["more than expected", "OBSERVATION_MODIFIER", 129, 147], ["frameshifting efficiency", "OBSERVATION", 168, 192], ["frameshffting", "OBSERVATION", 203, 216], ["frameshifting", "OBSERVATION", 228, 241], ["no evidence", "UNCERTAINTY", 269, 280], ["pseudoknot", "OBSERVATION", 331, 341]]], ["In this respect, it is interesting to know whether eukaryotic frameshifting signals, including the pseudoknot, are active in E. coli.", [["E. coli", "ORGANISM", 125, 132], ["E. coli", "SPECIES", 125, 132], ["E. coli", "SPECIES", 125, 132], ["eukaryotic frameshifting signals", "PROBLEM", 51, 83], ["the pseudoknot", "PROBLEM", 95, 109], ["E. coli", "PROBLEM", 125, 132], ["frameshifting", "OBSERVATION", 62, 75], ["active", "OBSERVATION_MODIFIER", 115, 121], ["E. coli", "OBSERVATION", 125, 132]]], ["Garcia et al.Ribosomal frameshffting[37] examined the eukaryotic frameshift signal of beet western yellows virus (BWYV) RNA in E. coli [37] .", [["beet western yellows virus", "ORGANISM", 86, 112], ["E. coli", "ORGANISM", 127, 134], ["beet western yellows virus (BWYV) RNA", "RNA", 86, 123], ["E. coli", "SPECIES", 127, 134], ["beet western yellows virus", "SPECIES", 86, 112], ["BWYV", "SPECIES", 114, 118], ["E. coli", "SPECIES", 127, 134], ["Ribosomal frameshffting", "TEST", 13, 36], ["beet western yellows virus (BWYV) RNA in E. coli", "PROBLEM", 86, 134], ["eukaryotic frameshift", "OBSERVATION", 54, 75]]], ["They showed that the frameshifting observed, which is relatively low in both the prokaryotic and the eukaryotic system, is only slightly sensitive to a disruption of the pseudoknot.", [["the frameshifting", "PROBLEM", 17, 34], ["a disruption of the pseudoknot", "PROBLEM", 150, 180], ["frameshifting", "OBSERVATION", 21, 34], ["relatively", "OBSERVATION_MODIFIER", 54, 64], ["low", "OBSERVATION_MODIFIER", 65, 68], ["prokaryotic", "OBSERVATION", 81, 92], ["eukaryotic system", "ANATOMY", 101, 118], ["slightly", "OBSERVATION_MODIFIER", 128, 136], ["sensitive", "OBSERVATION", 137, 146], ["disruption", "OBSERVATION", 152, 162], ["pseudoknot", "OBSERVATION", 170, 180]]], ["However, it cannot be excluded that a pseudoknot-including frameshift signal is dependent on other requirements in the prokaryote, e.g. a different spacer length between pseudoknot and shifty heptanucleotide or a more stable pseudoknot.Ribosomal frameshfftingA pseudoknot-dependent frameshift in beet western yellow virus in RNA was also reported by Kujawa et al. [38] , in contrast to an earlier paper which reported the involvement of a hairpin structure only [39] .Ribosomal frameshfftingExactly how pseudoknots stinmlate frameshifting (or readthrough) still remains unclear, although it could well be that the ribosome cannot easily handle this structure during the necessary unwinding.", [["frameshfftingA", "GENE_OR_GENE_PRODUCT", 246, 260], ["beet western yellow virus", "ORGANISM", 296, 321], ["ribosome", "CELLULAR_COMPONENT", 614, 622], ["Ribosomal frameshfftingA pseudoknot", "RNA", 236, 271], ["beet western yellow virus", "SPECIES", 296, 321], ["a pseudoknot-including frameshift signal", "PROBLEM", 36, 76], ["a different spacer length", "TREATMENT", 136, 161], ["pseudoknot and shifty heptanucleotide", "TREATMENT", 170, 207], ["Ribosomal frameshfftingA pseudoknot-dependent frameshift", "PROBLEM", 236, 292], ["yellow virus in RNA", "PROBLEM", 309, 328], ["a hairpin structure", "PROBLEM", 437, 456], ["Ribosomal frameshffting", "PROBLEM", 468, 491], ["pseudoknots stinmlate frameshifting", "PROBLEM", 503, 538], ["cannot be excluded", "UNCERTAINTY", 12, 30], ["pseudoknot", "OBSERVATION", 38, 48], ["dependent", "OBSERVATION_MODIFIER", 80, 89], ["stable", "OBSERVATION_MODIFIER", 218, 224], ["pseudoknot", "OBSERVATION", 225, 235], ["frameshfftingA pseudoknot", "OBSERVATION", 246, 271], ["dependent", "OBSERVATION_MODIFIER", 272, 281], ["frameshift", "OBSERVATION", 282, 292], ["western", "OBSERVATION_MODIFIER", 301, 308], ["yellow virus", "OBSERVATION", 309, 321], ["hairpin", "OBSERVATION", 439, 446], ["pseudoknots", "OBSERVATION", 503, 514], ["stinmlate frameshifting", "OBSERVATION", 515, 538], ["ribosome", "OBSERVATION", 614, 622]]], ["This may be due to the presence of structurally unusual connecting loops, especially L2 which is closest to the shifty heptanucleotide may be responsible for the stalling of the ribosome (see [33\"] ).Hepatitis delta virus ribozymeThe genomic and antigenomic RNAs of hepatitis delta virus contain a self-cleavage site formed from 85 nucleotides.", [["ribosome", "ANATOMY", 178, 186], ["Hepatitis delta virus ribozyme", "CHEMICAL", 200, 230], ["hepatitis delta", "DISEASE", 266, 281], ["nucleotides", "CHEMICAL", 332, 343], ["ribosome", "CELLULAR_COMPONENT", 178, 186], ["Hepatitis delta virus", "ORGANISM", 200, 221], ["hepatitis delta virus", "ORGANISM", 266, 287], ["shifty heptanucleotide", "PROTEIN", 112, 134], ["ribosome", "PROTEIN", 178, 186], ["antigenomic RNAs", "RNA", 246, 262], ["self-cleavage site", "DNA", 298, 316], ["Hepatitis delta virus", "SPECIES", 200, 221], ["hepatitis delta virus", "SPECIES", 266, 287], ["Hepatitis delta virus", "SPECIES", 200, 221], ["hepatitis delta virus", "SPECIES", 266, 287], ["structurally unusual connecting loops", "PROBLEM", 35, 72], ["Hepatitis delta virus ribozyme", "PROBLEM", 200, 230], ["hepatitis delta virus", "PROBLEM", 266, 287], ["a self-cleavage site", "TREATMENT", 296, 316], ["may be due to", "UNCERTAINTY", 5, 18], ["structurally", "OBSERVATION_MODIFIER", 35, 47], ["unusual", "OBSERVATION", 48, 55], ["loops", "OBSERVATION_MODIFIER", 67, 72], ["L2", "ANATOMY_MODIFIER", 85, 87], ["delta virus ribozyme", "OBSERVATION", 210, 230], ["hepatitis delta virus", "OBSERVATION", 266, 287]]], ["Three different secondary structure models have been proposed for the region around this cleavage site, and none of them resemble the canonical hammerhead or hairpin/paperclip motif.", [["canonical hammerhead or hairpin/paperclip motif", "PROTEIN", 134, 181], ["this cleavage site", "PROBLEM", 84, 102], ["hairpin/paperclip motif", "TREATMENT", 158, 181], ["secondary structure models", "OBSERVATION", 16, 42], ["canonical hammerhead", "OBSERVATION", 134, 154], ["hairpin", "OBSERVATION", 158, 165]]], ["One of the three models involves a pseudoknot-containing structure with four basepaired regions (see [40] and references therein).", [["basepaired regions", "PROTEIN", 77, 95], ["four basepaired regions", "PROBLEM", 72, 95], ["pseudoknot", "OBSERVATION", 35, 45], ["four", "OBSERVATION_MODIFIER", 72, 76], ["basepaired", "OBSERVATION_MODIFIER", 77, 87]]], ["The pseudoknot can be represented by the basepairing of a big hairpin-containing bulge loop with a sequence near the 5' end of the 85 nucleotides [4] .", [["nucleotides", "CHEMICAL", 134, 145], ["5' end", "DNA", 117, 123], ["a big hairpin", "TREATMENT", 56, 69], ["bulge loop", "PROBLEM", 81, 91], ["a sequence", "TEST", 97, 107], ["pseudoknot", "OBSERVATION", 4, 14], ["big hairpin", "OBSERVATION", 58, 69], ["bulge loop", "OBSERVATION", 81, 91]]], ["The proposed pairings have now been tested and confirmed by structure mapping and nmtational analysis by various groups [40] [41] [42] [43] .", [["[40] [41] [42] [43]", "SIMPLE_CHEMICAL", 120, 139], ["nmtational analysis", "TEST", 82, 101]]], ["Two of the stems that are essential for pseudoknot formation were found to be indispensable for the catalytic activity.ConclusionsIt has become clear that pseudoknots are an important structural motif in RNA folding, and that they are essential for the biological activity of many RNA molecules.", [["pseudok", "GENE_OR_GENE_PRODUCT", 40, 47], ["RNA molecules", "PROTEIN", 281, 294], ["pseudoknot formation", "PROBLEM", 40, 60], ["pseudoknots", "PROBLEM", 155, 166], ["an important structural motif in RNA folding", "PROBLEM", 171, 215], ["stems", "ANATOMY_MODIFIER", 11, 16], ["pseudoknots", "OBSERVATION", 155, 166], ["RNA folding", "OBSERVATION", 204, 215], ["RNA molecules", "OBSERVATION", 281, 294]]], ["These pseudoknot interactions are usually detected in a way that is basically no different from establishing any other double-stranded region in RNA --that is, by means of techniques such as sequence comparisons, chemical modification and enzymatic digestion, computer prediction and site-directed nmtagenesis.", [["double-stranded region", "DNA", 119, 141], ["any other double-stranded region in RNA", "PROBLEM", 109, 148], ["sequence comparisons", "TEST", 191, 211], ["chemical modification", "TREATMENT", 213, 234], ["enzymatic digestion", "TREATMENT", 239, 258], ["computer prediction", "TEST", 260, 279], ["pseudoknot", "OBSERVATION", 6, 16]]], ["In fact, one needs a minimum of two basepaired regions in order to describe a pseudoknot structure.", [["two basepaired regions", "TREATMENT", 32, 54], ["pseudoknot structure", "OBSERVATION", 78, 98]]], ["Many new pseudoknots have been proposed on the basis of these techniques and it is safe to predict that the list of proposed and proven pseudoknot structures will keep growing in the near future.", [["Many new pseudoknots", "PROBLEM", 0, 20], ["these techniques", "TREATMENT", 56, 72], ["pseudoknot structures", "PROBLEM", 136, 157], ["new", "OBSERVATION_MODIFIER", 5, 8], ["pseudoknots", "OBSERVATION", 9, 20]]], ["On the other hand, with RNA pseudoknots being both popular and fashionable at the current time [21] , some authors sometimes seem to forget that pseudoknot structures also need some experimental verification or support from sequence comparisons, especially when potential interactions of three basepairs or less are involved.", [["RNA pseudoknots", "PROBLEM", 24, 39], ["support from sequence comparisons", "TEST", 211, 244], ["pseudoknots", "OBSERVATION", 28, 39]]], ["Generally speaking, pseudoknots may serve to bring together RNA regions that are far apart in the sequence, so that a compact and biologically active RNA molecule is formed.", [["RNA regions", "DNA", 60, 71], ["RNA molecule", "PROTEIN", 150, 162], ["a compact and biologically active RNA molecule", "PROBLEM", 116, 162], ["RNA molecule", "OBSERVATION", 150, 162]]], ["In this way, RNA pseudoknots may be compared somewhat with S-S bridges in proteins (see [4] for a more elaborate discussion).ConclusionsThere are, however, a few fundamental aspects of pseudoknot structures that deserve special attention.", [["S-S", "CHEMICAL", 59, 62], ["RNA pseudoknots", "RNA", 13, 28], ["S-S bridges", "PROTEIN", 59, 70], ["RNA pseudoknots", "PROBLEM", 13, 28], ["a few fundamental aspects of pseudoknot structures", "PROBLEM", 156, 206], ["RNA pseudoknots", "OBSERVATION", 13, 28], ["few", "OBSERVATION_MODIFIER", 158, 161], ["pseudoknot structures", "OBSERVATION", 185, 206]]], ["First of all, it is essential that the structure of one or more pseudoknots of the simple type ( Fig. 1) is determined at atomic level, because certain mechanisms and processes seem to be directly related to, or dependent on, the proper folding of this motif.", [["this motif", "TREATMENT", 248, 258], ["one", "OBSERVATION_MODIFIER", 52, 55], ["more", "OBSERVATION_MODIFIER", 59, 63], ["pseudoknots", "OBSERVATION", 64, 75], ["simple type", "OBSERVATION_MODIFIER", 83, 94]]], ["Good examples are the pseudoknot-dependent frameshifting in many viral RNAs, the binding of gene 32 protein to the pseudoknot in its own messenger RNA, or the regulation of translation by the three consecutive pseudoknots in the 3' UTR of tobacco mosaic virus RNA.ConclusionsIt is also intriguing that a pseudoknot structure is sometimes specifically recognized by proteins.", [["3' UTR", "CELLULAR_COMPONENT", 229, 235], ["tobacco mosaic virus", "ORGANISM", 239, 259], ["viral RNAs", "RNA", 65, 75], ["messenger RNA", "RNA", 137, 150], ["3' UTR", "DNA", 229, 235], ["tobacco mosaic virus RNA", "RNA", 239, 263], ["tobacco mosaic virus", "SPECIES", 239, 259], ["tobacco mosaic virus", "SPECIES", 239, 259], ["the pseudoknot-dependent frameshifting", "PROBLEM", 18, 56], ["many viral RNAs", "PROBLEM", 60, 75], ["the three consecutive pseudoknots", "PROBLEM", 188, 221], ["tobacco mosaic virus RNA", "PROBLEM", 239, 263], ["a pseudoknot structure", "PROBLEM", 302, 324], ["pseudoknot", "OBSERVATION", 22, 32], ["dependent", "OBSERVATION_MODIFIER", 33, 42], ["frameshifting", "OBSERVATION", 43, 56], ["many", "OBSERVATION_MODIFIER", 60, 64], ["viral RNAs", "OBSERVATION", 65, 75], ["tobacco mosaic virus RNA", "OBSERVATION", 239, 263], ["pseudoknot structure", "OBSERVATION", 304, 324]]], ["Using their SELEX method for selecting RNAs that bind with a high affinity to a certain protein, they often find that the 'winning' ligands are pseudoknots.", [["their SELEX method", "TREATMENT", 6, 24], ["selecting RNAs", "TREATMENT", 29, 43], ["a high affinity", "PROBLEM", 59, 74], ["pseudoknots", "PROBLEM", 144, 155]]], ["This was first discov-4red for the HIV reverse transcriptase [44\" ], while a second example was provided when the nerve growth factor (NGF) was tested [45] .", [["nerve growth factor", "GENE_OR_GENE_PRODUCT", 114, 133], ["NGF", "GENE_OR_GENE_PRODUCT", 135, 138], ["HIV reverse transcriptase", "PROTEIN", 35, 60], ["nerve growth factor", "PROTEIN", 114, 133], ["NGF", "PROTEIN", 135, 138], ["HIV", "SPECIES", 35, 38], ["the HIV reverse transcriptase", "TREATMENT", 31, 60], ["nerve", "ANATOMY", 114, 119]]], ["Both pseudoknot structures were of the type illustrated in Fig. 1 , except that an extra hairpin is present in the L2 loop in the case of NGF.", [["NGF", "GENE_OR_GENE_PRODUCT", 138, 141], ["NGF", "PROTEIN", 138, 141], ["an extra hairpin", "TREATMENT", 80, 96], ["pseudoknot", "OBSERVATION", 5, 15], ["extra", "OBSERVATION_MODIFIER", 83, 88], ["hairpin", "OBSERVATION", 89, 96], ["L2 loop", "ANATOMY", 115, 122], ["NGF", "OBSERVATION", 138, 141]]], ["These findings suggest that pseudoknot struc-tures are very well equipped for binding to proteins.", [["pseudoknot struc-tures", "PROBLEM", 28, 50], ["pseudoknot struc", "OBSERVATION", 28, 44]]], ["It is obvious that elucidation of the detailed structure of a pseudoknot-protein complex is highly desirable.References and recommended readingPapers of particular interest, published within the annual period of review, have been highlighted as: \u2022 of special interest ,,\u2022 of outstanding interest", [["pseudoknot-protein complex", "PROTEIN", 62, 88], ["a pseudoknot-protein complex", "PROBLEM", 60, 88], ["pseudoknot", "OBSERVATION", 62, 72]]]], "PMC7252128": [["As this report is being written (04/09), there are 1.51 million confirmed COVID-19 cases worldwide, and 434,114 in the United States.", [["COVID", "TEST", 74, 79]]], ["The healthcare system is overwhelmed by patient volume and changing guidelines during this uncertain time [1].", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["changing guidelines", "TREATMENT", 59, 78]]], ["As a result, the ability of trauma centers to care for critically injured patients will be affected.", [["trauma", "DISEASE", 28, 34], ["critically injured", "DISEASE", 55, 73], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["trauma centers", "TREATMENT", 28, 42], ["critically injured patients", "PROBLEM", 55, 82]]], ["To alleviate the burden on trauma center preparation for triennial verification, the American College of Surgeons Committee on Trauma (ACS-COT) has granted extensions for trauma centers that are verified or applying for verification [2].", [["trauma", "DISEASE", 27, 33], ["Trauma", "DISEASE", 127, 133], ["ACS", "DISEASE", 135, 138], ["trauma", "DISEASE", 171, 177], ["trauma", "PROBLEM", 171, 177]]]], "PMC7416800": [["The response on this call shows an increasing scientific and quality-improving activity in this important area of care for older people, and we are proud to present the best of the submitted papers in this issue.", [["people", "ORGANISM", 129, 135], ["people", "SPECIES", 129, 135], ["increasing", "OBSERVATION_MODIFIER", 35, 45]]]], "PMC7380847": [["IntroductionCOVID-19 emerged in December 2019,1\u20134 and in a mere few months has spread to more than 104 countries, resulting in an outbreak of viral pneumonia worldwide.", [["pneumonia", "DISEASE", 148, 157], ["IntroductionCOVID", "TEST", 0, 17], ["viral pneumonia worldwide", "PROBLEM", 142, 167], ["viral", "OBSERVATION_MODIFIER", 142, 147], ["pneumonia", "OBSERVATION", 148, 157]]], ["As of 12 March 2020, the virus has reportedly caused 127 863 infections and 4718 deaths globally.5 The WHO declared COVID-19 a public health emergency of international concern on 30 January 2020 and further characterised it as a pandemic on 11 March 2020.", [["infections", "DISEASE", 61, 71], ["deaths", "DISEASE", 81, 87], ["the virus", "PROBLEM", 21, 30], ["COVID", "TEST", 116, 121]]], ["As there is no effective therapeutic or vaccine for the condition yet, rigorous implementation of traditional public health measures such as isolation, quarantine, social distancing and community containment is the principle strategy used to control the COVID-19 epidemic.6 In addition to isolating patients with confirmed COVID-19 infection from the non-infected population, it is equally if not more important to quarantine asymptomatic individuals with COVID-19 exposure in order to reduce viral spread in the community.", [["infection", "DISEASE", 332, 341], ["COVID-19", "CHEMICAL", 456, 464], ["COVID-19", "CHEMICAL", 456, 464], ["patients", "ORGANISM", 299, 307], ["COVID-19", "ORGANISM", 323, 331], ["patients", "SPECIES", 299, 307], ["COVID-19", "SPECIES", 323, 331], ["vaccine", "TREATMENT", 40, 47], ["the condition", "PROBLEM", 52, 65], ["traditional public health measures", "TREATMENT", 98, 132], ["isolation, quarantine", "TREATMENT", 141, 162], ["the principle strategy", "TREATMENT", 211, 233], ["the COVID", "TEST", 250, 259], ["COVID-19 infection", "PROBLEM", 323, 341], ["the non-infected population", "PROBLEM", 347, 374], ["COVID", "TREATMENT", 456, 461], ["viral spread", "PROBLEM", 493, 505], ["no effective", "UNCERTAINTY", 12, 24], ["infection", "OBSERVATION", 332, 341]]], ["Indeed, quarantine measures have been initiated in many countries and regions to restrict movement of asymptomatic individuals with COVID-19 exposure in the community.", [["COVID-19", "CHEMICAL", 132, 140], ["COVID-19", "CHEMICAL", 132, 140], ["quarantine measures", "TREATMENT", 8, 27], ["COVID", "TREATMENT", 132, 137]]], ["In addition, they are also asked to perform fever and symptom surveillance during the presumed incubation period (14 days).", [["fever", "DISEASE", 44, 49], ["fever", "PROBLEM", 44, 49], ["symptom surveillance", "TEST", 54, 74]]], ["However, as such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness Furthermore, it has been reported that as many as 50% of COVID-19 infected patients had no fever until developing full-blown disease,3 7 thereby body temperature surveillance per se may not be sufficient to detect early disease progression.IntroductionIn the past few decades, advances in technology has allowed progressive miniaturisation of electronic biosensors such that they can be incorporated into wearable devices to allow continuous monitoring of physiological parameters such as skin temperature, heart rate, respiratory rate, oxygen saturation, perspiration and activity of ambulatory subjects in a 24/7 basis.8 9 Together with state-of-the-art telecommunication technologies that allow instantaneous and multidirectional massive data transfer, it is now possible to remotely monitor physiological parameters of a large number of subjects in real time.", [["body", "ANATOMY", 271, 275], ["skin", "ANATOMY", 615, 619], ["heart", "ANATOMY", 633, 638], ["respiratory", "ANATOMY", 645, 656], ["fever", "DISEASE", 217, 222], ["oxygen", "CHEMICAL", 663, 669], ["oxygen", "CHEMICAL", 663, 669], ["COVID-19", "ORGANISM", 183, 191], ["patients", "ORGANISM", 201, 209], ["body", "ORGANISM_SUBDIVISION", 271, 275], ["skin", "ORGAN", 615, 619], ["heart", "ORGAN", 633, 638], ["oxygen", "SIMPLE_CHEMICAL", 663, 669], ["patients", "SPECIES", 201, 209], ["COVID", "TEST", 183, 188], ["fever", "PROBLEM", 217, 222], ["full-blown disease", "PROBLEM", 240, 258], ["body temperature surveillance", "TEST", 271, 300], ["early disease progression", "PROBLEM", 340, 365], ["IntroductionIn", "TREATMENT", 366, 380], ["electronic biosensors", "TREATMENT", 469, 490], ["wearable devices", "TREATMENT", 531, 547], ["continuous monitoring of physiological parameters", "TEST", 557, 606], ["skin temperature", "TEST", 615, 631], ["heart rate", "TEST", 633, 643], ["respiratory rate", "TEST", 645, 661], ["oxygen saturation", "TEST", 663, 680], ["perspiration", "PROBLEM", 682, 694], ["ambulatory subjects", "TREATMENT", 711, 730], ["no", "UNCERTAINTY", 214, 216], ["fever", "OBSERVATION", 217, 222], ["blown disease", "OBSERVATION", 245, 258], ["early", "OBSERVATION_MODIFIER", 340, 345], ["disease", "OBSERVATION", 346, 353], ["heart", "ANATOMY", 633, 638], ["respiratory rate", "OBSERVATION", 645, 661], ["oxygen saturation", "OBSERVATION", 663, 680], ["large", "OBSERVATION_MODIFIER", 951, 956]]], ["These data can subsequently be relayed to physicians to allow timely intervention.", [["timely intervention", "TREATMENT", 62, 81]]], ["Nonetheless, the potentials of using wearable biosensors to improve disease management have not been fully explored in real world settings.", [["wearable biosensors", "TREATMENT", 37, 56], ["disease management", "TREATMENT", 68, 86]]], ["The current study aims to assess the impact of performing continuous remote monitoring of asymptomatic subjects with COVID-19 exposure under mandatory quarantine at designated facilities in Hong Kong using the Biovitals Sentinel platform.", [["COVID-19", "CHEMICAL", 117, 125], ["COVID-19", "CHEMICAL", 117, 125], ["The current study", "TEST", 0, 17], ["COVID", "TREATMENT", 117, 122]]], ["The platform consists of a clinical-grade wearable biosensor worn on the upper arm called Everion (Biofourmis, Singapore) which allows continuous multidimensional physiological parameters monitoring and an artificial intelligence-powered physiology analytical platform Biovitals (Biofourmis, Singapore) for detecting disease progression.", [["continuous multidimensional physiological parameters monitoring", "TEST", 135, 198], ["an artificial intelligence", "TEST", 203, 229], ["disease progression", "PROBLEM", 317, 336], ["upper", "ANATOMY_MODIFIER", 73, 78], ["arm", "ANATOMY", 79, 82], ["disease", "OBSERVATION", 317, 324]]], ["The research hypothesis is that by collecting continuous physiological data using Biovitals Sentinel and patient-reported outcomes, and processing them with a cloud-based analytics platform, Biovitals, it will be possible to identify physiology changes and detect other clinically meaningful alerts that will indicate early clinical progression in quarantined subjects with COVID-19 exposure.Study design and participants ::: Methods and analysisThis is a prospective, randomised-controlled, open-labelled study.", [["COVID-19", "CHEMICAL", 374, 382], ["COVID-19", "CHEMICAL", 374, 382], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["participants", "SPECIES", 409, 421], ["physiology changes", "PROBLEM", 234, 252], ["COVID", "TEST", 374, 379], ["Methods and analysis", "TEST", 426, 446], ["open-labelled study", "TEST", 492, 511]]], ["Asymptomatic subjects with COVID-19 exposure at designated facilities under the compulsory quarantine measure introduced on 8 February 2020 in Hong Kong, fulfilling inclusion and exclusion criteria of the study will be invited to participate in this study.", [["COVID-19", "CHEMICAL", 27, 35], ["Asymptomatic subjects", "PROBLEM", 0, 21], ["the study", "TEST", 201, 210], ["this study", "TEST", 245, 255]]], ["Box 1 summarises the inclusion and exclusion criteria.Study design and participants ::: Methods and analysisThere will be two phases of subject recruitment.", [["participants", "SPECIES", 71, 83], ["Methods and analysis", "TEST", 88, 108], ["subject recruitment", "TREATMENT", 136, 155]]], ["The initial run-in phase is a single-arm, open-label study design confirmation phase with approximately 100 subjects.", [["open-label study", "TEST", 42, 58], ["arm", "ANATOMY", 37, 40]]], ["All subjects will undergo remote physiological monitoring using the Biovitals Sentinel platform.", [["remote physiological monitoring", "TEST", 26, 57]]], ["The data collected from the platform and clinical data from the health system will be used to validate the solution and the study design for the randomised phase.", [["The data", "TEST", 0, 8], ["the study", "TEST", 120, 129]]], ["In the subsequent randomised phase, subjects will be randomised in a 1:1 ratio to1 continuous remote physiological monitoring using the Biovitals Sentinel platform (intervention group) or2 usual care (control group) during the 14-day quarantine period (figure 1).Study design and participants ::: Methods and analysisIn addition to daily body temperature monitoring and symptom surveillance in the control group, subjects randomised to the intervention group will wear a multisensor-based wearable armband biosensor, Everion, during the quarantine period.", [["body", "ANATOMY", 338, 342], ["body", "ORGANISM_SUBDIVISION", 338, 342], ["participants", "SPECIES", 280, 292], ["the Biovitals Sentinel platform (intervention group)", "TREATMENT", 132, 184], ["daily body temperature monitoring", "TEST", 332, 365], ["symptom surveillance", "TEST", 370, 390], ["a multisensor-based wearable armband biosensor", "TREATMENT", 469, 515], ["Everion", "TREATMENT", 517, 524]]], ["Everion is a wearable vital sign monitor capable of tracking heart rate, heart rate variability, blood oxygen saturation, blood pulse wave, respiration rate at rest, skin blood perfusion, activity, steps, skin temperature, barometric pressure and electrodermal activity.", [["heart", "ANATOMY", 61, 66], ["heart", "ANATOMY", 73, 78], ["blood", "ANATOMY", 97, 102], ["blood", "ANATOMY", 122, 127], ["skin", "ANATOMY", 166, 170], ["blood", "ANATOMY", 171, 176], ["skin", "ANATOMY", 205, 209], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 103, 109], ["heart", "ORGAN", 61, 66], ["heart", "ORGAN", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["skin blood", "MULTI-TISSUE_STRUCTURE", 166, 176], ["skin", "ORGAN", 205, 209], ["a wearable vital sign monitor", "TEST", 11, 40], ["tracking heart rate", "TEST", 52, 71], ["heart rate variability", "TEST", 73, 95], ["blood oxygen saturation", "TEST", 97, 120], ["blood pulse wave", "TEST", 122, 138], ["respiration rate", "TEST", 140, 156], ["skin blood perfusion", "TEST", 166, 186], ["skin temperature", "TEST", 205, 221], ["barometric pressure", "TEST", 223, 242], ["electrodermal activity", "TEST", 247, 269], ["heart", "ANATOMY", 73, 78], ["skin", "ANATOMY", 166, 170], ["skin", "ANATOMY", 205, 209]]], ["The wearable biosensors will be worn for 22\u201323 hours per day and be recharged while bathing or showering.", [["The wearable biosensors", "TREATMENT", 0, 23]]], ["In addition, patients will be instructed to report their symptoms and record their cough sounds using the specially designed smartphone application daily.", [["cough", "DISEASE", 83, 88], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["their symptoms", "PROBLEM", 51, 65], ["their cough sounds", "PROBLEM", 77, 95]]], ["The physiological parameters obtained will be automatically transferred in real time through a specially designed smartphone application to a secured cloud storage for processing using the Biovitals Analytics Engine.", [["a secured cloud storage", "TREATMENT", 140, 163]]], ["The Biovitals Analytics Engine will process these multidimensional physiology parameters to detect subtle physiological changes preceding critical events, thereby enabling clinicians to promptly review and intervene.", [["subtle physiological changes", "PROBLEM", 99, 127]]], ["As an additional safety measure, specific alert thresholds for individual physiological parameters have also been set.", [["an additional safety measure", "TEST", 3, 31], ["specific alert thresholds", "TEST", 33, 58], ["individual physiological parameters", "TEST", 63, 98]]], ["Study investigators will remotely review the individual subject\u2019s physiological parameters every 4 hours, and order diagnostic tests for COVID-19 infection through instant communication (electronic communication and/or phone).", [["infection", "DISEASE", 146, 155], ["Study investigators", "TEST", 0, 19], ["diagnostic tests", "TEST", 116, 132], ["COVID", "TEST", 137, 142]]], ["In addition, after the initial run-in phase and having recruited an adequate number of subjects with subsequently confirmed COVID-19, the collected physiological data will be used to enhance the Biovitals prediction model for COVID-19 infection using machine learning technology.Outcomes ::: Methods and analysisThe primary outcome measure is the time to detection of COVID-19 infection using nasopharyngeal sampling for COVID-19 reverse transcription polymerase chain reaction (RT-PCR).Outcomes ::: Methods and analysisThe secondary outcomes include wearable device adherence, sensitivity, specificity, positive predictive value, negative predictive value and the area under the receiver operating characteristic curve of Biovitals Sentinel in identifying COVID-19 subjects, viral load of COVID-19 using nasopharyngeal sampling for RT-PCR at diagnosis, cross-infection rate within family cluster, length of hospital stay, length of intensive care unit stay, non-invasive and invasive ventilation use, National Early Warning Score 2, worsening of comorbidities and mortality.Sample size and statistical analysis ::: Methods and analysisThe sample size for the randomisation phase will be determined based on the result from the phase I run-in period involving approximately 100 subjects.", [["nasopharyngeal", "ANATOMY", 393, 407], ["nasopharyngeal", "ANATOMY", 805, 819], ["infection", "DISEASE", 235, 244], ["COVID-19", "CHEMICAL", 368, 376], ["infection", "DISEASE", 377, 386], ["nasopharyngeal", "ORGAN", 393, 407], ["nasopharyngeal", "ORGAN", 805, 819], ["COVID-19", "SPECIES", 226, 234], ["COVID-19", "SPECIES", 368, 376], ["COVID", "TEST", 124, 129], ["COVID-19 infection", "PROBLEM", 226, 244], ["learning technology", "TREATMENT", 259, 278], ["Methods and analysis", "TEST", 292, 312], ["COVID-19 infection", "PROBLEM", 368, 386], ["nasopharyngeal sampling", "TREATMENT", 393, 416], ["COVID", "TEST", 421, 426], ["RT-PCR", "TEST", 479, 485], ["Methods and analysis", "TEST", 500, 520], ["wearable device adherence", "TREATMENT", 551, 576], ["sensitivity", "TEST", 578, 589], ["Biovitals", "TEST", 723, 732], ["COVID", "TEST", 757, 762], ["viral load", "TEST", 776, 786], ["COVID", "TEST", 790, 795], ["nasopharyngeal sampling", "TEST", 805, 828], ["RT-PCR", "TEST", 833, 839], ["non-invasive and invasive ventilation", "TREATMENT", 959, 996], ["worsening of comorbidities", "PROBLEM", 1034, 1060], ["mortality", "PROBLEM", 1065, 1074], ["statistical analysis", "TEST", 1091, 1111], ["Methods and analysis", "TEST", 1116, 1136], ["the randomisation phase", "TEST", 1156, 1179], ["invasive ventilation", "OBSERVATION", 976, 996], ["size", "OBSERVATION_MODIFIER", 1082, 1086], ["size", "OBSERVATION_MODIFIER", 1147, 1151]]], ["The sample size of the run-in period was determined by convenience sampling because there were no previous research-themed studies.", [["themed studies", "TEST", 116, 130], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["To explore and estimate the effect of longitudinally measured clinical and physiological data on the time-to-event of primary and secondary outcomes, joint modelling of longitudinal and time-to-event data analysis, and other statistical and/or machine learning-based methods will be used.", [["primary and secondary outcomes", "PROBLEM", 118, 148], ["data analysis", "TEST", 200, 213], ["based methods", "TREATMENT", 261, 274], ["joint", "ANATOMY", 150, 155]]], ["Baseline characteristics of the two study groups will be compared using analysis of variance, \u03c72 or Fisher\u2019s exact tests, as appropriate.", [["the two study groups", "TEST", 28, 48], ["exact tests", "TEST", 109, 120]]], ["Cox regression analysis will be performed to compare the time to diagnosis of COVID-19 infection between the study groups with adjustment for potential confounders.", [["infection", "DISEASE", 87, 96], ["Cox regression analysis", "TEST", 0, 23], ["COVID-19 infection", "PROBLEM", 78, 96], ["the study", "TEST", 105, 114], ["infection", "OBSERVATION", 87, 96]]], ["For other secondary outcomes, the generalised estimating equations model will be used to compare the differential changes in each of the outcomes across the 14-day time points between the two study arms, with adjustment for potential confounders.Randomisation ::: Methods and analysisPatients will be randomised either to the Intervention group or Control group using a computer-generated random number to derive allocation sequence prior to enrolment in the study.", [["other secondary outcomes", "PROBLEM", 4, 28], ["the generalised estimating equations model", "PROBLEM", 30, 72], ["the study", "TEST", 455, 464]]], ["If a subject is found to be ineligible for the study after randomisation, the original assignment will be reassigned to the next eligible subject.", [["the study", "TEST", 43, 52]]], ["Data staff responsible for data entry will be blinded from randomisation assignment.Data collection and management ::: Methods and analysisAfter enrolment, each subject will be assigned a unique identifier to be used in the database.", [["Methods and analysisAfter enrolment", "TREATMENT", 119, 154]]], ["Data will be entered by study staff and data accuracy will be verified by the principal investigator of the study.", [["the study", "TEST", 104, 113]]], ["Data quality control measures include queries to identify missing data, outliers and discrepancies.", [["missing data", "PROBLEM", 58, 70]]], ["Subjects who withdraw from the study will have continuous monitoring stopped, usual care continued and final outcome collected for analysis.Data monitoring ::: Methods and analysisDue to the minimal risk nature of the study, there is no external data and safety monitoring board.", [["Subjects", "ORGANISM", 0, 8], ["the study", "TEST", 27, 36], ["continuous monitoring", "TEST", 47, 68], ["usual care", "TREATMENT", 78, 88], ["analysis", "TEST", 131, 139], ["Data monitoring", "TEST", 140, 155], ["Methods", "TREATMENT", 160, 167], ["the study", "TEST", 214, 223], ["external data", "TEST", 237, 250]]], ["The principal investigator and study staff will monitor data internally and meet weekly in person or by phone to ensure the study is proceeding as intended.Patient and public involvement ::: Methods and analysisWe received inputs from quarantined individuals and healthcare providers which guided the design of the current study and the choice of research questions.", [["person", "SPECIES", 91, 97], ["Patient", "SPECIES", 156, 163], ["the study", "TEST", 120, 129], ["the current study", "TEST", 311, 328]]], ["No quarantined individuals or the public were directly involved in the design of the study and choice of outcome measures.", [["quarantined individuals", "PROBLEM", 3, 26], ["the study", "TEST", 81, 90], ["outcome measures", "TREATMENT", 105, 121]]], ["No quarantined individuals or the public will be involved in recruitment or conduct of the study.", [["quarantined individuals", "PROBLEM", 3, 26], ["the study", "TEST", 87, 96]]], ["Results of the study will be disseminated to subjects, the public and the scientific community.Ethics and disseminationThe investigation conforms to the principles outlined in the Declaration of Helsinki.", [["the study", "TEST", 11, 20]]], ["The study protocol has been approved by the Institutional Review Board of The University of Hong Kong, and Hong Kong West Cluster, Hospital Authority, Hong Kong.", [["The study protocol", "TEST", 0, 18]]], ["Written informed consent will be obtained from all study participants by the study staff responsible for recruitment (online supplementary files 1 and 2).", [["participants", "SPECIES", 57, 69]]], ["Important protocol modifications will be conveyed to investigators, the institutional review board, trial registries, regulators, journals and trial participants.", [["participants", "SPECIES", 149, 161], ["Important protocol modifications", "TREATMENT", 0, 32]]], ["The personal identity of the subjects will not be used for any public purpose or for publication, nor will it be transmitted outside of the study team.Ethics and disseminationThe data set used during the study will be available from the corresponding author upon reasonable request.", [["the study", "TEST", 200, 209]]], ["Collaboration with other investigators interested in optimising quarantine strategies for COVID-19 will be welcomed.", [["quarantine strategies", "TREATMENT", 64, 85], ["COVID", "TREATMENT", 90, 95]]], ["The results of the trial will be published in peer-reviewed journals and presented in conferences.DiscussionEmerging in December 2019, COVID-19 has spread at a rate far outstripping the capacity of many medical systems.14 Traditionally, public health measures including isolation and quarantine are the cornerstone to curb the spread of infectious diseases by interrupting person-to-person transmission, and are particularly important when no specific therapeutics or vaccines are available.6 Indeed, early detection of infected individuals among those with viral exposure followed by isolation would effectively reduce overt viral shedding in the community; nonetheless, early detection can be challenging.DiscussionSymptom and fever surveillance among individuals with COVID-19 exposure is a commonly used method to detect infected individuals in the absence of medical testing.", [["infectious diseases", "DISEASE", 337, 356], ["fever", "DISEASE", 729, 734], ["COVID-19", "CHEMICAL", 771, 779], ["individuals", "ORGANISM", 529, 540], ["individuals", "ORGANISM", 754, 765], ["person", "SPECIES", 373, 379], ["COVID", "TEST", 135, 140], ["public health measures", "TREATMENT", 237, 259], ["isolation", "TREATMENT", 270, 279], ["quarantine", "TREATMENT", 284, 294], ["infectious diseases", "PROBLEM", 337, 356], ["vaccines", "TREATMENT", 468, 476], ["infected individuals", "PROBLEM", 520, 540], ["viral exposure", "TREATMENT", 558, 572], ["isolation", "TREATMENT", 585, 594], ["overt viral shedding", "PROBLEM", 620, 640], ["fever", "PROBLEM", 729, 734], ["COVID", "TEST", 771, 776], ["infected individuals", "PROBLEM", 825, 845], ["medical testing", "TEST", 864, 879], ["infectious", "OBSERVATION", 337, 347], ["infected", "OBSERVATION_MODIFIER", 520, 528], ["viral", "OBSERVATION", 626, 631]]], ["However, symptom declaration and intermittent body temperature measurement per se may not be sufficient to detect early disease progression.", [["body", "ANATOMY", 46, 50], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["symptom", "PROBLEM", 9, 16], ["intermittent body temperature measurement", "TEST", 33, 74], ["early disease progression", "PROBLEM", 114, 139], ["early", "OBSERVATION_MODIFIER", 114, 119], ["disease", "OBSERVATION", 120, 127]]], ["Indeed, up to 50% COVID-19 infected patients were so-called \u2018asymptomatic\u2019 and did not have fever until the full-blown disease.7 Conceivably, while fever is one of the cardinal symptoms specific for active infection, many other physiological alterations such as heart rate, respiratory rate, oxygen saturation, perspiration and so on may likewise indicate active infection.", [["heart", "ANATOMY", 262, 267], ["respiratory", "ANATOMY", 274, 285], ["fever", "DISEASE", 92, 97], ["fever", "DISEASE", 148, 153], ["infection", "DISEASE", 206, 215], ["oxygen", "CHEMICAL", 292, 298], ["infection", "DISEASE", 363, 372], ["oxygen", "CHEMICAL", 292, 298], ["patients", "ORGANISM", 36, 44], ["heart", "ORGAN", 262, 267], ["oxygen", "SIMPLE_CHEMICAL", 292, 298], ["patients", "SPECIES", 36, 44], ["fever", "PROBLEM", 92, 97], ["blown disease", "PROBLEM", 113, 126], ["fever", "PROBLEM", 148, 153], ["the cardinal symptoms", "PROBLEM", 164, 185], ["active infection", "PROBLEM", 199, 215], ["many other physiological alterations", "PROBLEM", 217, 253], ["heart rate", "TEST", 262, 272], ["respiratory rate", "TEST", 274, 290], ["oxygen saturation", "TEST", 292, 309], ["perspiration", "PROBLEM", 311, 323], ["active infection", "PROBLEM", 356, 372], ["blown disease", "OBSERVATION", 113, 126], ["active", "OBSERVATION_MODIFIER", 199, 205], ["infection", "OBSERVATION", 206, 215], ["heart", "ANATOMY", 262, 267], ["respiratory rate", "OBSERVATION", 274, 290], ["oxygen saturation", "OBSERVATION", 292, 309], ["active", "OBSERVATION_MODIFIER", 356, 362], ["infection", "OBSERVATION", 363, 372]]], ["However, practically speaking, they are more difficult to accurately measure without medical training.DiscussionThe intervention arm of the current study differs from the existing symptom and fever surveillance-based quarantine programme in several important aspects.", [["fever", "DISEASE", 192, 197], ["medical training", "TREATMENT", 85, 101], ["the current study", "TEST", 136, 153], ["the existing symptom", "PROBLEM", 167, 187], ["fever surveillance", "TEST", 192, 210], ["quarantine programme", "TREATMENT", 217, 237]]], ["By incorporating a wide range of continuously collected physiological parameters instead of solely relying on intermittent body temperature, it is possible to more accurately assess an individual\u2019s physiological changes for detecting early disease progression.9 At the same time, the use of contemporary mobile communication technology facilitates automatic collection and transfer of physiological data.", [["body", "ANATOMY", 123, 127], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["intermittent body temperature", "PROBLEM", 110, 139], ["early disease progression", "PROBLEM", 234, 259], ["contemporary mobile communication technology", "TREATMENT", 291, 335]]], ["These measures can enhance patient compliance with the monitoring system as well as greatly shorten the time between detection of an abnormality and subsequent intervention.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["the monitoring system", "TEST", 51, 72], ["an abnormality", "PROBLEM", 130, 144], ["subsequent intervention", "TREATMENT", 149, 172], ["abnormality", "OBSERVATION", 133, 144]]], ["In the past decades, wearable technology has been increasingly used for medical diagnosis, most notably in arrhythmia detection.15\u201321 Indeed, by continuously collecting multidimensional physiological parameters and analysing them with machine learning techniques, it is possible to acquire a much more in-depth understanding of different disease processes, which potentially allows us to improve clinical management.", [["arrhythmia", "DISEASE", 107, 117], ["wearable technology", "TREATMENT", 21, 40], ["machine learning techniques", "TREATMENT", 235, 262], ["different disease processes", "PROBLEM", 328, 355], ["clinical management", "TREATMENT", 396, 415], ["disease", "OBSERVATION", 338, 345]]], ["Nonetheless, such potentials have not been fully explored in real world disease management.", [["real world disease management", "TREATMENT", 61, 90]]], ["In the short term, the results of the current study may provide insights into detecting disease progression of COVID-19 through physiological data monitoring and possible ways to reduce the spread of the disease.", [["COVID-19", "CELL", 111, 119], ["the current study", "TEST", 34, 51], ["COVID", "TEST", 111, 116], ["physiological data monitoring", "TEST", 128, 157], ["the disease", "PROBLEM", 200, 211], ["short term", "OBSERVATION_MODIFIER", 7, 17], ["disease", "OBSERVATION", 204, 211]]], ["In the long term, the study may demonstrate an important example of how wearable technologies and machine learning techniques can be incorporated into existing medical services.DiscussionThe clinical trial is limited by its single-centred characteristic and being exploratory in nature.", [["the study", "TEST", 18, 27], ["machine learning techniques", "TREATMENT", 98, 125], ["long term", "OBSERVATION_MODIFIER", 7, 16]]]], "PMC7416587": [["HintergrundEnde Dezember 2019 wurde in der Stadt Wuhan, China, erstmalig eine durch ein neuartiges Coronavirus (SARS-CoV-2) verursachte Lungenerkrankung beschrieben, die am 11.02.2020 von der World Health Organization (WHO) als \u201ecoronavirus disease 2019\u201c (COVID-19) bezeichnet wurde [1\u20133].", [["\u201ecoronavirus disease", "DISEASE", 228, 248], ["erstmalig eine durch ein neuartiges Coronavirus (SARS-CoV-2) verursachte Lungenerkrankung beschrieben, die am 11.02.2020 von der World Health Organization (WHO) als \u201ecoronavirus disease 2019\u201c (COVID-19", "SPECIES", 63, 264], ["Coronavirus", "PROBLEM", 99, 110], ["als \u201ecoronavirus disease", "PROBLEM", 224, 248], ["COVID", "TEST", 256, 261]]], ["Um Krankenhauskapazit\u00e4ten, Schutzausr\u00fcstungen und Beatmungsger\u00e4te f\u00fcr eine steigende Zahl von COVID-19-Patienten bereitzustellen, wurden die chirurgischen Fachdisziplinen angewiesen, alle elektiven Operationen zu verschieben und Personal bei Bedarf auf Intensiv- und COVID-19-Stationen umzuverteilen [5].", [["Schutzausr\u00fcstungen und Beatmungsger\u00e4te f\u00fcr eine steigende Zahl von COVID-19-Patienten bereitzustellen, wurden die chirurgischen Fachdisziplinen angewiesen, alle elektiven Operationen zu verschieben und Personal bei Bedarf auf Intensiv- und COVID-19-Stationen umzuverteilen", "SPECIES", 27, 299], ["Schutzausr\u00fcstungen", "TREATMENT", 27, 45]]], ["Die Deutsche Gesellschaft f\u00fcr Allgemein- und Viszeralchirurgie ver\u00f6ffentlichte am 22.03.2020 eine Stellungnahme mit einem \u00dcberblick dringlicher Operationseingriffe, die als noch durchf\u00fchrbar anzusehen waren [6].", [["Die Deutsche Gesellschaft f\u00fcr Allgemein- und Viszeralchirurgie ver\u00f6ffentlichte am 22.03.2020 eine Stellungnahme mit einem \u00dcberblick dringlicher Operationseingriffe, die als noch durchf\u00fchrbar anzusehen waren", "SPECIES", 0, 206]]], ["Die langfristigen Auswirkungen der Aussetzung des Elektivprogramms auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken in Deutschland sind zum aktuellen Zeitpunkt noch nicht absehbar.HintergrundDie vorliegende Querschnittsstudie hat zum Ziel, den Einfluss der globalen SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken in Deutschland zu evaluieren.", [["Die langfristigen Auswirkungen der Aussetzung des Elektivprogramms auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken in Deutschland sind zum aktuellen Zeitpunkt noch nicht absehbar", "SPECIES", 0, 196], ["HintergrundDie vorliegende Querschnittsstudie hat zum Ziel, den Einfluss der globalen SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken in Deutschland zu evaluieren", "SPECIES", 197, 397], ["Pandemie auf die Allgemein", "TREATMENT", 294, 320]]], ["In der durchgef\u00fchrten Umfrage wurden Daten zu Erfahrungen bez\u00fcglich personeller Umstrukturierungen und finanziellen Belastungen sowie zur Einsch\u00e4tzung der zuk\u00fcnftigen Entwicklung erhoben.Studiendesign ::: MethodenF\u00fcr die vorliegende Querschnittsstudie wurden vom 03. bis 17.04.2020 alle Teilnehmer des Konvents der Ordinarien elektronisch zu einer anonymen Onlineumfrage eingeladen.", [["bis 17.04", "CHEMICAL", 267, 276], ["bis", "TEST", 267, 270], ["alle Teilnehmer des", "TREATMENT", 282, 301]]], ["Die Umfrage umfasste 67 Einzelfragen und Aussagen in 8 Kategorien (allgemeine Informationen, Politik, Gesundheitsbeh\u00f6rden, Krankenhausleitung, Kommunikation mit anderen Fachbereichen, Folgen der Umstrukturierungen, Auswirkungen auf die Fallzahlen, Ausblick auf die Zeit nach der SARS-CoV-2-Pandemie).", [["Folgen der Umstrukturierungen, Auswirkungen auf die Fallzahlen, Ausblick auf die Zeit nach der SARS-CoV", "SPECIES", 184, 287]]], ["Es wurde eine Kombination aus bipolaren, nummerierten Likert-Skalen (1 entspricht \u201estimme voll zu\u201c, 2 entspricht \u201estimme zu\u201c, 3 entspricht \u201eneutral\u201c, 4 entspricht \u201estimme nicht zu\u201c und 5 entspricht \u201estimme \u00fcberhaupt nicht zu\u201c), geschlossenen (ja/nein/unbekannt) und offenen Fragen verwendet.Umfrage ::: MethodenIm 1.", [["Skalen (1 entspricht \u201estimme voll zu\u201c", "TREATMENT", 61, 98], ["geschlossenen (ja/nein/unbekannt)", "TREATMENT", 228, 261], ["MethodenIm", "TREATMENT", 303, 313]]], ["Abschnitt wurden bei den Befragten allgemeine Charakteristiken (9 Fragen) erhoben.", [["Abschnitt wurden bei den Befragten allgemeine Charakteristiken (9 Fragen) erhoben", "SPECIES", 0, 81]]], ["(Politik, 5 Fragen) und 3.", [["Politik", "TEST", 1, 8]]], ["Abschnitt (Gesundheitsbeh\u00f6rden, 4 Fragen) wurden die Befragten gebeten, die Kommunikation und die von der Bundes- und Landesregierung sowie den Gesundheitsbeh\u00f6rden ergriffenen Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie zu bewerten.", [["Kommunikation und die von der Bundes- und Landesregierung sowie den Gesundheitsbeh\u00f6rden ergriffenen Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie zu bewerten", "SPECIES", 76, 236], ["CoV", "TEST", 210, 213]]], ["Kategorie (Krankenhausleitung/Klinikvorstand, 8 Fragen) wurde die Zusammenarbeit mit der Krankenhausverwaltung erfragt.", [["Kategorie (Krankenhausleitung/Klinikvorstand", "TREATMENT", 0, 44]]], ["Kategorie (Zusammenarbeit mit anderen Fachabteilungen w\u00e4hrend der SARS-CoV-2-Pandemie, 5 Fragen) untersuchte die Zusammenarbeit mit den anderen Fachabteilungen und insbesondere die Fortf\u00fchrung des interdisziplin\u00e4ren Tumorboards.", [["Zusammenarbeit mit anderen Fachabteilungen w\u00e4hrend der SARS-CoV-2-Pandemie, 5 Fragen) untersuchte die Zusammenarbeit mit den anderen Fachabteilungen und insbesondere die Fortf\u00fchrung des interdisziplin\u00e4ren", "SPECIES", 11, 215], ["Kategorie (Zusammenarbeit mit anderen Fachabteilungen", "TREATMENT", 0, 53], ["CoV", "TEST", 71, 74], ["Pandemie", "TREATMENT", 77, 85]]], ["Kategorie (Umstrukturierung/Pandemiefolgen, 28 Fragen) wurden jeweils die bisherigen Auswirkungen der SARS-CoV-2-Pandemie bewertet.", [["SARS-CoV-2-Pandemie bewertet", "SPECIES", 102, 130], ["Kategorie (Umstrukturierung/Pandemiefolgen", "TREATMENT", 0, 42]]], ["Kategorie gelegt, da die Aussetzung aller elektiven Operationen und die Neuzuweisung von Personal f\u00fcr die Betreuung der COVID-19-Patienten einen erheblichen strukturellen Einfluss auf die Abteilungen haben.", [["Aussetzung aller elektiven Operationen und die Neuzuweisung von Personal f\u00fcr die Betreuung der COVID-19-Patienten einen erheblichen strukturellen Einfluss auf die Abteilungen haben", "SPECIES", 25, 205]]], ["Kategorie (Ausblick f\u00fcr die Zeit nach der SARS-CoV-2-Pandemie, 8 Fragen) gebeten, m\u00f6gliche Ver\u00e4nderungen durch die Pandemie in der Zukunft zu bewerten.", [["Ausblick f\u00fcr die Zeit nach der SARS-CoV-2-Pandemie", "SPECIES", 11, 61], ["Pandemie", "TREATMENT", 53, 61]]], ["Die Angaben erfolgen als absolute sowie relative Zahlen und als Mittelwert (\u00b1 Standardabweichung).Allgemeine Charakteristiken ::: ErgebnisseInsgesamt nahmen 73 % der Befragten an der Umfrage teil.", [["ErgebnisseInsgesamt nahmen", "TREATMENT", 130, 156]]], ["Die Teilnehmer waren zu 93 % m\u00e4nnlich.", [["Die Teilnehmer waren zu 93", "SPECIES", 0, 26]]], ["Acht (28 %) der 29 Befragten waren unter 50 Jahre alt, 21 (72 %) waren \u00e4lter als 50 Jahre.", [["Acht", "TEST", 0, 4], ["Jahre alt", "TEST", 44, 53]]], ["Hinsichtlich der Krankenhausgr\u00f6\u00dfe (Anzahl an Betten) gaben 20 der 29 Befragten (69 %) eine Gr\u00f6\u00dfe von \u00fcber 1000 Betten an.", [["Hinsichtlich der Krankenhausgr\u00f6\u00dfe (Anzahl an Betten) gaben", "TREATMENT", 0, 58]]], ["Sieben (24 %) gaben an, unter 50 Intensivbetten im Krankenhaus zur Verf\u00fcgung zu haben.", [["Sieben", "CHEMICAL", 0, 6], ["gaben", "CHEMICAL", 14, 19], ["Sieben", "CHEMICAL", 0, 6]]], ["Zehn (34 %) bzw.", [["Zehn", "TEST", 0, 4]]], ["12 (41 %) gaben eine Gesamtzahl verf\u00fcgbarer Intensivbetten von 51 bis 100 bzw. \u00fcber 100 an.", [["bis", "TEST", 66, 69]]], ["1).Wahrnehmung der Politik und Kooperation mit den Beh\u00f6rden ::: ErgebnisseDer Aussage, dass die Informationsvermittlung der Politik zur SARS-CoV-2-Pandemie ausreichend war, stimmten 10 % und 59 % der Klinikdirektoren voll zu bzw. zu (Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 234, 237], ["Abb", "PROTEIN", 234, 237], ["Wahrnehmung der Politik und Kooperation mit den Beh\u00f6rden", "SPECIES", 3, 59], ["dass die Informationsvermittlung der Politik zur SARS-CoV-2-Pandemie ausreichend war, stimmten 10 % und 59 % der Klinikdirektoren voll zu bzw", "SPECIES", 87, 228], ["CoV", "TEST", 141, 144]]], ["Die Informationspolitik der Gesundheitsbeh\u00f6rden empfanden 48 % der Befragten als angemessen (3 % stimmten voll zu, 45 % stimmten zu).", [["3 % stimmten voll zu", "TREATMENT", 93, 113]]], ["Auch der Aussage, dass die Ma\u00dfnahmen zur Eind\u00e4mmung der Pandemie ad\u00e4quat waren, stimmte die Mehrheit zu: 21 % stimmten voll zu und 45 % stimmten zu.", [["Ma\u00dfnahmen zur Eind\u00e4mmung der Pandemie ad\u00e4quat waren, stimmte die Mehrheit zu: 21 % stimmten voll zu und 45 % stimmten", "SPECIES", 27, 144]]], ["Der Aussetzung der elektiven Operationen als ad\u00e4quate Ma\u00dfnahme stimmten 14 % voll zu und 38 % stimmten zu, hingegen stimmten 24 % nicht zu und 7 % stimmten \u00fcberhaupt nicht zu.", [["Der Aussetzung der elektiven Operationen als ad\u00e4quate Ma\u00dfnahme stimmten 14 % voll zu und 38 % stimmten zu, hingegen stimmten 24 % nicht zu und 7 % stimmten", "SPECIES", 0, 155], ["Ma\u00dfnahme stimmten", "TREATMENT", 54, 71], ["hingegen stimmten", "TREATMENT", 107, 124]]], ["Mehrheitlich zeigte sich, dass sich die Klinikdirektoren mehr finanzielle Unterst\u00fctzung gew\u00fcnscht h\u00e4tten: Insgesamt 52 % stimmten voll und 21 % stimmten der Aussage zu.Interne Kommunikation mit der Krankenhausleitung ::: ErgebnisseInsgesamt 48 % der Teilnehmer stimmten voll zu und 34 % stimmten zu, dass die Krankenhausleitung zuvor vereinbarte finanzielle Zielvorgaben aktuell als nachrangig ansieht (Abb.", [["Interne Kommunikation mit der Krankenhausleitung ::: ErgebnisseInsgesamt 48 % der Teilnehmer stimmten voll zu und 34 % stimmten zu, dass die Krankenhausleitung zuvor vereinbarte finanzielle Zielvorgaben aktuell als nachrangig ansieht", "SPECIES", 168, 401], ["zuvor", "TREATMENT", 328, 333]]], ["Insgesamt 10 % stimmten dieser Aussage nicht zu.", [["Insgesamt", "TREATMENT", 0, 9]]], ["Der Aussage, dass es finanzielle Kompensationen bei der Umverteilung des Personals gab, stimmten 3 % voll zu und 3 % stimmten zu, jedoch stimmten insgesamt 76 % der Befragten nicht zu.", [["dass es finanzielle Kompensationen bei der Umverteilung des Personals gab, stimmten 3 % voll zu und 3 % stimmten zu, jedoch stimmten insgesamt 76 % der Befragten nicht zu", "SPECIES", 13, 183]]], ["41 % stimmten voll und 24 % stimmten zu, dass ihre Krankenhausleitung zugesichert hat, dass die vorgehaltenen Betten nach der Pandemie wieder f\u00fcr die Chirurgie freigegeben werden.Zusammenarbeit mit anderen Fachabteilungen ::: ErgebnisseZwischen 75 und 86 % der Befragten stimmten den jeweiligen Aussagen zu, einen interdisziplin\u00e4ren Austausch mit der An\u00e4sthesie, Intensivmedizin, Infektiologie, Virologie, Onkologie und der Gastroenterologie zu f\u00fchren (Abb.", [["Zusammenarbeit mit anderen Fachabteilungen ::: ErgebnisseZwischen 75 und 86 % der Befragten stimmten den jeweiligen Aussagen zu, einen interdisziplin\u00e4ren Austausch mit der An\u00e4sthesie, Intensivmedizin, Infektiologie, Virologie, Onkologie und der Gastroenterologie zu f\u00fchren", "SPECIES", 179, 451], ["Intensivmedizin", "TREATMENT", 363, 378]]], ["In keinem Klinikum wurde das Tumorboard pausiert (Supplement Abb.", [["keinem Klinikum wurde das Tumorboard pausiert", "SPECIES", 3, 48]]], ["Zusatzmaterial online).Auswirkungen der Pandemie auf die Viszeralchirurgie ::: ErgebnisseIn der Umfrage zeigte sich, dass aufgrund der SARS-CoV-2-Pandemie die Bettenkapazit\u00e4t der universit\u00e4ren Allgemein- und Viszeralchirurgie vor\u00fcbergehend im Mittel um 38 \u00b1 19 % reduziert wurde (Tab.", [["ErgebnisseIn der Umfrage zeigte sich, dass aufgrund der SARS-CoV-2-Pandemie die Bettenkapazit\u00e4t der universit\u00e4ren Allgemein- und Viszeralchirurgie vor\u00fcbergehend im Mittel um 38 \u00b1 19 % reduziert wurde", "SPECIES", 79, 278], ["Pandemie", "TREATMENT", 146, 154], ["Bettenkapazit\u00e4t der universit\u00e4ren Allgemein", "TREATMENT", 159, 202], ["Viszeralchirurgie vor\u00fcbergehend im Mittel um", "TREATMENT", 208, 252]]], ["Die Bettenauslastung wurde dabei mit 62 \u00b1 23 % angegeben.", [["angegeben", "CHEMICAL", 47, 56]]], ["Die Operationssaalkapazit\u00e4t wurde um durchschnittlich 45 \u00b1 16 % reduziert.", [["Die Operationssaalkapazit\u00e4t wurde um durchschnittlich", "TREATMENT", 0, 53]]], ["Die Auslastung der reduzierten Operationsaalkapazit\u00e4t lag im Mittel bei 69 \u00b1 28 %.", [["Die Auslastung der reduzierten Operationsaalkapazit\u00e4t lag im Mittel bei 69", "SPECIES", 0, 74]]], ["Laut Studienteilnehmern waren auch andere operative Fachabteilungen von einer Reduktion der Betten- sowie Operationsaalkapazit\u00e4t betroffen.", [["Operationsaalkapazit\u00e4t betroffen", "TREATMENT", 106, 138]]], ["Der erwartete Verlust f\u00fcr den Umsatz 2020 wurde im Mittel bei 28 \u00b1 16 % angegeben.", [["angegeben", "CHEMICAL", 72, 81], ["Der erwartete Verlust f\u00fcr den Umsatz 2020 wurde im Mittel bei 28 \u00b1 16 % angegeben", "SPECIES", 0, 81], ["bei", "TEST", 58, 61]]], ["93 % der Studienteilnehmer waren \u00fcberzeugt, dass Patienten aus Sorge vor einer COVID-19-Infektion elektive Operationen absagten (Tab.", [["COVID", "TEST", 79, 84]]], ["26 % stimmten zu, dass die Anzahl der Notfalloperationen gesunken ist, bei 56 % war diese gleich und bei 19 % stieg die Anzahl an Notoperationen an.", [["Anzahl der Notfalloperationen gesunken ist, bei 56 % war diese gleich und bei 19 % stieg", "SPECIES", 27, 115]]], ["Es zeigte sich eine deutliche Auswirkung der Pandemie auf die Behandlung onkologischer Patienten: 65 % der Befragten gaben an, weniger onkologische Patienten in der Sprechstunde zu behandeln, lediglich 27 % gaben eine gleichbleibende Anzahl an.Ausblick auf die Zeit nach der SARS-CoV2-Pandemie ::: ErgebnisseDie Studienteilnehmer wurden zu den Auswirkungen der Pandemie auf die Bezahlung des Pflege- und \u00c4rztepersonals befragt.", [["Ausblick auf die Zeit nach der SARS-CoV2-Pandemie", "SPECIES", 244, 293], ["ErgebnisseDie Studienteilnehmer wurden zu den Auswirkungen der Pandemie auf die Bezahlung des Pflege- und \u00c4rztepersonals befragt", "SPECIES", 298, 426]]], ["Etwa 44 % der Ordinarien gehen davon aus, dass vor allem Pflegekr\u00e4fte k\u00fcnftig besser bezahlt werden.", [["Etwa", "TEST", 0, 4]]], ["Hingegen stimmte keiner der Aussage zu, dass es zuk\u00fcnftig eine bessere Bezahlung f\u00fcr das \u00e4rztliche Personal geben werde.", [["Hingegen stimmte keiner der Aussage zu, dass es zuk\u00fcnftig eine bessere Bezahlung f\u00fcr das \u00e4rztliche Personal geben werde", "SPECIES", 0, 119]]], ["10 % stimmten voll und 21 % stimmten zu, dass die Allgemein- und Viszeralchirurgie geschw\u00e4cht aus der SARS-CoV-2-Pandemie hervorgehen wird, wohingegen insgesamt 62 % der Aussage nicht zustimmten (Abb.", [["dass die Allgemein- und Viszeralchirurgie geschw\u00e4cht aus der SARS-CoV-2-Pandemie hervorgehen wird, wohingegen insgesamt 62 % der Aussage nicht zustimmten", "SPECIES", 41, 194], ["CoV", "TEST", 107, 110], ["Pandemie hervorgehen wird", "TREATMENT", 113, 138]]], ["76\u201379 % der Studienteilnehmer gingen davon aus, dass es nicht zu Ver\u00e4nderungen des Personals und der Bettenanzahl kommen wird und lediglich 7\u201310 % der Befragten gingen davon aus, in Bezug auf diese Parameter nach der Pandemie geschw\u00e4cht zu sein.DiskussionDie vorliegende Querschnittsstudie liefert erste Daten zur Auswirkungen der SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken w\u00e4hrend der Aussetzung aller Elektivoperationen.", [["dass es nicht zu Ver\u00e4nderungen des Personals und der Bettenanzahl kommen wird und lediglich 7\u201310 % der Befragten gingen davon aus, in Bezug auf diese Parameter nach der Pandemie geschw\u00e4cht zu sein", "SPECIES", 48, 244], ["DiskussionDie vorliegende Querschnittsstudie liefert erste Daten zur Auswirkungen der SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der Universit\u00e4tskliniken w\u00e4hrend der Aussetzung aller Elektivoperationen", "SPECIES", 245, 464], ["Pandemie auf die Allgemein", "TREATMENT", 342, 368]]], ["Die Teilnahmerate von 73 % weist auf die gro\u00dfe Bedeutung der Thematik f\u00fcr die Ordinarien der Allgemein- und Viszeralchirurgie hin.DiskussionDie Ergebnisse zeigen, dass die Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie \u00fcberwiegend positiv seitens der Ordinarien aufgenommen wurden.", [["Die Teilnahmerate von 73 % weist auf die gro\u00dfe Bedeutung der Thematik f\u00fcr die Ordinarien der Allgemein- und Viszeralchirurgie hin", "SPECIES", 0, 129], ["DiskussionDie Ergebnisse zeigen, dass die Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie \u00fcberwiegend positiv seitens der Ordinarien aufgenommen wurden", "SPECIES", 130, 282], ["CoV", "TEST", 206, 209], ["Pandemie", "TREATMENT", 212, 220]]], ["Die Zusammenarbeit der Allgemein- und Viszeralchirurgie mit der Krankenhausverwaltung und anderen Fachdisziplinen erfolgte \u00fcberwiegend erfolgreich.", [["Die Zusammenarbeit der Allgemein- und Viszeralchirurgie mit der Krankenhausverwaltung und anderen Fachdisziplinen erfolgte \u00fcberwiegend erfolgreich", "SPECIES", 0, 146]]], ["Hervorzuheben sind auch die Ergebnisse zur Nachrangigkeit der finanziellen Zielvorgaben.", [["Hervorzuheben", "TREATMENT", 0, 13]]], ["Die Arbeit der Gesundheitsbeh\u00f6rden im Hinblick auf den Schutz der Mitarbeiter in den Krankenh\u00e4usern wurde \u00fcberwiegend als ausreichend empfunden.", [["Die Arbeit der Gesundheitsbeh\u00f6rden im Hinblick auf den Schutz der Mitarbeiter in den Krankenh\u00e4usern wurde \u00fcberwiegend als ausreichend empfunden", "SPECIES", 0, 143]]], ["So herrscht aufgrund der SARS-CoV-2-Pandemie weltweit in immer mehr Gesundheitseinrichtungen ein Mangel an wichtiger Ausr\u00fcstung wie Desinfektionsmittel und pers\u00f6nlicher Schutzausr\u00fcstung [10].", [["CoV", "TEST", 30, 33], ["Pandemie weltweit", "TREATMENT", 36, 53]]], ["Daraus folgt die Erkenntnis und Forderung, Reserven f\u00fcr k\u00fcnftige Pandemien aufzubauen, um sie z\u00fcgiger bereitstellen zu k\u00f6nnen.DiskussionDie chirurgischen Kliniken wurden am 16.", [["Daraus folgt die Erkenntnis und Forderung, Reserven f\u00fcr k\u00fcnftige Pandemien aufzubauen, um sie z\u00fcgiger bereitstellen zu k\u00f6nnen", "SPECIES", 0, 125]]], ["M\u00e4rz 2020 aufgefordert, alle medizinisch nicht zwingend notwendigen planbaren Aufnahmen und Operationen zu verschieben [11].", [["alle medizinisch", "TREATMENT", 24, 40]]], ["Zur Finanzierung dieser Einbu\u00dfe wurde das \u201eCOVID-19-Krankenhausentlastungsgesetz\u201c verabschiedet [13].", [["Zur Finanzierung dieser Einbu\u00dfe wurde das \u201eCOVID-19-Krankenhausentlastungsgesetz\u201c verabschiedet", "SPECIES", 0, 95], ["COVID", "TEST", 43, 48]]], ["Insgesamt kam es zur durchschnittlichen Reduktion der Betten- bzw.", [["Insgesamt kam es zur durchschnittlichen Reduktion der Betten- bzw", "SPECIES", 0, 65]]], ["Operationskapazit\u00e4t um 38 \u00b1 19 % bzw.", [["Operationskapazit\u00e4t um", "TREATMENT", 0, 22]]], ["Die Reduktion der chirurgischen Kapazit\u00e4ten lie\u00df die Befragten einen Verlust der Einnahmen im Jahr 2020 von 28 \u00b1 16 % sch\u00e4tzen.", [["Die Reduktion der chirurgischen Kapazit\u00e4ten lie\u00df die Befragten einen Verlust der Einnahmen im Jahr 2020 von 28 \u00b1 16 % sch\u00e4tzen", "SPECIES", 0, 126]]], ["Auch nach R\u00fcckbau der Ma\u00dfnahmen k\u00f6nnten durch strukturelle Gegebenheiten bei Personal und Betten- bzw.", [["Betten- bzw", "CELL", 90, 101], ["Ma\u00dfnahmen k\u00f6nnten durch strukturelle Gegebenheiten bei Personal und Betten- bzw", "SPECIES", 22, 101]]], ["Operationskapazit\u00e4t diese Verluste nicht aufgeholt werden.", [["Operationskapazit\u00e4t", "TREATMENT", 0, 19]]], ["Dies gilt nicht nur f\u00fcr die Allgemein- und Viszeralchirurgie.", [["Viszeralchirurgie", "CHEMICAL", 43, 60]]], ["Aufgrund der erheblichen Einschr\u00e4nkung der operativen Kapazit\u00e4ten und der Umverteilung von Personal wurden in den meisten Einrichtungen nur noch dringliche Operationen und Notfalloperationen durchgef\u00fchrt, wobei die Durchf\u00fchrung von Notfalloperationen an den Universit\u00e4tskliniken in 93 % der F\u00e4lle uneingeschr\u00e4nkt funktionierte.", [["Aufgrund der erheblichen Einschr\u00e4nkung der operativen Kapazit\u00e4ten und der Umverteilung von Personal wurden in den meisten Einrichtungen nur noch dringliche Operationen und Notfalloperationen durchgef\u00fchrt, wobei die Durchf\u00fchrung von Notfalloperationen an den Universit\u00e4tskliniken", "SPECIES", 0, 278]]], ["Die Mehrheit der Lehrstuhlinhaber berichtete zudem von einer zunehmenden Verunsicherung der Patienten mit der Folge von Absagen und Verschiebungen von Operationen.", [["Die Mehrheit der Lehrstuhlinhaber berichtete zudem von einer zunehmenden Verunsicherung der Patienten mit der Folge von Absagen und Verschiebungen von Operationen", "SPECIES", 0, 162]]], ["Au\u00dferdem ist abgezogenes Personal aus den vorgehaltenen COVID-19-Bereichen zur\u00fcckzuf\u00fchren, um die erforderliche Bettenkapazit\u00e4t zu gew\u00e4hrleisten.DiskussionDie Ordinarien gehen davon aus, dass Pflegekr\u00e4fte zuk\u00fcnftig besser bezahlt werden.", [["Au\u00dferdem ist abgezogenes Personal aus den vorgehaltenen COVID-19-Bereichen zur\u00fcckzuf\u00fchren, um die erforderliche Bettenkapazit\u00e4t zu gew\u00e4hrleisten", "SPECIES", 0, 144]]], ["Aus Sicht der \u00c4rzteschaft ist dies ein positives Signal hin zur St\u00e4rkung der Pflege.", [["Aus Sicht der \u00c4rzteschaft ist dies ein positives Signal hin zur St\u00e4rkung der Pflege", "SPECIES", 0, 83], ["Aus Sicht der \u00c4rzteschaft ist dies", "TEST", 0, 34]]], ["Bereits vor der SARS-CoV-2-Pandemie war zum einen die geringe Verg\u00fctung dieser systemrelevanten Berufsgruppe und zum anderen der prognostizierte Fachkr\u00e4ftemangel im Pflegesektor diskutiert worden [14, 15].", [["CoV", "TEST", 21, 24], ["Pandemie war zum", "TREATMENT", 27, 43]]], ["Die jetzige Situation k\u00f6nnte als Wendepunkt dienen, um den Pflegebereich nachhaltig zu st\u00e4rken.", [["Die jetzige Situation k\u00f6nnte als Wendepunkt dienen, um den Pflegebereich nachhaltig zu st\u00e4rken", "SPECIES", 0, 94]]], ["Es bleibt zu hoffen, dass nach R\u00fcckbau der COVID-19-Kapazit\u00e4ten noch gen\u00fcgend Pflegekr\u00e4fte zur Verf\u00fcgung stehen, da in der Pandemiehochphase die Neurekrutierung nicht im Vordergrund stand und es weiterhin schwierig bleibt, in Ballungsgebieten ausreichend Pflegepersonal zu finden.DiskussionDie vorliegende Querschnittsstudie geht mit Limitationen einher.", [["Es bleibt zu hoffen, dass nach R\u00fcckbau der COVID-19-Kapazit\u00e4ten noch gen\u00fcgend Pflegekr\u00e4fte zur Verf\u00fcgung stehen, da in der Pandemiehochphase die Neurekrutierung nicht im Vordergrund stand und es weiterhin schwierig bleibt", "SPECIES", 0, 221], ["DiskussionDie vorliegende Querschnittsstudie geht mit Limitationen einher", "SPECIES", 280, 353], ["Kapazit\u00e4ten", "TREATMENT", 52, 63]]], ["Der Befragungszeitraum erfolgte w\u00e4hrend des vorerst ersten H\u00f6hepunkts der SARS-CoV-2-Pandemie, sodass die Ergebnisse als vorl\u00e4ufig zu betrachten sind und die weitere Entwicklung bzw. die abschlie\u00dfenden Auswirkungen in geplanten Folgeumfragen evaluiert werden sollten.DiskussionUnseres Wissens ist dies bislang die erste Umfrage, die die Einfl\u00fcsse der SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der deutschen Universit\u00e4tsklinika umfassend darstellt und somit einen \u00dcberblick \u00fcber die Herausforderungen in der universit\u00e4ren, chirurgischen Versorgungsrealit\u00e4t gibt.", [["Der Befragungszeitraum erfolgte w\u00e4hrend des vorerst ersten H\u00f6hepunkts der SARS-CoV-2-Pandemie, sodass die Ergebnisse als vorl\u00e4ufig zu betrachten sind und die weitere Entwicklung bzw", "SPECIES", 0, 181], ["DiskussionUnseres Wissens ist dies bislang die erste Umfrage, die die Einfl\u00fcsse der SARS-CoV-2-Pandemie auf die Allgemein- und Viszeralchirurgie der deutschen Universit\u00e4tsklinika umfassend darstellt und somit einen \u00dcberblick \u00fcber die Herausforderungen in der universit\u00e4ren, chirurgischen Versorgungsrealit\u00e4t gibt", "SPECIES", 267, 579]]], ["W\u00e4hrend des Befragungszeitraums befand sich Deutschland noch in einem fr\u00fchen Stadium der SARS-CoV-2-Pandemie, sodass zuk\u00fcnftige Auswirkungen derzeit noch schwer absehbar sind.", [["CoV", "TEST", 94, 97], ["Pandemie", "PROBLEM", 100, 108]]], ["Offen bleibt, ob die Reduktion der Operationskapazit\u00e4t und das Aussetzen der elektiven Operationen zu einer Minderung der chirurgischen Versorgungsqualit\u00e4t in Deutschland f\u00fchren und ob es zu Nachteilen in der Versorgung und den Ergebnissen bei onkologischen Patienten kommen wird.", [["Reduktion der Operationskapazit\u00e4t und das Aussetzen der elektiven Operationen zu einer Minderung der chirurgischen Versorgungsqualit\u00e4t in Deutschland f\u00fchren und ob es zu Nachteilen in der Versorgung und den Ergebnissen bei onkologischen Patienten kommen wird", "SPECIES", 21, 279]]], ["Folgeerhebungen m\u00fcssen hierzu zuk\u00fcnftig weitere Evidenz liefern.", [["Folgeerhebungen m\u00fcssen hierzu zuk\u00fcnftig weitere Evidenz liefern", "SPECIES", 0, 63], ["Folgeerhebungen", "TREATMENT", 0, 15]]], ["Betrachtet man die Ergebnisse zur Bereitstellung der Schutzausr\u00fcstung f\u00fcr das Personal, zur Bezahlung der Pflegekr\u00e4fte und zu den finanziellen Belastungen f\u00fcr die Kliniken, muss man von der Politik L\u00f6sungsvorschl\u00e4ge erwarten.", [["man", "SPECIES", 11, 14], ["Betrachtet man die Ergebnisse zur Bereitstellung der Schutzausr\u00fcstung f\u00fcr das Personal, zur Bezahlung der Pflegekr\u00e4fte und zu den finanziellen Belastungen f\u00fcr die Kliniken, muss man von der Politik L\u00f6sungsvorschl\u00e4ge erwarten", "SPECIES", 0, 224]]], ["Dabei sollte auch eine m\u00f6gliche n\u00e4chste SARS-CoV-2-Pandemiewelle ber\u00fccksichtigt werden, die nach Lockerung der Eind\u00e4mmungsma\u00dfnahmen m\u00f6glich erscheint.", [["Dabei sollte auch eine m\u00f6gliche n\u00e4chste SARS-CoV-2-Pandemiewelle ber\u00fccksichtigt werden, die nach Lockerung der Eind\u00e4mmungsma\u00dfnahmen m\u00f6glich erscheint", "SPECIES", 0, 149], ["Pandemiewelle ber\u00fccksichtigt werden", "TREATMENT", 51, 86]]], ["Dabei muss das Ausma\u00df der Vorhaltungen f\u00fcr Universit\u00e4tsklinika und nichtuniversit\u00e4re Krankenh\u00e4user pr\u00e4zise definiert werden, um Planungssicherheiten zu bieten.", [["Dabei muss das Ausma\u00df der Vorhaltungen f\u00fcr Universit\u00e4tsklinika und nichtuniversit\u00e4re Krankenh\u00e4user pr\u00e4zise definiert werden, um Planungssicherheiten zu bieten", "SPECIES", 0, 158]]], ["Zudem steht zur Diskussion, ob eine Konzentrierung von COVID-19-Patienten zuk\u00fcnftig auf ausgew\u00e4hlte Krankenh\u00e4user erfolgen sollte, um die Versorgung aller anderen Patienten gew\u00e4hrleisten zu k\u00f6nnen.FazitBei einem Viertel der Befragten stand zu Beginn der Pandemie zu wenig Schutzausr\u00fcstung zur Verf\u00fcgung.", [["Zudem steht zur Diskussion, ob eine Konzentrierung von COVID-19-Patienten zuk\u00fcnftig auf ausgew\u00e4hlte Krankenh\u00e4user erfolgen sollte, um die Versorgung aller anderen Patienten gew\u00e4hrleisten zu k\u00f6nnen", "SPECIES", 0, 196], ["FazitBei einem Viertel der Befragten stand zu Beginn der Pandemie zu wenig Schutzausr\u00fcstung zur Verf\u00fcgung", "SPECIES", 197, 302], ["COVID", "TEST", 55, 60]]], ["Operationskapazit\u00e4t wurde um 38 % bzw.", [["Operationskapazit\u00e4t wurde um", "TREATMENT", 0, 28]]], ["Die verschobenen Operationen werden zus\u00e4tzlich zum wiederaufgenommenen Elektivprogramm anfallen und bew\u00e4ltigt werden m\u00fcssen.Die Ordinarien sch\u00e4tzen den Verlust der Einnahmen im Jahr 2020 auf ca.", [["Die Ordinarien sch\u00e4tzen den Verlust der Einnahmen im Jahr 2020 auf ca", "SPECIES", 124, 193], ["Die", "PROBLEM", 0, 3]]], ["Eine Kompensation dieses Verlusts aus eigener Kraft scheint nur schwer m\u00f6glich.Die chirurgische Versorgungsqualit\u00e4t ist aktuell kaum eingeschr\u00e4nkt, nur 7 % der Notfalloperationen an den befragten Universit\u00e4tskliniken konnten nicht durchgef\u00fchrt werden.Die chirurgischen Kliniken ben\u00f6tigen weitere Planungssicherheiten, um w\u00e4hrend der anhaltenden Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie die chirurgische Versorgung der Patienten zu gew\u00e4hrleisten.", [["Die chirurgische Versorgungsqualit\u00e4t ist aktuell kaum eingeschr\u00e4nkt, nur 7 % der Notfalloperationen an den befragten Universit\u00e4tskliniken konnten nicht durchgef\u00fchrt werden", "SPECIES", 79, 250], ["Die chirurgischen Kliniken ben\u00f6tigen weitere Planungssicherheiten, um w\u00e4hrend der anhaltenden Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie die chirurgische Versorgung der Patienten zu gew\u00e4hrleisten", "SPECIES", 251, 452], ["Eine Kompensation", "TEST", 0, 17], ["Kraft scheint", "OBSERVATION", 46, 59]]]], "51711e5dec0601f17ad05f4250b4d4f47daae5a4": [["Substance misuse during COVID-19: protecting people who use drugsPeople who use drugs (PWUD) face additional risks from COVID-19, linked to drug use behaviours, settings where drug use takes place, and related healthcare needs.Substance misuse during COVID-19: protecting people who use drugsThese marginalised groups are present in countries of all incomes, 1 meaning they must be included in global public health strategies to safeguard them, their healthcare workers, and the wider public.Substance misuse during COVID-19: protecting people who use drugsPWUD suffer significant acute and long-term health consequences due to direct and indirect effects of drug misuse, including acute intoxication, mental ill-health, and reduced access to healthcare through stigmatisation and discrimination.", [["Substance misuse", "DISEASE", 0, 16], ["COVID-19", "CHEMICAL", 24, 32], ["Substance misuse", "DISEASE", 227, 243], ["COVID-19", "CHEMICAL", 251, 259], ["Substance misuse", "DISEASE", 492, 508], ["COVID-19", "CHEMICAL", 516, 524], ["drugsPWUD", "CHEMICAL", 552, 561], ["people", "ORGANISM", 45, 51], ["People", "ORGANISM", 65, 71], ["people", "ORGANISM", 272, 278], ["people", "ORGANISM", 537, 543], ["people", "SPECIES", 45, 51], ["People", "SPECIES", 65, 71], ["people", "SPECIES", 272, 278], ["people", "SPECIES", 537, 543], ["drugs", "TREATMENT", 60, 65], ["drugs", "TREATMENT", 80, 85], ["drugs", "TREATMENT", 287, 292], ["significant acute and long-term health consequences", "PROBLEM", 569, 620], ["acute intoxication", "PROBLEM", 682, 700]]], ["2 The high prevalence of chronic conditions among PWUD, including respiratory diseases like asthma and COPD, 3 may put them at increased risk of COVID-19 infection and severe disease.", [["respiratory", "ANATOMY", 66, 77], ["PWUD", "DISEASE", 50, 54], ["respiratory diseases", "DISEASE", 66, 86], ["asthma", "DISEASE", 92, 98], ["COPD", "DISEASE", 103, 107], ["infection", "DISEASE", 154, 163], ["COVID-19", "SPECIES", 145, 153], ["chronic conditions", "PROBLEM", 25, 43], ["respiratory diseases", "PROBLEM", 66, 86], ["asthma", "PROBLEM", 92, 98], ["COPD", "PROBLEM", 103, 107], ["COVID-19 infection", "PROBLEM", 145, 163], ["severe disease", "PROBLEM", 168, 182], ["high prevalence", "OBSERVATION_MODIFIER", 6, 21], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["conditions", "OBSERVATION", 33, 43], ["respiratory diseases", "OBSERVATION", 66, 86], ["asthma", "OBSERVATION", 92, 98], ["COPD", "OBSERVATION", 103, 107], ["infection", "OBSERVATION", 154, 163], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["disease", "OBSERVATION", 175, 182]]], ["4 In addition, public health measures may exacerbate poor outcomes for PWUD, as social isolation is associated with increased substance misuse.", [["PWUD", "DISEASE", 71, 75], ["public health measures", "TREATMENT", 15, 37], ["PWUD", "TREATMENT", 71, 75], ["social isolation", "TREATMENT", 80, 96], ["substance misuse", "OBSERVATION", 126, 142]]], ["5 COVID-19 is primarily transmitted by respiratory droplets and contact routes, 6 which informs public health mitigation measures including social distancing and hand hygiene.", [["respiratory", "ANATOMY", 39, 50], ["hand", "ANATOMY", 162, 166], ["hand", "ORGANISM_SUBDIVISION", 162, 166], ["respiratory droplets", "OBSERVATION", 39, 59]]], ["In addition, drug use often takes place in crowded or substandard living conditions, threatening social distancing and hand hygiene adherence, and placing both PWUD and the wider public at risk.", [["hand", "ANATOMY", 119, 123], ["hand", "ORGANISM_SUBDIVISION", 119, 123]]], ["PWUD are also disproportionately represented in homeless, vulnerably housed, and incarcerated populations, which face additional risks from COVID-19 infection.", [["infection", "DISEASE", 149, 158], ["PWUD", "CANCER", 0, 4], ["COVID-19", "ORGANISM", 140, 148], ["incarcerated populations", "PROBLEM", 81, 105], ["COVID-19 infection", "PROBLEM", 140, 158], ["disproportionately", "OBSERVATION_MODIFIER", 14, 32], ["incarcerated", "OBSERVATION_MODIFIER", 81, 93], ["infection", "OBSERVATION", 149, 158]]], ["7, 8 Surges in demand for emergency care during COVID-19 are forcing health systems to scale down routine services, risking discontinuity of care across many domains of health, including substance misuse services.", [["emergency care", "TREATMENT", 26, 40], ["routine services", "TREATMENT", 98, 114]]], ["This threatens PWUD with reduced access to vital medications, psychological support, and clean drug equipment.", [["vital medications", "TREATMENT", 43, 60], ["psychological support", "TREATMENT", 62, 83], ["clean drug equipment", "TREATMENT", 89, 109]]], ["In addition, physical distancing and self-isolation public health measures raise further barriers to accessing health and social services within this already-disadvantaged group.Substance misuse during COVID-19: protecting people who use drugsThere is urgent need to protect PWUD against the direct impacts of COVID-19 infection, and to secure the continuity of care provided by substance misuse services.", [["Substance misuse", "DISEASE", 178, 194], ["COVID-19", "CHEMICAL", 202, 210], ["COVID-19", "CHEMICAL", 310, 318], ["infection", "DISEASE", 319, 328], ["people", "ORGANISM", 223, 229], ["PWUD", "CANCER", 275, 279], ["people", "SPECIES", 223, 229], ["self-isolation public health measures", "TREATMENT", 37, 74], ["drugs", "TREATMENT", 238, 243], ["PWUD", "TREATMENT", 275, 279], ["COVID-19 infection", "PROBLEM", 310, 328], ["infection", "OBSERVATION", 319, 328]]], ["Public health messaging should sensitively target this group to discourage drug and paraphernalia sharing, promote social distancing and hand hygiene, and empower PWUD to appropriately seek medical attention, while safeguarding provision of drug misuse services, and protecting the health workers delivering them.Substance misuse during COVID-19: protecting people who use drugsThis will require re-imagining services, such as telemedicine and online care, and maintaining infrastructure vital to treating addiction, including housing and welfare.", [["hand", "ANATOMY", 137, 141], ["Substance misuse", "DISEASE", 313, 329], ["COVID-19", "CHEMICAL", 337, 345], ["hand", "ORGANISM_SUBDIVISION", 137, 141], ["people", "ORGANISM", 358, 364], ["people", "SPECIES", 358, 364], ["drugs", "TREATMENT", 373, 378], ["re-imagining services", "TREATMENT", 396, 417], ["online care", "TREATMENT", 444, 455]]]], "ddab3cc959be9b31f8babd27a540a81bc32a4915": [["The mathematical expression for the Basic Reproduction Number for SARS-CoV-2 in a jail ( \" #$ ) is equal to:", [["SARS", "DISEASE", 66, 70]]]], "PMC3750644": [["IntroductionShigella species are a common cause of acute diarrheal disease worldwide, with an estimated 167 million cases per year and resulting in approximately 1.1 million deaths; 97.6% of the cases occur in developing countries [1].", [["diarrheal disease", "DISEASE", 57, 74], ["deaths", "DISEASE", 174, 180], ["Shigella species", "ORGANISM", 12, 28], ["IntroductionShigella species", "PROBLEM", 0, 28], ["acute diarrheal disease", "PROBLEM", 51, 74], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["diarrheal disease", "OBSERVATION", 57, 74]]], ["According to the Chinese National Infectious Disease Internet Reporting System, the annual incidence of shigellosis in China made it rank in the top three of the most notable infectious diseases for four consecutive years (2005 to 2008), with close to 500000 cases of shigellosis per year (http://www.moh.gov.cn); this number is now widely believed to be underestimated [2].IntroductionShigellosis is caused by four species, S. dysenteriae, S. flexneri, S. boydii, and S. sonnei.", [["Infectious Disease", "DISEASE", 34, 52], ["shigellosis", "DISEASE", 104, 115], ["infectious diseases", "DISEASE", 175, 194], ["shigellosis", "DISEASE", 268, 279], ["Shigellosis", "DISEASE", 386, 397], ["S. dysenteriae", "ORGANISM", 425, 439], ["S. flexneri", "ORGANISM", 441, 452], ["S. boydii", "ORGANISM", 454, 463], ["S. sonnei", "ORGANISM", 469, 478], ["S. dysenteriae", "SPECIES", 425, 439], ["S. flexneri", "SPECIES", 441, 452], ["S. boydii", "SPECIES", 454, 463], ["S. sonnei", "SPECIES", 469, 478], ["S. dysenteriae", "SPECIES", 425, 439], ["S. flexneri", "SPECIES", 441, 452], ["S. boydii", "SPECIES", 454, 463], ["S. sonnei", "SPECIES", 469, 478], ["shigellosis", "PROBLEM", 104, 115], ["notable infectious diseases", "PROBLEM", 167, 194], ["shigellosis", "PROBLEM", 268, 279], ["Shigellosis", "PROBLEM", 386, 397], ["four species", "PROBLEM", 411, 423], ["S. dysenteriae", "PROBLEM", 425, 439], ["shigellosis", "OBSERVATION", 104, 115], ["notable", "OBSERVATION_MODIFIER", 167, 174], ["infectious", "OBSERVATION", 175, 185], ["shigellosis", "OBSERVATION", 268, 279], ["Shigellosis", "OBSERVATION", 386, 397]]], ["Shigella species can be identified by serotyping with group-specific antigens; serotyping is based on structural differences within the O-antigen repeating unit of lipopolysaccharide [3].", [["lipopolysaccharide", "CHEMICAL", 164, 182], ["Shigella species", "ORGANISM", 0, 16], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 164, 182], ["group-specific antigens", "PROTEIN", 54, 77], ["Shigella species", "PROBLEM", 0, 16], ["serotyping", "TREATMENT", 79, 89]]], ["A total of 47 serotypes of Shigella have been recognized, including 15 for S. flexneri, 13 for S. dysenteriae, 18 for S. boydii, and a single one for S. sonnei[4].", [["Shigella", "ORGANISM", 27, 35], ["S. flexneri", "ORGANISM", 75, 86], ["S. dysenteriae", "ORGANISM", 95, 109], ["S. boydii", "ORGANISM", 118, 127], ["S. sonnei", "ORGANISM", 150, 159], ["S. flexneri", "SPECIES", 75, 86], ["S. dysenteriae", "SPECIES", 95, 109], ["S. boydii", "SPECIES", 118, 127], ["S. sonnei", "SPECIES", 150, 159], ["S. flexneri", "SPECIES", 75, 86], ["S. dysenteriae", "SPECIES", 95, 109], ["S. boydii", "SPECIES", 118, 127], ["S. sonnei", "SPECIES", 150, 159], ["Shigella", "PROBLEM", 27, 35], ["S. dysenteriae", "PROBLEM", 95, 109]]], ["The distribution of species and serotypes of Shigella is heterogeneous over time and place [5].IntroductionThe World Health Organization has made the development of a safe and effective vaccine against S. flexneri[1,6-8], but the vaccine effectiveness depends on the distribution patterns of local species and serotypes, because only type-specific immunity has been demonstrated in humans [9-12] and moreover cross-serotype protection is controversial [11,13].IntroductionAccording to a previous multicenter study of Shigella diarrhea in six Asian countries, S. flexneri is the most common species in Bangladesh, China, Pakistan, Indonesia, and Vietnam; whereas S. sonnei is predominant in industrialized countries [14].", [["Shigella diarrhea", "DISEASE", 517, 534], ["S. flexneri", "ORGANISM", 202, 213], ["humans", "ORGANISM", 382, 388], ["Shigella diarrhea", "ORGANISM", 517, 534], ["S. flexneri", "ORGANISM", 559, 570], ["S. sonnei", "ORGANISM", 662, 671], ["S. flexneri", "SPECIES", 202, 213], ["humans", "SPECIES", 382, 388], ["S. flexneri", "SPECIES", 559, 570], ["S. sonnei", "SPECIES", 662, 671], ["S. flexneri", "SPECIES", 202, 213], ["humans", "SPECIES", 382, 388], ["Shigella diarrhea", "SPECIES", 517, 534], ["S. flexneri", "SPECIES", 559, 570], ["S. sonnei", "SPECIES", 662, 671], ["species", "PROBLEM", 20, 27], ["serotypes", "PROBLEM", 32, 41], ["Shigella", "PROBLEM", 45, 53], ["a safe and effective vaccine", "TREATMENT", 165, 193], ["S. flexneri", "PROBLEM", 202, 213], ["the vaccine effectiveness", "TREATMENT", 226, 251], ["local species", "PROBLEM", 292, 305], ["serotypes", "PROBLEM", 310, 319], ["a previous multicenter study", "TEST", 485, 513], ["Shigella diarrhea", "PROBLEM", 517, 534], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["species", "OBSERVATION", 20, 27], ["serotypes", "OBSERVATION_MODIFIER", 32, 41], ["Shigella", "OBSERVATION_MODIFIER", 45, 53], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70], ["local species", "OBSERVATION", 292, 305]]], ["Two recent reports have indicated that S. flexneri 2a is the most frequently isolated Shigella organism in China [15,16].", [["S. flexneri 2a", "ORGANISM", 39, 53], ["S. flexneri", "SPECIES", 39, 50], ["S. flexneri", "SPECIES", 39, 50], ["S. flexneri 2a", "PROBLEM", 39, 53], ["Shigella organism", "PROBLEM", 86, 103], ["Shigella", "OBSERVATION", 86, 94]]], ["However, these reports may not be generalizable for the whole China; the time period of these studies is short, and surveillance is performed only in less-developed areas of China.IntroductionLittle is known about the distribution of Shigella serotypes in Beijing, the political, educational, cultural, and economic center of China with a population of over 30 million.", [["Shigella serotypes", "ORGANISM", 234, 252], ["these studies", "TEST", 88, 101], ["surveillance", "TEST", 116, 128], ["Shigella serotypes", "PROBLEM", 234, 252], ["may not be", "UNCERTAINTY", 23, 33], ["Shigella serotypes", "OBSERVATION", 234, 252]]], ["The present study describes the trends in Shigella species and their serotypes isolated from patients with diarrhea in a national infectious disease hospital in Beijing, China, from 1994 to 2010.Study sites and settings ::: Materials and methodsThe location was a clinical diagnostic center at the 302nd Hospital of the People\u2019s Liberation Army in Beijing, China.", [["diarrhea", "DISEASE", 107, 115], ["infectious disease", "DISEASE", 130, 148], ["Shigella species", "ORGANISM", 42, 58], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["The present study", "TEST", 0, 17], ["Shigella species", "PROBLEM", 42, 58], ["their serotypes", "PROBLEM", 63, 78], ["diarrhea", "PROBLEM", 107, 115]]], ["The 302nd Hospital is the largest infectious disease teaching hospital in Beijing, China, with 1300 beds and receiving more than 36400 patients annually.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["largest", "OBSERVATION_MODIFIER", 26, 33], ["infectious", "OBSERVATION", 34, 44]]], ["From January 1994 to December 2010, fresh stool specimens were collected from patients with diarrhea and clinically suspected dysentery.", [["stool specimens", "ANATOMY", 42, 57], ["diarrhea", "DISEASE", 92, 100], ["dysentery", "DISEASE", 126, 135], ["stool specimens", "ORGANISM_SUBSTANCE", 42, 57], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["fresh stool specimens", "TEST", 36, 57], ["diarrhea", "PROBLEM", 92, 100], ["dysentery", "PROBLEM", 126, 135], ["dysentery", "OBSERVATION", 126, 135]]], ["The specimens were submitted to the microbiology laboratory of the 302nd Hospital.", [["specimens", "ANATOMY", 4, 13], ["specimens", "CANCER", 4, 13], ["The specimens", "TEST", 0, 13]]], ["All experimental research have been performed with the approval of ethics committee of 302nd Hospital of the People\u2019s Liberation Army, with reference number 2004013D.Serotyping ::: Bacterial isolation ::: Materials and methodsSerologic identification was performed by slide agglutination with polyvalent somatic (O) antigen grouping sera, followed by testing with available monovalent antisera for specific identification of serotypes according to the manufacturer\u2019s instructions (Denka Seiken, Japan).", [["sera", "ANATOMY", 333, 337], ["O) antigen", "GENE_OR_GENE_PRODUCT", 313, 323], ["sera", "ORGANISM_SUBSTANCE", 333, 337], ["polyvalent somatic (O) antigen", "PROTEIN", 293, 323], ["methodsSerologic identification", "TEST", 219, 250], ["slide agglutination", "TEST", 268, 287], ["testing", "TEST", 351, 358], ["monovalent antisera", "TREATMENT", 374, 393], ["serotypes", "PROBLEM", 425, 434], ["isolation", "OBSERVATION", 191, 200]]], ["Only one Shigella isolate per patient per diarrheal episode was included in the analysis.Statistical analysis ::: Bacterial isolation ::: Materials and methodsStatistical comparisons were performed using the CHISS software (version 2001, Yuan YiTang Sci-Tech Co., Ltd., Beijing, China).", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["diarrheal episode", "PROBLEM", 42, 59], ["the analysis", "TEST", 76, 88], ["isolation", "OBSERVATION", 124, 133]]], ["Categorical data were expressed as percentages and calculated using a chi-square test, and p \u2264 0.05 was considered statistically significant.Subgroup trends ::: ResultsA statistically significant decreasing trend in S. flexneri and an increasing trend in S. sonnei were observed by chi-square analysis (p < 0.01) (Figure 1).", [["S. flexneri", "ORGANISM", 216, 227], ["S. sonnei", "ORGANISM", 255, 264], ["S. flexneri", "SPECIES", 216, 227], ["S. sonnei", "SPECIES", 255, 264], ["S. flexneri", "SPECIES", 216, 227], ["S. sonnei", "SPECIES", 255, 264], ["Categorical data", "TEST", 0, 16], ["a chi-square test", "TEST", 68, 85], ["S. flexneri", "PROBLEM", 216, 227], ["an increasing trend", "PROBLEM", 232, 251], ["S. sonnei", "PROBLEM", 255, 264], ["chi-square analysis", "TEST", 282, 301], ["significant", "OBSERVATION_MODIFIER", 184, 195], ["decreasing", "OBSERVATION_MODIFIER", 196, 206], ["trend", "OBSERVATION_MODIFIER", 207, 212], ["flexneri", "OBSERVATION_MODIFIER", 219, 227], ["increasing", "OBSERVATION_MODIFIER", 235, 245]]], ["The trends in Shigella spp. isolated from Beijing between 1994 and 2010 are shown in Figure 2.", [["Shigella spp", "ORGANISM", 14, 26], ["Shigella spp", "SPECIES", 14, 26], ["Shigella spp", "PROBLEM", 14, 26], ["Shigella spp", "OBSERVATION", 14, 26]]], ["The recording of annual Shigella isolation began in 1994, and the maximum number of isolates was reported in 1996 (n = 1194).", [["annual Shigella isolation", "PROBLEM", 17, 42]]], ["The annual total number of isolated Shigella organisms had been decreasing since then, reaching a low point in 2008 (n = 22).", [["isolated Shigella organisms", "PROBLEM", 27, 54], ["annual", "OBSERVATION_MODIFIER", 4, 10], ["total", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["Shigella organisms", "OBSERVATION", 36, 54], ["decreasing", "OBSERVATION_MODIFIER", 64, 74], ["low point", "OBSERVATION_MODIFIER", 98, 107]]], ["This trend may be related to the strict hygiene inspection and adequate sanitation during the 2008 Olympic season [17].", [["the strict hygiene inspection", "TEST", 29, 58], ["may be related to", "UNCERTAINTY", 11, 28]]], ["Four peaks were observed during the 17-year collection period.", [["peaks", "OBSERVATION_MODIFIER", 5, 10]]], ["Peak 1 appeared in 1996, with subsequent peaks in 1998 (peak 2, n = 602), 2002 (peak 3, n = 398), and 2004 (peak 4, n = 251).", [["Peak", "TEST", 0, 4], ["peak", "TEST", 56, 60], ["peak", "TEST", 80, 84], ["peak", "TEST", 108, 112]]], ["A sudden decrease in Shigella isolation was observed more in 2003 than in 2002 and 2004; one possible explanation is that resources were redirected to identify severe acute respiratory syndrome cases in China in 2003, thereby limiting bacterial diarrheal isolation.", [["acute respiratory syndrome", "DISEASE", 167, 193], ["diarrheal", "DISEASE", 245, 254], ["A sudden decrease in Shigella isolation", "PROBLEM", 0, 39], ["severe acute respiratory syndrome", "PROBLEM", 160, 193], ["bacterial diarrheal isolation", "TREATMENT", 235, 264], ["sudden", "OBSERVATION_MODIFIER", 2, 8], ["decrease", "OBSERVATION_MODIFIER", 9, 17], ["Shigella isolation", "OBSERVATION", 21, 39], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory syndrome", "OBSERVATION", 173, 193], ["bacterial", "OBSERVATION_MODIFIER", 235, 244], ["diarrheal isolation", "OBSERVATION", 245, 264]]], ["It should be noted that as the numbers of observed cases of shigellosis were decreasing, China\u2019s per capita gross domestic product (GDP) was increasing (Figure 3).Subgroups ::: ResultsThe distribution of typeable Shigella during the study period was S. flexneri, 71.7% (n = 4295); S. sonnei, 27.3% (n = 1639); S. dysenteriae, 0.55% (n = 33); and S. boydii, 0.33% (n = 20).", [["shigellosis", "DISEASE", 60, 71], ["S. flexneri", "ORGANISM", 250, 261], ["S. sonnei", "ORGANISM", 281, 290], ["S. dysenteriae", "ORGANISM", 310, 324], ["S. boydii", "ORGANISM", 346, 355], ["S. flexneri", "SPECIES", 250, 261], ["S. sonnei", "SPECIES", 281, 290], ["S. dysenteriae", "SPECIES", 310, 324], ["S. boydii", "SPECIES", 346, 355], ["S. flexneri", "SPECIES", 250, 261], ["S. sonnei", "SPECIES", 281, 290], ["S. dysenteriae", "SPECIES", 310, 324], ["S. boydii", "SPECIES", 346, 355], ["shigellosis", "PROBLEM", 60, 71], ["typeable Shigella", "PROBLEM", 204, 221], ["the study", "TEST", 229, 238], ["S. flexneri", "TEST", 250, 261], ["S. sonnei", "TEST", 281, 290], ["S. dysenteriae", "TEST", 310, 324], ["S. boydii", "TEST", 346, 355], ["shigellosis", "OBSERVATION", 60, 71]]], ["The distribution of Shigella species changed over the 17-year observation period (Figure 4).", [["Shigella species", "ORGANISM", 20, 36], ["Shigella species", "PROBLEM", 20, 36], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["Shigella species", "OBSERVATION", 20, 36]]], ["Between 1994 and 2005, Shigella isolation rates were largely driven by S. flexneri, reaching peak numbers in 1996 when 90% of all isolated Shigella were S. flexneri.", [["S. flexneri", "ORGANISM", 71, 82], ["S. flexneri", "ORGANISM", 153, 164], ["S. flexneri", "SPECIES", 71, 82], ["S. flexneri", "SPECIES", 153, 164], ["S. flexneri", "SPECIES", 71, 82], ["S. flexneri", "SPECIES", 153, 164], ["Shigella isolation rates", "TEST", 23, 47], ["peak numbers", "TEST", 93, 105], ["all isolated Shigella", "PROBLEM", 126, 147], ["flexneri", "OBSERVATION", 156, 164]]], ["In 2006, S. sonnei became the dominant subgroup.", [["S. sonnei", "ORGANISM", 9, 18], ["S. sonnei", "SPECIES", 9, 18], ["S. sonnei", "SPECIES", 9, 18], ["dominant", "OBSERVATION_MODIFIER", 30, 38]]], ["In 2009, the lowest percentage of isolated S. flexneri (6%) was recorded.", [["S. flexneri", "ORGANISM", 43, 54], ["S. flexneri", "SPECIES", 43, 54], ["S. flexneri", "SPECIES", 43, 54], ["flexneri", "OBSERVATION_MODIFIER", 46, 54]]], ["The apparent isolation rates of S. boydii and S. dysenteriae increased during this period, e.g., S. boydii isolation rates increased from 0% to 4.2% (n = 5), 3.8% (n = 3), 4.5% (n = 1), 8.3% (n = 3), and 7.6% (n = 2) in 2006, 2007, 2008, 2009, and 2010, respectively.", [["S. boydii", "ORGANISM", 32, 41], ["S. dysenteriae", "ORGANISM", 46, 60], ["S. boydii", "ORGANISM", 97, 106], ["S. boydii", "SPECIES", 32, 41], ["S. dysenteriae", "SPECIES", 46, 60], ["S. boydii", "SPECIES", 97, 106], ["S. boydii", "SPECIES", 32, 41], ["S. dysenteriae", "SPECIES", 46, 60], ["S. boydii", "SPECIES", 97, 106], ["S. boydii", "PROBLEM", 32, 41], ["S. dysenteriae", "PROBLEM", 46, 60], ["S. boydii isolation rates", "TEST", 97, 122]]], ["However, the absolute numbers of S. boydii and S. dysenteriae did not change during this period, remaining between 0 and 5 per year.", [["S. boydii", "ORGANISM", 33, 42], ["S. dysenteriae", "ORGANISM", 47, 61], ["S. boydii", "SPECIES", 33, 42], ["S. dysenteriae", "SPECIES", 47, 61], ["S. boydii", "SPECIES", 33, 42], ["S. dysenteriae", "SPECIES", 47, 61], ["S. boydii", "PROBLEM", 33, 42], ["S. dysenteriae", "PROBLEM", 47, 61], ["absolute", "OBSERVATION_MODIFIER", 13, 21], ["numbers", "OBSERVATION_MODIFIER", 22, 29], ["dysenteriae", "OBSERVATION", 50, 61]]], ["This result suggests that although uncommon, sources of S. dysenteriae and S. boydii remain in the Beijing area.Serotypes of S. flexneri and S. sonnei ::: ResultsAs revealed by 17 years\u2019 worth of data, 27/47 (57.4%) Shigella serotypes were identified; these serotypes included S. boydii serotypes 1, 2, 5, 15, and 17; S. dysenteriae serotypes 1, 2, 3, 4, 5, 7, and 8; S. flexneri serotypes 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 4c, 5, 6, x, and y; and S. sonnei.", [["S. dysenteriae", "ORGANISM", 56, 70], ["S. boydii", "ORGANISM", 75, 84], ["S. flexneri", "ORGANISM", 125, 136], ["S. sonnei", "ORGANISM", 141, 150], ["Shigella serotypes", "ORGANISM", 216, 234], ["S. boydii serotypes 1", "ORGANISM", 277, 298], ["2", "GENE_OR_GENE_PRODUCT", 300, 301], ["5", "GENE_OR_GENE_PRODUCT", 303, 304], ["15", "GENE_OR_GENE_PRODUCT", 306, 308], ["S. dysenteriae serotypes 1", "ORGANISM", 318, 344], ["2", "GENE_OR_GENE_PRODUCT", 346, 347], ["3", "GENE_OR_GENE_PRODUCT", 349, 350], ["4", "GENE_OR_GENE_PRODUCT", 352, 353], ["5", "GENE_OR_GENE_PRODUCT", 355, 356], ["7", "GENE_OR_GENE_PRODUCT", 358, 359], ["8", "GENE_OR_GENE_PRODUCT", 365, 366], ["S. flexneri serotypes 1a", "ORGANISM", 368, 392], ["1b", "GENE_OR_GENE_PRODUCT", 394, 396], ["2a", "GENE_OR_GENE_PRODUCT", 398, 400], ["2b", "GENE_OR_GENE_PRODUCT", 402, 404], ["3", "GENE_OR_GENE_PRODUCT", 406, 407], ["b", "GENE_OR_GENE_PRODUCT", 411, 412], ["4a", "GENE_OR_GENE_PRODUCT", 414, 416], ["4b", "GENE_OR_GENE_PRODUCT", 418, 420], ["4c", "GENE_OR_GENE_PRODUCT", 422, 424], ["5", "ORGANISM", 426, 427], ["S. sonnei", "ORGANISM", 446, 455], ["S. dysenteriae", "SPECIES", 56, 70], ["S. boydii", "SPECIES", 75, 84], ["S. flexneri", "SPECIES", 125, 136], ["S. sonnei", "SPECIES", 141, 150], ["S. boydii", "SPECIES", 277, 286], ["S. dysenteriae", "SPECIES", 318, 332], ["S. flexneri", "SPECIES", 368, 379], ["S. sonnei", "SPECIES", 446, 455], ["S. dysenteriae", "SPECIES", 56, 70], ["S. boydii", "SPECIES", 75, 84], ["S. flexneri", "SPECIES", 125, 136], ["S. sonnei", "SPECIES", 141, 150], ["S. boydii", "SPECIES", 277, 286], ["S. dysenteriae", "SPECIES", 318, 332], ["S. flexneri", "SPECIES", 368, 379], ["S. sonnei", "SPECIES", 446, 455], ["S. dysenteriae", "PROBLEM", 56, 70], ["S. boydii", "PROBLEM", 75, 84], ["Shigella serotypes", "PROBLEM", 216, 234], ["S. boydii serotypes", "TREATMENT", 277, 296], ["4b", "TEST", 418, 420], ["4c", "TEST", 422, 424], ["dysenteriae", "OBSERVATION", 59, 70], ["flexneri", "OBSERVATION_MODIFIER", 128, 136], ["sonnei", "OBSERVATION", 449, 455]]], ["Given the small numbers of S. boydii and S. dysenteriae (n = 53 combined), only isolates of S. flexneri and S. sonnei were further analyzed.", [["S. boydii", "ORGANISM", 27, 36], ["S. dysenteriae", "ORGANISM", 41, 55], ["S. flexneri", "ORGANISM", 92, 103], ["S. sonnei", "ORGANISM", 108, 117], ["S. boydii", "SPECIES", 27, 36], ["S. dysenteriae", "SPECIES", 41, 55], ["S. flexneri", "SPECIES", 92, 103], ["S. sonnei", "SPECIES", 108, 117], ["S. boydii", "SPECIES", 27, 36], ["S. dysenteriae", "SPECIES", 41, 55], ["S. flexneri", "SPECIES", 92, 103], ["S. sonnei", "SPECIES", 108, 117], ["S. boydii", "PROBLEM", 27, 36], ["S. dysenteriae", "PROBLEM", 41, 55], ["S. flexneri", "PROBLEM", 92, 103], ["small", "OBSERVATION_MODIFIER", 10, 15], ["numbers", "OBSERVATION_MODIFIER", 16, 23]]], ["Surveillance data indicated large differences in the serotypes of S. flexneri isolated between 1994 and 2010, in addition to the change in dominant species in 2006 (Table 1).", [["S. flexneri", "ORGANISM", 66, 77], ["S. flexneri", "SPECIES", 66, 77], ["S. flexneri", "SPECIES", 66, 77], ["Surveillance data", "TEST", 0, 17], ["large differences", "PROBLEM", 28, 45], ["S. flexneri", "PROBLEM", 66, 77], ["the change in dominant species", "PROBLEM", 125, 155], ["large", "OBSERVATION_MODIFIER", 28, 33], ["differences", "OBSERVATION_MODIFIER", 34, 45], ["dominant", "OBSERVATION_MODIFIER", 139, 147], ["species", "OBSERVATION", 148, 155]]], ["S. flexneri 2a and S. sonnei were observed in every year of the study, and S. sonnei surpassed S. flexneri 2a as the predominant single Shigella type in 2000.", [["S. flexneri 2a", "ORGANISM", 0, 14], ["S. sonnei", "ORGANISM", 19, 28], ["S. sonnei", "ORGANISM", 75, 84], ["S. flexneri 2a", "ORGANISM", 95, 109], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["S. sonnei", "SPECIES", 75, 84], ["S. flexneri", "SPECIES", 95, 106], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["S. sonnei", "SPECIES", 75, 84], ["S. flexneri", "SPECIES", 95, 106], ["the study", "TEST", 60, 69]]], ["The number and proportion of S. flexneri 2a isolates decreased from 42.6% (n = 262) in 1994 to 13.6% (n = 3) in 2010, whereas the proportion of S. sonnei increased from 36.6% (n = 225) to 82.3% (n = 20) during the entire period of data collection.", [["S. flexneri 2a", "ORGANISM", 29, 43], ["S. sonnei", "ORGANISM", 144, 153], ["S. flexneri", "SPECIES", 29, 40], ["S. sonnei", "SPECIES", 144, 153], ["S. flexneri", "SPECIES", 29, 40], ["S. sonnei", "SPECIES", 144, 153], ["S. flexneri 2a isolates", "TEST", 29, 52], ["S. sonnei", "TEST", 144, 153]]], ["S. flexneri 2a ranked the first among the S. flexneri subtypes except in 2003, 2004, and 2005.", [["S. flexneri 2a", "ORGANISM", 0, 14], ["S. flexneri", "ORGANISM", 42, 53], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 42, 53], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 42, 53]]], ["S. flexneri 4c, 4a, and S. flexneri x were seldom isolated, accounting for only about 3% (n = 180) of the 5934 S. flexneri and S. sonnei isolates.", [["S. flexneri 4c", "ORGANISM", 0, 14], ["4a", "GENE_OR_GENE_PRODUCT", 16, 18], ["S. flexneri x", "ORGANISM", 24, 37], ["S. flexneri", "ORGANISM", 111, 122], ["S. sonnei", "ORGANISM", 127, 136], ["isolates", "ORGANISM", 137, 145], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 24, 35], ["S. flexneri", "SPECIES", 111, 122], ["S. sonnei", "SPECIES", 127, 136], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 24, 35], ["S. flexneri", "SPECIES", 111, 122], ["S. sonnei", "SPECIES", 127, 136], ["S. flexneri", "PROBLEM", 24, 35], ["flexneri", "OBSERVATION", 27, 35]]], ["However, S. flexneri 4c was the most frequently isolated S. flexneri serotype in 2004 (26.4%, n = 65) and 2005 (20.3%, n = 30).", [["S. flexneri 4c", "ORGANISM", 9, 23], ["S. flexneri serotype", "ORGANISM", 57, 77], ["S. flexneri", "SPECIES", 9, 20], ["S. flexneri serotype", "SPECIES", 57, 77], ["S. flexneri", "SPECIES", 9, 20], ["S. flexneri", "SPECIES", 57, 68], ["flexneri serotype", "TEST", 60, 77]]], ["S. flexneri 4c and S. sonnei were isolated in equal numbers in 2004.Seasonality ::: ResultsShigella isolates were recovered routinely throughout the study but were frequently recovered in the summer months (June to September; t = 7.83, p < 0.001; Table 2).", [["S. flexneri 4c", "ORGANISM", 0, 14], ["S. sonnei", "ORGANISM", 19, 28], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["Shigella isolates", "TEST", 91, 108], ["the study", "TEST", 145, 154], ["t", "TEST", 226, 227]]], ["Isolation of Shigella almost always peaked in July and August; 2003 and 2008 were exceptional years during which a September peak was observed.", [["Shigella", "PROBLEM", 13, 21], ["Shigella", "OBSERVATION_MODIFIER", 13, 21]]], ["In September 2008, the amount of rainfall was 98.1 mm, which was twice the amount of rainfall during the same month in 2007 (Provided by China Meteorological Data Sharing Service System, http://cdc.cma.gov.cn/home.do).", [["amount", "OBSERVATION_MODIFIER", 23, 29], ["amount", "OBSERVATION_MODIFIER", 75, 81]]], ["Both factors may have contributed to the late seasonal peaks.Age distribution ::: ResultsEpidemiological information was available for all 5999 patients.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["the late seasonal peaks", "PROBLEM", 37, 60]]], ["Patient age ranged from 3 months to 90 years.", [["Patient", "SPECIES", 0, 7]]], ["The age distribution for the 5934 cases of S. flexneri and S. sonnei is shown in Table 3.", [["S. flexneri", "ORGANISM", 43, 54], ["S. sonnei", "ORGANISM", 59, 68], ["S. flexneri", "SPECIES", 43, 54], ["S. sonnei", "SPECIES", 59, 68], ["S. flexneri", "SPECIES", 43, 54], ["S. sonnei", "SPECIES", 59, 68]]], ["Adults aged between 21 and 25 years were the most commonly affected group (n = 978; 16.3%), followed closely by children aged less than 6 years (n = 821; 13.6%).", [["Adults", "ORGANISM", 0, 6], ["children", "ORGANISM", 112, 120], ["Adults", "SPECIES", 0, 6], ["children", "SPECIES", 112, 120]]], ["S. flexneri 2a and S. sonnei were recovered from patients in each age group, although most infections caused by S. sonnei were found in children (n = 1639; 48%); children aged 0 to 5, 6 to 10, and 11 to 15 years accounted for 17.6% (n = 289), 15.2% (n = 250), and 14.8% (n = 242) of the cases, respectively.", [["infections", "DISEASE", 91, 101], ["S. flexneri 2a", "ORGANISM", 0, 14], ["S. sonnei", "ORGANISM", 19, 28], ["patients", "ORGANISM", 49, 57], ["S. sonnei", "ORGANISM", 112, 121], ["children", "ORGANISM", 136, 144], ["children", "ORGANISM", 162, 170], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["patients", "SPECIES", 49, 57], ["S. sonnei", "SPECIES", 112, 121], ["children", "SPECIES", 136, 144], ["children", "SPECIES", 162, 170], ["S. flexneri", "SPECIES", 0, 11], ["S. sonnei", "SPECIES", 19, 28], ["S. sonnei", "SPECIES", 112, 121]]], ["S. flexneri 2a occurred frequently in adults, especially those in the 21 to 25 (n = 594; 18.8%) and 26 to 30 (n = 380, 12%) age groups, although a high percentage (n = 400; 12.7%) was found to affect children aged less than 6 years.Gender ::: ResultsInformation about patient gender was known for all of the patients infected with S. flexneri and S. sonnei; distribution was slightly biased toward male patients (n = 3616; 60%; Table 4).", [["S. flexneri 2a", "ORGANISM", 0, 14], ["children", "ORGANISM", 200, 208], ["patient", "ORGANISM", 268, 275], ["patients", "ORGANISM", 308, 316], ["S. flexneri", "ORGANISM", 331, 342], ["S. sonnei", "ORGANISM", 347, 356], ["patients", "ORGANISM", 403, 411], ["S. flexneri", "SPECIES", 0, 11], ["children", "SPECIES", 200, 208], ["patient", "SPECIES", 268, 275], ["patients", "SPECIES", 308, 316], ["S. flexneri", "SPECIES", 331, 342], ["S. sonnei", "SPECIES", 347, 356], ["patients", "SPECIES", 403, 411], ["S. flexneri", "SPECIES", 0, 11], ["S. flexneri", "SPECIES", 331, 342], ["S. sonnei", "SPECIES", 347, 356], ["flexneri 2a", "OBSERVATION", 3, 14]]], ["Unexpectedly, the ratio for some of the predominant serotypes of S. flexneri and S. sonnei differed in distribution between male and female patients.", [["S. flexneri", "ORGANISM", 65, 76], ["S. sonnei", "ORGANISM", 81, 90], ["patients", "ORGANISM", 140, 148], ["S. flexneri", "SPECIES", 65, 76], ["S. sonnei", "SPECIES", 81, 90], ["patients", "SPECIES", 140, 148], ["S. flexneri", "SPECIES", 65, 76], ["S. sonnei", "SPECIES", 81, 90], ["the ratio", "TEST", 14, 23], ["S. flexneri", "PROBLEM", 65, 76], ["predominant", "OBSERVATION_MODIFIER", 40, 51], ["serotypes", "OBSERVATION_MODIFIER", 52, 61], ["flexneri", "OBSERVATION_MODIFIER", 68, 76]]], ["The most prevalent S. flexneri serotype (2a) was found more frequently in males (63.5%, p < 0.0001) than in females (36.5%).", [["S. flexneri serotype", "ORGANISM", 19, 39], ["S. flexneri serotype", "SPECIES", 19, 39], ["S. flexneri", "SPECIES", 19, 30], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["flexneri serotype", "OBSERVATION", 22, 39]]], ["Similarly, S. flexneri 5 affected more males than females (ratio of infected males to females, 28 [46%]:5 [44%]; p < 0.001), although this serotype is not common in Beijing.", [["S. flexneri 5", "ORGANISM", 11, 24], ["S. flexneri", "SPECIES", 11, 22], ["S. flexneri", "SPECIES", 11, 22], ["p", "TEST", 113, 114], ["flexneri", "OBSERVATION_MODIFIER", 14, 22]]], ["By contrast, S. flexneri 2b and 6 as well as S. sonnei were more often associated with women than with men (p < 0.003, p < 0.04, and p < 0.0001, respectively).Consent ::: DiscussionWritten informed consent was obtained from the patient for the publication of this report and any accompanying images.Competing interestsThe authors declared that they have no competing interests.Authors\u2019 contributionsYM, EC, CB, ZL, SC, JZ, HW, CZ performed the experiments and provided clinical samples and patient data, JZ analyzed the data, JDK and BZ wrote the first draft of the manuscript, FQ and ZW designed the study, supervised the experiments and contributed to the manuscript.", [["BZ", "CHEMICAL", 534, 536], ["FQ", "CHEMICAL", 578, 580], ["S. flexneri 2b", "ORGANISM", 13, 27], ["S. sonnei", "ORGANISM", 45, 54], ["women", "ORGANISM", 87, 92], ["men", "ORGANISM", 103, 106], ["patient", "ORGANISM", 228, 235], ["EC", "CELL", 403, 405], ["patient", "ORGANISM", 490, 497], ["S. flexneri", "SPECIES", 13, 24], ["S. sonnei", "SPECIES", 45, 54], ["women", "SPECIES", 87, 92], ["men", "SPECIES", 103, 106], ["patient", "SPECIES", 228, 235], ["patient", "SPECIES", 490, 497], ["S. flexneri", "SPECIES", 13, 24], ["S. sonnei", "SPECIES", 45, 54], ["S. flexneri", "TEST", 13, 24], ["any accompanying images", "TEST", 275, 298], ["EC", "TEST", 403, 405], ["clinical samples", "TEST", 469, 485], ["patient data", "TEST", 490, 502], ["the study", "TEST", 597, 606], ["ZL", "ANATOMY", 411, 413], ["SC", "ANATOMY", 415, 417]]]], "PMC7357925": [["\u75c5\u4f8b\u8d44\u6599\u4f8b1\uff0c\u5973\uff0c78\u5c81\uff0c\u65e2\u5f80\u6709\u51a0\u5fc3\u75c5\u53f2\u3002\u5165\u9662\u524d13 d\u51fa\u73b0\u95f4\u65ad\u54b3\u55fd\u4f34\u80f8\u95f7\u3001\u6c14\u77ed\uff0c\u65e0\u53d1\u70ed\uff0c\u81ea\u884c\u53e3\u670d\u836f\u7269\u6cbb\u7597\uff08\u4e0d\u8be6\uff09\u540e\uff0c\u75c7\u72b6\u9010\u6e10\u52a0\u91cd\uff0c\u5916\u9662\u884c\u8840\u5e38\u89c4\uff1aWBC 3.52\u00d7109/L\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u7edd\u5bf9\u503c2.09\u00d7109/L\u3001\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u503c0.73\u00d7109/L\u3001HGB 137 g/L\u3001PLT 133\u00d7109/L\u3001C\u53cd\u5e94\u86cb\u767d\uff08CRP\uff09108 mg/L\uff0c\u80ba\u90e8CT\u68c0\u67e5\u793a\uff1a\u53cc\u80ba\u591a\u53d1\u78e8\u73bb\u7483\u5f71\uff0c\u63d0\u793a\u201c\u75c5\u6bd2\u611f\u67d3\u3001\u80ba\u6c14\u80bf\u201d\u30022019-nCoV\u6838\u9178\u68c0\u6d4b\u5f31\u9633\u6027\uff0c\u8bca\u65ad\u4e3aCOVID-19\u3002\u5c45\u5bb6\u9694\u79bb\u6cbb\u7597\uff0c\u54b3\u5598\u3001\u80f8\u95f7\u75c7\u72b6\u8fdb\u884c\u6027\u52a0\u91cd\u3002\u518d\u6b21\u5230\u53d1\u70ed\u95e8\u8bca\u68c0\u67e5\uff0c\u8840\u6c27\u9971\u548c\u5ea6\uff08SPO2\uff0984\uff05\uff0c\u5165\u9662\u9694\u79bb\u6cbb\u7597\u3002\u5165\u9662\u7b2c1\u5929\uff0c\u60a3\u8005\u610f\u8bc6\u6e05\u695a\uff0c\u65e0\u53d1\u70ed\uff0c\u5fc3\u7387120\u6b21/min\uff0c\u547c\u543844\u6b21/min\uff0c\u8840\u538b155/93 mmHg\uff081 mmHg\uff1d0.133 kPa\uff09\uff0cSPO2 80\uff05\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u503e\u5411\u3002\u8840\u5e38\u89c4\uff1aWBC 15.03\u00d7109/L\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u7edd\u5bf9\u8ba1\u657013.12\u00d7109/L\uff0c\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u8ba1\u65700.73\u00d7109/L\uff0cHGB 137 g/L\uff0cPLT 88\u00d7109/L\u3002\u51dd\u8840\u529f\u80fd\uff1a\u51dd\u8840\u9176\u539f\u65f6\u95f4\uff08PT\uff0918.6 s\uff0c\u6d3b\u5316\u90e8\u5206\u51dd\u8840\u6d3b\u9176\u65f6\u95f4\uff08APTT\uff0937.6 s\uff0c\u7ea4\u7ef4\u86cb\u767d\u539f\uff08FIB\uff091.50 g/L\uff08\u53c2\u8003\u503c2.00\uff5e4.00\uff09\uff0cD-\u4e8c\u805a\u4f538.3 mg/L\uff08\u53c2\u8003\u503c0\uff5e0.5 mg/L\uff09\u3002\u751f\u5316\uff1aAST 44 U/L\uff0cALT 18 U/L\uff0cCRP 174 mg/L\uff08\u6b63\u5e38\u53c2\u8003\u503c0\uff5e8 mg/L\uff09\uff0cLDH 767 U/L\uff1b\u964d\u9499\u7d20\u539f\uff08PCT\uff090.67 \u00b5g/L\uff08\u6b63\u5e38\u53c2\u8003\u503c<0.05 \u00b5g/L\uff09\uff0c\u8d85\u654f\u808c\u9499\u86cb\u767d\uff08hsTNI\uff093 058.8 ng/L\uff08\u6b63\u5e38\u53c2\u8003\u503c<26.2 ng/L\uff09\uff0c\u78f7\u9178\u808c\u9178\u6fc0\u9176\u540c\u5de5\u9176\uff08CK-MB\uff0911.8 \u00b5g/L\uff08\u6b63\u5e38\u53c2\u8003\u503c<6.6 \u00b5g/L\uff09\uff0c\u8111\u94a0\u80bd\uff08BNP\uff09782.2 ng/L\uff08\u6b63\u5e38\u53c2\u8003\u503c<100.0 ng/L\uff09\u3002\u5fc3\u7535\u56fe\u793a\uff1a\u5ba4\u4e0a\u6027\u5fc3\u52a8\u8fc7\u901f\u3002\u53c2\u7167\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u5458\u4f1a\u529e\u516c\u5385\u3001\u56fd\u5bb6\u4e2d\u533b\u836f\u7ba1\u7406\u5c40\u53d1\u5e03\u7684\u300a\u65b0\u578b\u51a0\u72b6\u75c5\u6bd2\u80ba\u708e\u8bca\u7597\u65b9\u6848\uff08\u8bd5\u884c\u7b2c\u516d\u7248\uff09\u300b\uff0c\u8bca\u65ad\u4e3a\u201cCOVID-19\uff08\u5371\u91cd\u578b\uff09\uff0c\u5408\u5e76\u4e25\u91cd\u5fc3\u808c\u635f\u4f24\u3001\u5fc3\u529f\u80fd\u4e0d\u5168\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u51dd\u8840\u529f\u80fd\u5f02\u5e38\u3001\u7ee7\u53d1\u7ec6\u83cc\u611f\u67d3\u201d\u3002\u7ed9\u4e88\u9762\u7f69\u5438\u6c2710 L/min\uff0cSPO2 82\uff05\uff0c\u6c27\u5408\u6307\u6570136 mmHg\u3002\u7acb\u5373\u6539\u7528\u65e0\u521b\u901a\u6c14\uff08ST\u6a21\u5f0f\uff09\uff0c\u5438\u6c14\u6c14\u9053\u6b63\u538b\uff08IPAP\uff0912 cmH2O\uff081 cmH2O\uff1d0.098 kPa\uff09\uff0c\u547c\u6c14\u6c14\u9053\u6b63\u538b\uff08EPAP\uff095 cmH2O\uff0c\u5438\u5165\u6c27\u6d53\u5ea6\uff08FiO2\uff0980\uff05\uff1b\u540c\u65f6\u7ed9\u4e0e\u963f\u6bd4\u591a\u5c14\u3001\u83ab\u897f\u6c99\u661f\u3001\u7532\u6cfc\u5c3c\u9f99\uff0840 mg/d\uff09\u6297\u75c5\u6bd2\u6297\u7ec6\u83cc\u6cbb\u7597\u53ca\u6291\u5236\u708e\u75c7\u53cd\u5e94\uff1b\u80fa\u7898\u916e\u590d\u5f8b\uff0c\u767d\u86cb\u767d\u8865\u5145\u80f6\u4f53\u6e17\u900f\u538b\uff0c\u544b\u585e\u7c73\u5229\u5c3f\u7ea0\u6b63\u5fc3\u8870\uff0c\u7ef4\u6301\u6c34\u7535\u89e3\u8d28\u5e73\u8861\uff0c\u4fdd\u62a4\u80c3\u9ecf\u819c\u30022 h\u540e\u7f3a\u6c27\u75c7\u72b6\u5f97\u5230\u7f13\u89e3\uff0c\u7aa6\u6027\u5fc3\u5f8b98\u6b21/min\uff0c\u547c\u543828\u6b21/min\uff0cSPO2 94\uff05\uff0c\u6c27\u5408\u6307\u6570156 mmHg\u3002\u5165\u9662\u7b2c2\u5929\uff1a\u60a3\u8005\u51fa\u73b0\u610f\u8bc6\u969c\u788d\uff0c\u547c\u5438\u56f0\u96be\u52a0\u91cd\uff0c\u4f53\u6e2936.3 \u00b0C\uff0c\u8109\u7387114\u6b21/min\uff0c\u547c\u543835\u6b21/min\uff0c\u8840\u538b90/55 mmHg\uff0cSPO2 74\uff05\uff0c\u6c27\u5408\u6307\u6570123 mmHg\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u3002\u8840\u5e38\u89c4\uff1aWBC 12.52\u00d7109/L\u3001PLT 36\u00d7109/L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT 19.3 s\uff0cAPTT 44.9 s\uff0cFIB 0.71 g/L\uff0cD-\u4e8c\u805a\u4f539.1 mg/L\uff0cAST 111 U/L\uff0cALT 108 U/L\uff0c\u8003\u8651DIC\u7684\u53ef\u80fd\uff0c\u7ed9\u4e88\u4f4e\u5206\u5b50\u809d\u7d204 000 IU/d\uff0c\u8f93\u6ce8\u8840\u5c0f\u677f1 U\u548c\u51b7\u6c89\u6dc06 U\uff0c\u591a\u5df4\u80fa\u5347\u538b\uff0c\u7ea0\u6b63\u4f11\u514b\uff0c\u540c\u65f6\u7ed9\u4e88\u80c3\u7ba1\u9f3b\u9972\u8425\u517b\u652f\u6301\u3002\u5165\u9662\u7b2c4\u5929\uff0c\u60a3\u8005\u610f\u8bc6\u6062\u590d\uff0c\u5076\u6709\u54b3\u55fd\u54b3\u75f0\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\uff0cSpO2 93\uff05\uff0c\u4f53\u6e2936.5 \u00b0C\uff0c\u8109\u738781\u6b21/min\uff0c\u547c\u543820\u6b21/min\uff0c\u8840\u538b139/85 mmHg\uff0cSPO2 94\uff05\uff0c\u6c27\u5408\u6307\u6570156 mmHg\uff0cWBC 10.26\u00d7109/L\uff0cPLT 77\u00d7109/L\uff0cPT 15.6 s\uff0cAPTT 36.0 s\uff0cFIB 2.05 g/L\uff0cD-\u4e8c\u805a\u4f535.35 mg/L\uff0c\u505c\u7528\u591a\u5df4\u80fa\u3002\u5165\u9662\u7b2c15\u65e5\uff0c\u60a3\u8005\u54b3\u55fd\u54b3\u75f0\u51cf\u8f7b\uff0c\u7f3a\u6c27\u75c7\u72b6\u6539\u5584\uff0c\u9010\u6b65\u8fc7\u6e21\u5230\u9762\u7f69\u5438\u6c27\uff0cSpO2 95\uff05\uff0c\u6c27\u5408\u6307\u6570158 mmHg\uff0c\u4f53\u6e2936.5 \u00b0C\uff0c\u8109\u738781\u6b21/min\uff0c\u547c\u543824\u6b21/min\uff0c\u8840\u538b139/85 mmHg\u3002\u5165\u9662\u7b2c18\u5929\uff0c\u60a3\u8005\u7cbe\u795e\u72b6\u6001\u826f\u597d\uff0c\u505c\u6b62\u9f3b\u9972\uff0cSpO2 95\uff05\uff5e98\uff05\u3002\u4f53\u6e2936.3 \u00b0C\uff0c\u8109\u738785\u6b21/min\uff0c\u547c\u543822\u6b21/min\uff0c\u8840\u538b106/62 mmHg\uff0cSPO2 95\uff05\uff5e98\uff05\uff0c\u6c27\u5408\u6307\u6570237 mmHg\u3002\u7ee7\u7eed\u6297\u75c5\u6bd2\u3001\u6297\u611f\u67d3\u3001\u8865\u5145\u767d\u86cb\u767d\u53ca\u5bf9\u75c7\u652f\u6301\u6cbb\u7597\u3002PLT\u5347\u4e3a174\u00d7109/L\uff0cPT 14.5 s\uff0cAPTT 33.1 s\uff0cFIB 2.96 g/L\uff0cD-\u4e8c\u805a\u4f535.35 mg/L\u3002\u751f\u5316\uff1aAST 30 U/L\uff0cALT 51 U/L\uff0cCRP 13.82 mg/L\u3001LDH325 U/L\uff1bPCT0.10 \u00b5g/L\uff0chsTNI 22.9 ng/L\uff0cCK-MB6.3 \u00b5g/L\uff0cBNP 42.9 ng/L\u3002\u590d\u67e5\u5e8a\u65c1\u80f8\u7247\u793a\uff1a\u4e24\u80ba\u6de1\u8584\u7d6e\u72b6\u78e8\u73bb\u7483\u5f71\u3002\u75c5\u4f8b\u8d44\u6599\u4f8b2\uff0c\u7537\uff0c79\u5c81\uff0c\u95f4\u65ad\u53d1\u70ed\u3001\u80f8\u95f7\u4f34\u5168\u8eab\u808c\u8089\u9178\u75db16 d\uff0c\u6700\u9ad8\u4f53\u6e2937.8 \u00b0C\uff0c\u793e\u533a\u533b\u9662\u884c\u80ba\u90e8CT\u63d0\u793a\u201c\u75c5\u6bd2\u6027\u80ba\u708e\u8868\u73b0\u201d\uff0c\u7ed9\u4e88\u6297\u75c5\u6bd2\u6cbb\u7597\u65e0\u660e\u663e\u6539\u5584\uff0c\u80f8\u95f7\u52a0\u91cd\u3002\u518d\u6b21\u5230\u53d1\u70ed\u95e8\u8bca\u68c0\u67e5\uff0c\u80ba\u90e8\u611f\u67d3\u8fdb\u5c55\uff0c2019-nCoV\u6838\u9178\u68c0\u6d4b\u9633\u6027\uff0cSPO2 84\uff05\uff0c\u7ecf\u7edf\u4e00\u5b89\u6392\u6536\u81f3\u534f\u548c\u533b\u9662\u897f\u9662\u9694\u79bb\u6cbb\u7597\u3002\u5165\u9662\u7b2c1\u5929\uff0c\u60a3\u8005\u610f\u8bc6\u6e05\u695a\uff0c\u65e0\u53d1\u70ed\uff0c\u5fc3\u738796\u6b21/min\uff0c\u547c\u543822\u6b21/min\uff0c\u8840\u538b157/81 mmHg\uff0cSPO2 90\uff05\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u503e\u5411\u3002\u8840\u5e38\u89c4\uff1aWBC 15.25\u00d7109/L\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u7edd\u5bf9\u8ba1\u657014.72\u00d7109/L\u3001\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u8ba1\u65700.32\u00d7109/L\u3001HGB 137 g/L\u3001PLT 95\u00d7109/L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT 17.9 s\uff0cAPTT 40.1 s\uff0cFIB 0.25 g/L\uff0cD-\u4e8c\u805a\u4f538.3 mg/L\u3002\u751f\u5316\uff1aAST 40 U/L\uff0cALT 48 U/L\uff0cCRP 58.35 mg/L\u3001LDH 623 U/L\uff1bPCT 0.14 \u00b5g/L\uff0chsTNI 94.5 ng/L\uff0cCK-MB 1.7 \u00b5g/L\uff0cBNP 454.1 ng/L\u3002\u53c2\u7167\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u5458\u4f1a\u529e\u516c\u5385\u3001\u56fd\u5bb6\u4e2d\u533b\u836f\u7ba1\u7406\u5c40\u53d1\u5e03\u7684\u300a\u65b0\u578b\u51a0\u72b6\u75c5\u6bd2\u80ba\u708e\u8bca\u7597\u65b9\u6848\uff08\u8bd5\u884c\u7b2c\u516d\u7248\uff09\u300b\uff0c\u8bca\u65ad\u4e3a\u201cCOVID-19\uff08\u91cd\u578b\uff09\u201d\u3002\u7ed9\u4e88\u9762\u7f69\u5438\u6c27\uff088 L/min\uff09\uff0cSPO2 94\uff05\u3002\u540c\u65f6\u7ed9\u4e0e\u963f\u6bd4\u591a\u5c14\u3001\u83ab\u897f\u6c99\u661f\u3001\u7532\u6cfc\u5c3c\u9f9940 mg/d \u6cbb\u7597\u3002\u5165\u9662\u7b2c2\u5929\uff0c\u60a3\u8005\u70e6\u8e81\uff0c\u547c\u5438\u6025\u4fc3\uff0c\u4f53\u6e2937.3 \u00b0C\uff0c\u5fc3\u7387110\u6b21/min\uff0c\u547c\u543833\u6b21/min\uff0c\u8840\u538b150/100 mmHg\uff0cSPO2 80\uff05\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u3002\u5fc3\u7535\u56fe\u793a\uff1a\u5ba4\u4e0a\u6027\u5fc3\u52a8\u8fc7\u901f\u3002\u8840\u5e38\u89c4\uff1aWBC 18.85\u00d7109/L\uff0cPLT 71\u00d7109/L\u3002PT 18.5 s\uff0cAPTT 34.7 s\uff0cFIB 0.25 g/L\uff0cD-\u4e8c\u805a\u4f538.7 mg/L\uff0chsTNI 2 063.7 ng/L\uff0cCK-MB 4.7 \u00b5g/L\uff0cBNP 339.9 ng/L\u3002\u8003\u8651DIC\u7684\u53ef\u80fd\uff0c\u7ed9\u4e88\u4f4e\u5206\u5b50\u809d\u7d204 000 IU/d\uff0c\u8f93\u6ce8\u51b7\u6c89\u6dc06 U\u3001\u65b0\u9c9c\u51b0\u51bb\u8840\u6d46400 ml\u3002\u6539\u4e3a\u65e0\u521b\u547c\u5438\u673a\u8f85\u52a9\u547c\u5438\uff0cSpO2 \u5347\u81f396\uff05\u3002\u5165\u9662\u7b2c3\u5929\uff1a\u60a3\u8005\u547c\u5438\u8f83\u5e73\u7a33\uff0cSpO2 98\uff05\uff5e100\uff05\u3002\u4f53\u6e2937.1 \u00b0C\uff0c\u8109\u738785\u6b21/min\uff0c\u547c\u543828\u6b21/min\uff0c\u8840\u538b135/78 mmHg\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u3002\u8840\u5e38\u89c4\uff1aWBC10.55\u00d7109/L\u3001PLT 71\u00d7109/L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT 15.8 s\uff0cAPTT 42.9 s\uff0cFIB 1.87 g/L\uff0cD-\u4e8c\u805a\u4f538.4 mg/L\uff0c\u7ee7\u7eed\u4f7f\u7528\u4f4e\u5206\u5b50\u809d\u7d20\u6297\u51dd\u3002\u5165\u9662\u7b2c5\u5929\uff0c\u60a3\u8005\u547c\u5438\u8f83\u5e73\u7a33\uff0cSpO2 98\uff05\uff5e100\uff05\uff0c\u4f53\u6e2937.2 \u00b0C\uff0c\u8109\u738789\u6b21/min\uff0c\u547c\u543824\u6b21/min\uff0cPLT 75\u00d7109/L\uff0cPT15.8 s\uff0cAPTT40.4 s\uff0cFIB 2.33 g/L\uff0cD-\u4e8c\u805a\u4f538.1 mg/L\uff0chsTNI 210.2 ng/L\uff0cCK-MB 0.9 \u00b5g/L\u3002\u75c5\u4f8b\u8d44\u6599\u4f8b1\u548c\u4f8b2\u60a3\u8005\u8840\u5c0f\u677f\u8ba1\u6570\u3001\u51dd\u8840\u6307\u6807\u53ca\u4e2d\u56fd\u5f25\u6563\u6027\u8840\u7ba1\u5185\u51dd\u8840\u8bca\u65ad\u79ef\u5206\u7cfb\u7edf\uff08CDSS\uff09\uff3b2\uff3d\u2013\uff3b3\uff3d\u8bc4\u5206\u89c1\u88681\u3001\u88682\u3002\u8ba8\u8bba\u6b7b\u4ea1\u7684COVID-19\u60a3\u8005\u5f80\u5f80\u4f34\u6709\u591a\u5668\u5b98\u529f\u80fd\u7684\u8870\u7aed\uff0c\u800c\u975e\u5355\u7eaf\u547c\u5438\u7a98\u8feb\uff0c\u76ee\u524d\u7684\u4e3b\u6d41\u89c2\u70b9\u8ba4\u4e3a\u662f\u75c5\u6bd2\u89e6\u53d1\u708e\u75c7\u56e0\u5b50\u98ce\u66b4\uff0c\u5bfc\u81f4\u591a\u810f\u5668\u4e0d\u53ef\u9006\u6027\u91cd\u5ea6\u708e\u75c7\u635f\u4f24\u6240\u81f4\uff3b4\uff3d\u3002\u7136\u800c\uff0c\u708e\u75c7\u56e0\u5b50\u5bfc\u81f4\u4f55\u79cd\u75c5\u7406\u6539\u53d8\u7814\u7a76\u5f97\u5e76\u4e0d\u900f\u5f7b\uff0c\u6709\u5f85\u66f4\u8be6\u5c3d\u7684\u75c5\u7406\u5b66\u548c\u5b9e\u9a8c\u5ba4\u7814\u7a76\u52a0\u4ee5\u9610\u8ff0\u3002\u8ba8\u8bba\u5728\u5df2\u53d1\u8868\u7684COVID-19\u60a3\u8005\u4e34\u5e8a\u7279\u5f81\u63cf\u8ff0\u6027\u6587\u7ae0\u4e2d\uff0c\u90fd\u63d0\u5230\u4e86\u8840\u5c0f\u677f\u8ba1\u6570\u53d8\u5316\u548c\u51dd\u8840\u6307\u6807\u5f02\u5e38\u3002\u5728\u7b2c\u4e00\u7bc7\u53d1\u8868\u4e8eLANCET\u6742\u5fd7\u7684\u62a5\u9053\u4e2d\uff0c41\u4f8b\u60a3\u8005\u8840\u5c0f\u677f\u51cf\u5c11\u7684\u53d1\u751f\u7387\u4e3a5\uff05\uff0cPT\u5ef6\u957f\u548cD-\u4e8c\u805a\u4f53\u5347\u9ad8\u5728ICU\u60a3\u8005\u4e0e\u975eICU\u60a3\u8005\u95f4\u7684\u5dee\u5f02\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\uff3b1\uff3d\uff1b\u7b2c\u4e8c\u7bc7LANCET\u6587\u732e\u4e2d\u63d0\u5230\uff1a99\u4f8b\u60a3\u8005\u4e2d\uff0c\u8840\u5c0f\u677f\u51cf\u5c11\u53d1\u751f\u738712\uff05\uff0cPT\u5ef6\u957f\u6bd4\u4f8b\u4e3a5\uff05\uff0cD-\u4e8c\u805a\u4f53\u5347\u9ad8\u6bd4\u4f8b\u4e3a36\uff05\uff3b5\uff3d\uff1bWang\u7b49\uff3b6\uff3d\u7eb3\u5165138\u4f8b\u60a3\u8005\u7684\u62a5\u9053\u4e2d\uff0cICU\u60a3\u8005\u4e0e\u975eICU\u60a3\u8005\u7684D-\u4e8c\u805a\u4f53\u5206\u522b\u4e3a414 mg/L\u3001166 mg/L\uff0cPT\u8f7b\u5ea6\u5ef6\u957f\u3002\u949f\u5357\u5c71\u9662\u58eb\u56e2\u961f\u603b\u7ed3\u4e861 099\u4f8b\u4e2d\u56fdCOVID-19\u60a3\u8005\u4e34\u5e8a\u7279\u5f81\uff0c\u663e\u793a\u8840\u5c0f\u677f\u8ba1\u6570\u4f4e\u4e8e150\u00d7109/L\u7684\u60a3\u8005\u536036.2\uff05\u3001D-\u4e8c\u805a\u4f53\u5347\u9ad8\u536046.4\uff05\uff0c\u5728\u5371\u91cd\u60a3\u8005\u4e2d\u5206\u522b\u4e3a57.7\uff05\u300159.6\uff05\uff3b7\uff3d\u3002\u672c\u7814\u7a762\u4f8b\u91cd\u75c7/\u5371\u91cd\u75c7\u60a3\u8005D-\u4e8c\u805a\u4f53\u660e\u663e\u5347\u9ad8\u3001\u8840\u5c0f\u677f\u51cf\u5c11\u3001PT\u8f7b\u4e2d\u5ea6\u5ef6\u957f\u3001APTT\u65e0\u5f02\u5e38\uff0c\u4e0e\u4e0a\u8ff0\u62a5\u9053\u975e\u5e38\u543b\u5408\u3002\u8ba8\u8bbaDIC\u662f\u5728\u8bb8\u591a\u75be\u75c5\u57fa\u7840\u4e0a\uff0c\u81f4\u75c5\u56e0\u7d20\u635f\u4f24\u5fae\u8840\u7ba1\u4f53\u7cfb\uff0c\u5bfc\u81f4\u51dd\u8840\u6d3b\u5316\uff0c\u5168\u8eab\u5fae\u8840\u7ba1\u8840\u6813\u5f62\u6210\u3001\u51dd\u8840\u56e0\u5b50\u5927\u91cf\u6d88\u8017\u5e76\u7ee7\u53d1\u7ea4\u6eb6\u4ea2\u8fdb\uff0c\u5f15\u8d77\u4ee5\u51fa\u8840\u53ca\u5fae\u5faa\u73af\u8870\u7aed\u4e3a\u7279\u5f81\u7684\u4e34\u5e8a\u7efc\u5408\u5f81\uff3b6\uff3d\u3002\u5371\u91cd\u578b\u65b0\u578b\u51a0\u72b6\u75c5\u6bd2\u80ba\u708e\u60a3\u8005\u56e0\u514d\u75ab\u529b\u4f4e\u4e0b\u7ee7\u53d1\u7ec6\u83cc\u771f\u83cc\u611f\u67d3\u4ee5\u53ca\u4f53\u5185\u7684\u708e\u75c7\u56e0\u5b50\u98ce\u66b4\u90fd\u662f\u8bf1\u53d1DIC\u7684\u9ad8\u5371\u56e0\u7d20\u30022\u4f8b\u60a3\u8005\u9662\u5916\u75c5\u7a0b\u8f83\u957f\uff0c\u5165\u9662\u65f6LDH\u3001CRP\u3001PCT\u5747\u8f83\u9ad8\uff0c\u63d0\u793a\u9664\u4e862019-nCoV\u611f\u67d3\u5916\uff0c\u8fd8\u6709\u7ee7\u53d1\u7ec6\u83cc\u611f\u67d3\u7684\u53ef\u80fd\uff0c\u5b58\u5728\u53d1\u751fDIC\u7684\u57fa\u7840\u8bf1\u56e0\u3002\u8ba8\u8bba\u65e2\u5f80\u6587\u732e\u663e\u793a\uff0c\u591a\u53d1\u51fa\u8840\u503e\u5411\u662fDIC\u6700\u5e38\u89c1\u7684\u4e34\u5e8a\u8868\u73b0\u4e4b\u4e00\uff3b2\uff3d\uff0c\u4f46\u672c\u7814\u7a762\u4f8b\u60a3\u8005\u4e2d\u5e76\u672a\u53d1\u751f\u51fa\u8840\uff0c\u800c\u4ee5\u5fae\u5faa\u73af\u969c\u788d\u3001\u4f11\u514b\u548c\u810f\u5668\u529f\u80fd\u8870\u7aed\u8868\u73b0\u66f4\u4e3a\u7a81\u51fa\u3002\u4f8b1\u60a3\u8005\u5165\u9662\u540e\u7ecf\u8fc7\u65e0\u521b\u547c\u5438\u673a\u8f85\u52a9\u547c\u5438\uff0c\u7f3a\u6c27\u75c7\u72b6\u66fe\u4e00\u5ea6\u597d\u8f6c\uff0c\u7136\u800c\u5165\u9662\u7b2c2\u5929\u7a81\u53d1\u610f\u8bc6\u969c\u788d\u3001\u547c\u5438\u7a98\u8feb\u3001\u8840\u538b\u4e0b\u964d\u3001\u809d\u9176\u5347\u9ad8\uff1b\u4f8b2\u60a3\u8005\u5165\u9662\u7b2c2\u5929\u51fa\u73b0\u547c\u5438\u7a98\u8feb\u3001\u5fc3\u5f8b\u5931\u5e38\u3001\u5fc3\u808c\u9176\u5347\u9ad8\uff0c\u63d0\u793a\u5fc3\u808c\u53d7\u635f\u3002\u7ed3\u54082\u4f8b\u60a3\u8005\u540c\u65f6\u4f34\u6709\u8840\u5c0f\u677f\u8fdb\u884c\u6027\u964d\u4f4e\u3001PT\u5ef6\u957f\u3001FIB\u6781\u5ea6\u51cf\u5c11\uff0c\u63a8\u6d4b\u4e3a\u591a\u4e2a\u810f\u5668\uff08\u80ba\u3001\u8111\u3001\u809d\u810f\u3001\u5fc3\u810f\uff09\u5fae\u8840\u7ba1\u5185\u5fae\u8840\u6813\u5f62\u6210\uff0c\u4f34\u6709\u51dd\u8840\u56e0\u5b50\u7684\u6d88\u8017\uff0c\u53d1\u751f\u4e86DIC\u3002\u7acb\u5373\u7ed9\u4e88\u4f4e\u5206\u5b50\u809d\u7d20\u6297\u51dd\u3001\u66ff\u4ee3\u6cbb\u7597\uff08\u8f93\u6ce8\u8840\u5c0f\u677f\u3001\u51b7\u6c89\u6dc0/\u8840\u6d46\uff09\u5e76\u79ef\u6781\u6cbb\u7597\u539f\u53d1\u75c5\uff08\u83ab\u897f\u6c99\u661f\u6297\u611f\u67d3/\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6291\u5236\u708e\u75c7\u635f\u4f24\uff09\uff0c\u8f85\u4ee5\u7ea0\u6b63\u4f11\u514b\u3001\u7ea0\u6b63\u5fc3\u8870\u3001\u7ef4\u6301\u7535\u89e3\u8d28\u5e73\u8861\u7b49\u7efc\u5408\u6cbb\u7597\uff0cDIC\u77ed\u671f\u5185\u5f97\u5230\u7ea0\u6b63\uff0c\u4e34\u5e8a\u75c7\u72b6\u660e\u663e\u597d\u8f6c\u3002\u8ba8\u8bbaDIC\u7684\u8bca\u65ad\u4f9d\u8d56\u4e34\u5e8a\u8868\u73b0\u548c\u5b9e\u9a8c\u5ba4\u6307\u6807\u52a8\u6001\u89c2\u5bdf\u3001\u7efc\u5408\u5224\u65ad\u3002\u4e3a\u7cbe\u786e\u91cf\u5316DIC\u7684\u8bca\u65ad\u6807\u51c6\uff0c\u4e2d\u534e\u533b\u5b66\u4f1a\u8840\u6db2\u5b66\u5206\u4f1a\u8840\u6813\u4e0e\u6b62\u8840\u5b66\u7ec4\u4e8e2014\u5e74\u8d77\u901a\u8fc7\u591a\u4e2d\u5fc3\u3001\u5927\u6837\u672c\u7684\u56de\u987e\u6027\u4e0e\u524d\u77bb\u6027\u7814\u7a76\uff0c\u5efa\u7acb\u4e86CDSS\u8bc4\u5206\u7cfb\u7edf\uff3b2\uff3d\u2013\uff3b3\uff3d\u3002CDSS\u8bc4\u5206\u7cfb\u7edf\u7a81\u51fa\u4e86\u57fa\u7840\u75be\u75c5\u548c\u4e34\u5e8a\u8868\u73b0\u7684\u91cd\u8981\u6027\uff0c\u5f3a\u5316\u52a8\u6001\u76d1\u6d4b\u539f\u5219\uff0c\u800c\u4e14\u6d89\u53ca\u7684\u5b9e\u9a8c\u5ba4\u68c0\u6d4b\u6307\u6807\u7b80\u5355\uff0c\u8f83\u65e2\u5f80\u7684\u56fd\u9645\u8840\u6813\u4e0e\u6b62\u8840\u534f\u4f1a\u6807\u51c6\uff08ISTH\uff09\u79ef\u5206\u7cfb\u7edf\u548c\u65e5\u672c\u6025\u8bca\u533b\u5b66\u5b66\u4f1a\u6807\u51c6\u79ef\u5206\u7cfb\u7edf\uff0c\u66f4\u6613\u4e8e\u666e\u53ca\uff0c\u591a\u6570\u533b\u9662\u7684\u68c0\u9a8c\u79d1\u90fd\u80fd\u5b8c\u6210\uff3b8\uff3d\u3002\u6211\u4eec\u53c2\u7167\u8be5\u7cfb\u7edf\u5bf92\u4f8b\u60a3\u8005\u8fdb\u884c\u56de\u987e\u6027\u79ef\u5206\uff08\u88681\u30012\uff09\uff0c\u53d1\u73b0\u4f8b1\u60a3\u8005\u5728\u5165\u9662\u5f53\u5929\u79ef\u5206\u4e3a7\uff0c\u5df2\u6ee1\u8db3\u975e\u6076\u6027\u8840\u6db2\u75c5DIC\u8bca\u65ad\u6807\u51c6\uff0c\u4f46\u672a\u884c\u7ea0\u6b63DIC\u7684\u6cbb\u7597\u3002\u7b2c\u4e8c\u5929\u75c5\u60c5\u52a0\u91cd\uff0cDIC\u79ef\u5206\u5347\u81f311\uff0c\u7ecf\u79ef\u6781\u7efc\u5408\u6cbb\u7597\u540e\uff0c\u79ef\u5206\u9010\u6e10\u4e0b\u964d\u81f34\u3002\u4f8b2\u60a3\u8005\u5165\u9662\u5f53\u5929\u79ef\u5206\u4e3a5\uff0c\u7b2c\u4e8c\u5929\u75c7\u72b6\u52a0\u91cd\u79ef\u5206\u4e3a7\uff0c\u6cbb\u7597\u540e\u5fc3\u808c\u9176\u4e0b\u964d\uff0c\u547c\u5438\u56f0\u96be\u6539\u5584\uff0c\u79ef\u5206\u4ea6\u4e0b\u964d\u4e3a5\u3002\u521d\u6b65\u8868\u660eCDSS\u79ef\u5206\u7cfb\u7edf\u80fd\u591f\u65e9\u671f\u8bc6\u522b\u65b0\u578b\u51a0\u72b6\u75c5\u6bd2\u80ba\u708e\u5408\u5e76DIC\uff0c\u5e76\u4e0eDIC\u7684\u4e25\u91cd\u7a0b\u5ea6\u6709\u76f8\u5173\u6027\u3002\u8ba8\u8bba\u65e2\u5f80\u5bf9SARS-Cov\u7684\u7814\u7a76\u4e2d\u65e9\u5df2\u53d1\u73b0\uff0c\u60a3\u8005\u7684\u80ba\u7ec4\u7ec7\u4e2d\u5b58\u5728\u4e0d\u540c\u5bfb\u5e38\u7684\u5f25\u6563\u6027\u5c0f\u8840\u6813\u5f62\u6210\uff3b9\uff3d\uff0c\u8840\u7ba1\u7684\u635f\u4f24\u4e5f\u666e\u904d\u5b58\u5728\u4e8e\u4e0d\u540c\u7ec4\u7ec7\u5668\u5b98\u4e2d\uff3b10\uff3d\u3002Enjuanes\u7b49\uff3b11\uff3d\u62a5\u9053\uff0cSARS-Cov\u611f\u67d3\u673a\u4f53\u540e\uff0c\u4f1a\u4e0a\u8c03\u51dd\u8840\u9014\u5f84\u7684\u76f8\u5173\u57fa\u56e0\u8868\u8fbe\uff0c\u5bfc\u81f4\u51dd\u8840\u6d3b\u5316\u3002\u7814\u7a76\u663e\u793a\uff0c2019-nCoV\u5bfc\u81f4\u7684\u51dd\u8840\u6307\u6807\u5f02\u5e38\u7279\u70b9\u4e0eSARS-Cov\u4e0d\u5c3d\u76f8\u540c\uff0c\u800c\u4e14\u66f4\u5bb9\u6613\u53d1\u751f\u9664\u80ba\u90e8\u4ee5\u5916\u7684\u591a\u810f\u5668\u529f\u80fd\u8870\u7aed\uff3b12\uff3d\u3002\u56e0\u6b64\uff0c2019-nCoV\u8bf1\u53d1\u51dd\u8840\u5f02\u5e38\u7684\u5206\u5b50\u673a\u5236\u3001\u4e0e\u708e\u75c7\u56e0\u5b50\u98ce\u66b4\u95f4\u7684\u5173\u8054\u3001COVID-19\u60a3\u8005\u7279\u522b\u662f\u5371\u91cd\u75c7\u60a3\u8005\u6025\u901f\u8fdb\u5c55\u7684\u591a\u810f\u5668\u529f\u80fd\u8870\u7aed/\u547c\u5438\u7a98\u8feb\u4e0eDIC\u4e4b\u95f4\u7684\u5173\u7cfb\u8fd8\u6709\u5f85\u4e8e\u66f4\u4e3a\u6df1\u5165\u548c\u8be6\u5c3d\u7684\u57fa\u7840\u7814\u7a76\u548c\u75c5\u7406\u5b66\u7814\u7a76\u3002", [["D-\u4e8c", "SIMPLE_CHEMICAL", 534, 537], ["CRP", "GENE_OR_GENE_PRODUCT", 2430, 2433], ["APTT", "PROTEIN", 489, 493], ["CRP", "PROTEIN", 588, 591], ["CRP", "PROTEIN", 1950, 1953], ["AST", "PROTEIN", 2408, 2411], ["CRP", "PROTEIN", 2430, 2433], ["APTT", "PROTEIN", 3061, 3065], ["PLT", "PROTEIN", 3170, 3173], ["PLT", "TEST", 137, 140], ["SPO2", "TEST", 351, 355], ["WBC", "TEST", 375, 378], ["L\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u7edd\u5bf9", "TEST", 389, 398], ["L", "TEST", 429, 430], ["HGB", "TEST", 431, 434], ["g", "TEST", 439, 440], ["L", "TEST", 441, 442], ["PLT", "TEST", 443, 446], ["L", "TEST", 454, 455], ["PT", "TEST", 468, 470], ["\uff09", "TEST", 470, 471], ["s\uff0c\u6d3b\u5316\u90e8\u5206\u51dd\u8840\u6d3b\u9176\u65f6\u95f4", "TEST", 476, 488], ["\uff08", "TEST", 488, 489], ["APTT", "TEST", 489, 493], ["FIB", "TEST", 507, 510], ["D", "TEST", 534, 535], ["\u4f53", "TEST", 538, 539], ["mg", "TEST", 543, 545], ["L\uff08\u53c2\u8003", "TEST", 546, 550], ["\u503c", "TEST", 550, 551], ["\uff5e", "TEST", 552, 553], ["mg", "TEST", 557, 559], ["L\uff09\u3002\u751f\u5316", "TEST", 560, 565], ["\uff1a", "TEST", 565, 566], ["AST", "TEST", 566, 569], ["U", "TEST", 573, 574], ["L", "TEST", 575, 576], ["\uff0c", "TEST", 576, 577], ["ALT", "TEST", 577, 580], ["U", "TEST", 584, 585], ["L", "TEST", 586, 587], ["\uff0c", "TEST", 587, 588], ["CRP", "TEST", 588, 591], ["mg", "TEST", 596, 598], ["L\uff08\u6b63\u5e38\u53c2\u8003", "TEST", 599, 605], ["\u503c", "TEST", 605, 606], ["mg", "TEST", 610, 612], ["L\uff09", "TEST", 613, 615], ["\uff0c", "TEST", 615, 616], ["LDH", "TEST", 616, 619], ["U", "TEST", 624, 625], ["L\uff1b\u964d\u9499\u7d20\u539f", "TEST", 626, 632], ["\uff08", "TEST", 632, 633], ["PCT", "TEST", 633, 636], ["\uff09", "TEST", 636, 637], ["\u00b5g", "TEST", 642, 644], ["L\uff08\u6b63\u5e38\u53c2\u8003", "TEST", 645, 651], ["\u503c", "TEST", 651, 652], ["\u00b5g", "TEST", 658, 660], ["L\uff09\uff0c\u8d85\u654f\u808c\u9499\u86cb\u767d\uff08hsTNI\uff093", "TEST", 661, 678], ["ng", "TEST", 685, 687], ["L\uff08\u6b63\u5e38\u53c2\u8003", "TEST", 688, 694], ["\u503c", "TEST", 694, 695], ["ng", "TEST", 701, 703], ["L\uff09\uff0c\u78f7\u9178\u808c\u9178\u6fc0\u9176\u540c\u5de5\u9176\uff08CK", "TEST", 704, 719], ["MB", "TEST", 720, 722], ["\u00b5g", "TEST", 728, 730], ["L\uff08\u6b63\u5e38\u53c2\u8003", "TEST", 731, 737], ["\u503c", "TEST", 737, 738], ["\u00b5g", "TEST", 743, 745], ["L\uff09\uff0c\u8111\u94a0\u80bd", "TEST", 746, 752], ["BNP", "TEST", 753, 756], ["\uff09", "TEST", 756, 757], ["ng", "TEST", 763, 765], ["L\uff08\u6b63\u5e38\u53c2\u8003", "TEST", 766, 772], ["\u503c", "TEST", 772, 773], ["L/min\uff0cSPO2", "TEST", 910, 920], ["mmHg\u3002\u7acb\u5373\u6539\u7528\u65e0\u521b\u901a\u6c14\uff08ST\u6a21\u5f0f\uff09\uff0c\u5438\u6c14\u6c14\u9053\u6b63\u538b\uff08IPAP", "TEST", 933, 964], ["cmH2O", "TEST", 968, 973], ["cmH2O", "TEST", 976, 981], ["kPa\uff09\uff0c\u547c\u6c14\u6c14\u9053\u6b63\u538b\uff08EPAP\uff095", "TEST", 988, 1006], ["mmHg\uff0cSPO2", "TEST", 1231, 1240], ["\u5408", "TEST", 1246, 1247], ["mmHg\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u3002\u8840\u5e38\u89c4\uff1a", "TEST", 1253, 1271], ["WBC", "TEST", 1271, 1274], ["L", "TEST", 1285, 1286], ["PLT", "TEST", 1287, 1290], ["\u00d7", "TEST", 1293, 1294], ["L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT", "TEST", 1298, 1307], ["s", "TEST", 1313, 1314], ["APTT", "TEST", 1315, 1319], ["s", "TEST", 1325, 1326], ["FIB", "TEST", 1327, 1330], ["g", "TEST", 1336, 1337], ["L\uff0cD", "TEST", 1338, 1341], ["\u4e8c\u805a", "TEST", 1342, 1344], ["\u4f53", "TEST", 1344, 1345], ["mg", "TEST", 1349, 1351], ["L", "TEST", 1352, 1353], ["AST", "TEST", 1354, 1357], ["U", "TEST", 1362, 1363], ["L", "TEST", 1364, 1365], ["ALT", "TEST", 1366, 1369], ["U", "TEST", 1374, 1375], ["L\uff0c\u8003\u8651DIC\u7684\u53ef\u80fd\uff0c\u7ed9\u4e88\u4f4e\u5206\u5b50\u809d\u7d204", "TEST", 1376, 1395], ["IU", "TEST", 1400, 1402], ["d\uff0c\u8f93\u6ce8\u8840\u5c0f", "TEST", 1403, 1409], ["\u677f", "TEST", 1409, 1410], ["U\u548c\u51b7\u6c89", "TEST", 1412, 1416], ["\u6dc0", "TEST", 1416, 1417], ["U\uff0c\u591a\u5df4\u80fa\u5347\u538b\uff0c\u7ea0\u6b63\u4f11\u514b\uff0c\u540c\u65f6\u7ed9\u4e88\u80c3\u7ba1\u9f3b\u9972\u8425\u517b\u652f\u6301\u3002\u5165\u9662\u7b2c4\u5929\uff0c\u60a3\u8005\u610f\u8bc6\u6062\u590d\uff0c\u5076\u6709\u54b3\u55fd\u54b3\u75f0\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\uff0cSpO2", "TEST", 1419, 1478], ["\u4f53\u6e29", "TEST", 1483, 1485], ["\u00b0", "TEST", 1490, 1491], ["C\uff0c\u8109", "TEST", 1491, 1494], ["\u7387", "TEST", 1494, 1495], ["min\uff0c", "TEST", 1499, 1503], ["\u547c", "TEST", 1503, 1504], ["\u5438", "TEST", 1504, 1505], ["min\uff0c", "TEST", 1509, 1513], ["\u8840", "TEST", 1513, 1514], ["\u538b", "TEST", 1514, 1515], ["mmHg", "TEST", 1522, 1526], ["SPO2", "TEST", 1527, 1531], ["\u6c27", "TEST", 1536, 1537], ["\u5408", "TEST", 1537, 1538], ["\u6307", "TEST", 1538, 1539], ["\u6570", "TEST", 1539, 1540], ["mmHg", "TEST", 1544, 1548], ["\uff0c", "TEST", 1548, 1549], ["WBC", "TEST", 1549, 1552], ["109/L", "TEST", 1559, 1564], ["PLT", "TEST", 1565, 1568], ["\u00d7", "TEST", 1571, 1572], ["L\uff0cPT", "TEST", 1576, 1580], ["s", "TEST", 1586, 1587], ["APTT", "TEST", 1588, 1592], ["s", "TEST", 1598, 1599], ["FIB", "TEST", 1600, 1603], ["g", "TEST", 1609, 1610], ["L\uff0cD", "TEST", 1611, 1614], ["\u4f53", "TEST", 1617, 1618], ["mg", "TEST", 1623, 1625], ["L\uff0c\u505c\u7528\u591a\u5df4\u80fa\u3002\u5165\u9662\u7b2c15\u65e5\uff0c\u60a3\u8005\u54b3\u55fd\u54b3\u75f0\u51cf\u8f7b\uff0c\u7f3a\u6c27\u75c7\u72b6\u6539\u5584\uff0c\u9010\u6b65\u8fc7\u6e21\u5230\u9762\u7f69\u5438\u6c27\uff0cSpO2", "TEST", 1626, 1671], ["\u5408", "TEST", 1677, 1678], ["mmHg\uff0c", "TEST", 1684, 1689], ["\u4f53", "TEST", 1689, 1690], ["\u6e29", "TEST", 1690, 1691], ["C\uff0c\u8109\u738781\u6b21", "TEST", 1697, 1704], ["min\uff0c", "TEST", 1705, 1709], ["\u547c", "TEST", 1709, 1710], ["\u5438", "TEST", 1710, 1711], ["24\u6b21/min\uff0c", "TEST", 1711, 1719], ["\u8840", "TEST", 1719, 1720], ["mmHg\u3002\u5165\u9662\u7b2c18\u5929\uff0c\u60a3\u8005\u7cbe\u795e\u72b6\u6001\u826f\u597d\uff0c\u505c\u6b62\u9f3b\u9972\uff0cSpO2", "TEST", 1728, 1758], ["\u4f53", "TEST", 1767, 1768], ["\u6e29", "TEST", 1768, 1769], ["\u00b0", "TEST", 1774, 1775], ["C\uff0c\u8109", "TEST", 1775, 1778], ["\u7387", "TEST", 1778, 1779], ["min\uff0c", "TEST", 1783, 1787], ["\u547c", "TEST", 1787, 1788], ["min\uff0c", "TEST", 1793, 1797], ["\u8840", "TEST", 1797, 1798], ["mmHg", "TEST", 1806, 1810], ["SPO2", "TEST", 1811, 1815], ["\u5408", "TEST", 1825, 1826], ["mmHg\u3002\u7ee7\u7eed\u6297\u75c5\u6bd2\u3001\u6297\u611f\u67d3\u3001\u8865\u5145\u767d\u86cb\u767d\u53ca\u5bf9\u75c7\u652f\u6301\u6cbb\u7597\u3002PLT\u5347\u4e3a174\u00d7109/L\uff0cPT", "TEST", 1832, 1877], ["s", "TEST", 1883, 1884], ["\uff0c", "TEST", 1884, 1885], ["APTT", "TEST", 1885, 1889], ["s\uff0c", "TEST", 1895, 1897], ["FIB", "TEST", 1897, 1900], ["g", "TEST", 1906, 1907], ["L\uff0cD", "TEST", 1908, 1911], ["\u4e8c", "TEST", 1912, 1913], ["\u805a", "TEST", 1913, 1914], ["\u4f53", "TEST", 1914, 1915], ["mg", "TEST", 1920, 1922], ["L\u3002\u751f\u5316", "TEST", 1923, 1927], ["\uff1a", "TEST", 1927, 1928], ["AST", "TEST", 1928, 1931], ["U", "TEST", 1935, 1936], ["L", "TEST", 1937, 1938], ["\uff0c", "TEST", 1938, 1939], ["ALT", "TEST", 1939, 1942], ["U", "TEST", 1946, 1947], ["L", "TEST", 1948, 1949], ["\uff0c", "TEST", 1949, 1950], ["CRP", "TEST", 1950, 1953], ["mg", "TEST", 1960, 1962], ["L\u3001", "TEST", 1963, 1965], ["LDH325", "TEST", 1965, 1971], ["U", "TEST", 1972, 1973], ["L", "TEST", 1974, 1975], ["\uff1b", "TEST", 1975, 1976], ["PCT0.10", "TEST", 1976, 1983], ["\u00b5g", "TEST", 1984, 1986], ["L\uff0chsTNI", "TEST", 1987, 1994], ["ng", "TEST", 2000, 2002], ["L\uff0cCK", "TEST", 2003, 2007], ["MB6.3", "TEST", 2008, 2013], ["\u00b5g", "TEST", 2014, 2016], ["L\uff0cBNP", "TEST", 2017, 2022], ["\u00b0C\uff0c\u793e\u533a\u533b\u9662\u884c\u80ba\u90e8CT\u63d0\u793a\u201c\u75c5\u6bd2\u6027\u80ba\u708e\u8868\u73b0", "TEST", 2093, 2115], ["\u201d\uff0c\u7ed9\u4e88\u6297\u75c5\u6bd2\u6cbb\u7597\u65e0\u660e\u663e\u6539\u5584\uff0c\u80f8\u95f7\u52a0\u91cd\u3002\u518d\u6b21\u5230\u53d1\u70ed\u95e8\u8bca\u68c0\u67e5\uff0c\u80ba\u90e8\u611f\u67d3\u8fdb\u5c55\uff0c2019-nCoV\u6838\u9178\u68c0\u6d4b\u9633\u6027\uff0cSPO2", "TEST", 2115, 2172], ["mmHg\uff0cSPO2", "TEST", 2241, 2250], ["WBC", "TEST", 2270, 2273], ["L\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u7edd\u5bf9", "TEST", 2284, 2293], ["L\u3001\u6dcb\u5df4\u7ec6\u80de\u7edd\u5bf9\u8ba1\u65700.32\u00d7109/L\u3001", "TEST", 2305, 2326], ["HGB", "TEST", 2326, 2329], ["g", "TEST", 2334, 2335], ["L", "TEST", 2336, 2337], ["PLT", "TEST", 2338, 2341], ["L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT", "TEST", 2349, 2358], ["s", "TEST", 2364, 2365], ["\uff0c", "TEST", 2365, 2366], ["APTT", "TEST", 2366, 2370], ["s\uff0c", "TEST", 2376, 2378], ["FIB", "TEST", 2378, 2381], ["g", "TEST", 2387, 2388], ["L\uff0cD", "TEST", 2389, 2392], ["\u4f53", "TEST", 2395, 2396], ["AST", "TEST", 2408, 2411], ["U", "TEST", 2415, 2416], ["L", "TEST", 2417, 2418], ["ALT", "TEST", 2419, 2422], ["U", "TEST", 2426, 2427], ["L", "TEST", 2428, 2429], ["CRP", "TEST", 2430, 2433], ["mg", "TEST", 2440, 2442], ["LDH", "TEST", 2445, 2448], ["U", "TEST", 2453, 2454], ["L", "TEST", 2455, 2456], ["PCT", "TEST", 2457, 2460], ["\u00b5g", "TEST", 2466, 2468], ["L\uff0chsTNI", "TEST", 2469, 2476], ["ng", "TEST", 2482, 2484], ["L\uff0cCK", "TEST", 2485, 2489], ["MB", "TEST", 2490, 2492], ["\u00b5g", "TEST", 2497, 2499], ["L\uff0cBNP", "TEST", 2500, 2505], ["ng", "TEST", 2512, 2514], ["L/min\uff09\uff0cSPO2", "TEST", 2592, 2603], ["C\uff0c\u5fc3", "TEST", 2661, 2664], ["min\uff0c", "TEST", 2670, 2674], ["min\uff0c", "TEST", 2680, 2684], ["\u538b", "TEST", 2685, 2686], ["mmHg", "TEST", 2694, 2698], ["SPO2", "TEST", 2699, 2703], ["\u5168", "TEST", 2708, 2709], ["\uff1a", "TEST", 2733, 2734], ["WBC", "TEST", 2734, 2737], ["\u00d7", "TEST", 2743, 2744], ["L", "TEST", 2748, 2749], ["\uff0c", "TEST", 2749, 2750], ["PLT", "TEST", 2750, 2753], ["\u00d7", "TEST", 2756, 2757], ["L", "TEST", 2761, 2762], ["\u3002", "TEST", 2762, 2763], ["PT", "TEST", 2763, 2765], ["s", "TEST", 2771, 2772], ["\uff0c", "TEST", 2772, 2773], ["APTT", "TEST", 2773, 2777], ["s", "TEST", 2783, 2784], ["\uff0c", "TEST", 2784, 2785], ["FIB", "TEST", 2785, 2788], ["g", "TEST", 2794, 2795], ["L\uff0cD", "TEST", 2796, 2799], ["\u4e8c", "TEST", 2800, 2801], ["\u805a", "TEST", 2801, 2802], ["\u4f53", "TEST", 2802, 2803], ["mg", "TEST", 2807, 2809], ["L\uff0chsTNI", "TEST", 2810, 2817], ["ng", "TEST", 2826, 2828], ["L\uff0cCK", "TEST", 2829, 2833], ["MB", "TEST", 2834, 2836], ["\u00b5g", "TEST", 2841, 2843], ["L", "TEST", 2844, 2845], ["BNP", "TEST", 2846, 2849], ["ng", "TEST", 2856, 2858], ["L\u3002\u8003\u8651DIC", "TEST", 2859, 2866], ["\u7684", "TEST", 2866, 2867], ["\u53ef\u80fd\uff0c\u7ed9\u4e88\u4f4e\u5206\u5b50\u809d\u7d204", "TEST", 2867, 2878], ["IU", "TEST", 2883, 2885], ["d\uff0c\u8f93\u6ce8\u51b7", "TEST", 2886, 2891], ["\u6c89", "TEST", 2891, 2892], ["\u6dc0", "TEST", 2892, 2893], ["U\u3001\u65b0\u9c9c\u51b0\u51bb\u8840", "TEST", 2895, 2902], ["\u6d46", "TEST", 2902, 2903], ["ml\u3002\u6539\u4e3a\u65e0\u521b\u547c\u5438\u673a\u8f85\u52a9\u547c\u5438", "TEST", 2907, 2921], ["\uff0c", "TEST", 2921, 2922], ["SpO2", "TEST", 2922, 2926], ["\uff05\u3002\u5165", "TEST", 2931, 2934], ["\u9662", "TEST", 2934, 2935], ["\u7b2c3", "TEST", 2935, 2937], ["\u5929\uff1a", "TEST", 2937, 2939], ["\u60a3", "TEST", 2939, 2940], ["\u8005\u547c\u5438", "TEST", 2940, 2943], ["\u8f83\u5e73\u7a33", "TEST", 2943, 2946], ["\uff0c", "TEST", 2946, 2947], ["SpO2", "TEST", 2947, 2951], ["\uff05", "TEST", 2954, 2955], ["\uff5e", "TEST", 2955, 2956], ["\u4f53", "TEST", 2961, 2962], ["\u6e29", "TEST", 2962, 2963], ["\u00b0", "TEST", 2968, 2969], ["C\uff0c\u8109", "TEST", 2969, 2972], ["\u7387", "TEST", 2972, 2973], ["min\uff0c", "TEST", 2977, 2981], ["\u547c", "TEST", 2981, 2982], ["\u543828\u6b21", "TEST", 2982, 2986], ["min\uff0c", "TEST", 2987, 2991], ["\u538b", "TEST", 2992, 2993], ["mmHg\uff0c\u5168\u8eab\u65e0\u6d3b\u52a8\u6027\u51fa\u8840\u3002\u8840\u5e38\u89c4\uff1aWBC10.55\u00d7109/", "TEST", 3000, 3031], ["L\u3001", "TEST", 3031, 3033], ["PLT", "TEST", 3033, 3036], ["\u00d7", "TEST", 3039, 3040], ["L\u3002\u51dd\u8840\u529f\u80fd\uff1aPT", "TEST", 3044, 3053], ["s", "TEST", 3059, 3060], ["\uff0c", "TEST", 3060, 3061], ["APTT", "TEST", 3061, 3065], ["s\uff0c", "TEST", 3071, 3073], ["FIB", "TEST", 3073, 3076], ["g", "TEST", 3082, 3083], ["L\uff0cD", "TEST", 3084, 3087], ["\u4e8c\u805a", "TEST", 3088, 3090], ["\u4f53", "TEST", 3090, 3091], ["mg", "TEST", 3095, 3097], ["L\uff0c\u7ee7\u7eed\u4f7f\u7528\u4f4e\u5206\u5b50\u809d\u7d20\u6297\u51dd\u3002\u5165\u9662\u7b2c5\u5929\uff0c\u60a3\u8005\u547c\u5438\u8f83\u5e73\u7a33\uff0cSpO2", "TEST", 3098, 3130], ["\u00b0", "TEST", 3147, 3148], ["C\uff0c\u8109", "TEST", 3148, 3151], ["\u7387", "TEST", 3151, 3152], ["min\uff0c", "TEST", 3156, 3160], ["\u547c", "TEST", 3160, 3161], ["\u5438", "TEST", 3161, 3162], ["PLT", "TEST", 3170, 3173], ["\u00d7", "TEST", 3176, 3177], ["\uff0c", "TEST", 3182, 3183], ["PT", "TEST", 3183, 3185], ["s", "TEST", 3190, 3191], ["\uff0c", "TEST", 3191, 3192], ["APTT40.4", "TEST", 3192, 3200], ["s", "TEST", 3201, 3202], ["\uff0c", "TEST", 3202, 3203], ["FIB", "TEST", 3203, 3206], ["g", "TEST", 3212, 3213], ["L\uff0cD", "TEST", 3214, 3217], ["\u4e8c\u805a", "TEST", 3218, 3220], ["\u4f53", "TEST", 3220, 3221], ["mg", "TEST", 3225, 3227], ["L\uff0chsTNI", "TEST", 3228, 3235], ["ng", "TEST", 3242, 3244], ["L\uff0cCK", "TEST", 3245, 3249], ["MB", "TEST", 3250, 3252], ["\u00b5g", "TEST", 3257, 3259]]]], "PMC7106424": [["Introduction: the need for plasma-derived products is still there and growingSeveral plasma proteins (factor VIII, factor IX, activated factor VII, antithrombin, and C1-inhibitor) produced by recombinant DNA technologies using mammalian cell expression or transgenic animals [1] are now on the market.", [["plasma", "ANATOMY", 27, 33], ["plasma", "ANATOMY", 85, 91], ["cell", "ANATOMY", 237, 241], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["plasma", "ORGANISM_SUBSTANCE", 85, 91], ["factor VIII", "GENE_OR_GENE_PRODUCT", 102, 113], ["factor IX", "GENE_OR_GENE_PRODUCT", 115, 124], ["factor VII", "GENE_OR_GENE_PRODUCT", 136, 146], ["antithrombin", "GENE_OR_GENE_PRODUCT", 148, 160], ["C1", "GENE_OR_GENE_PRODUCT", 166, 168], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["mammalian cell", "CELL", 227, 241], ["plasma proteins", "PROTEIN", 85, 100], ["factor VIII", "PROTEIN", 102, 113], ["factor IX", "PROTEIN", 115, 124], ["activated factor VII", "PROTEIN", 126, 146], ["antithrombin", "PROTEIN", 148, 160], ["C1", "PROTEIN", 166, 168], ["plasma-derived products", "TREATMENT", 27, 50], ["Several plasma proteins", "PROBLEM", 77, 100], ["factor IX", "TEST", 115, 124], ["activated factor VII", "TREATMENT", 126, 146], ["antithrombin", "TREATMENT", 148, 160], ["C1-inhibitor", "TREATMENT", 166, 178], ["recombinant DNA technologies", "TREATMENT", 192, 220], ["mammalian cell expression", "TREATMENT", 227, 252], ["transgenic animals", "PROBLEM", 256, 274]]], ["Several decades after their introduction, controversies are still ongoing to determine the benefits, limits, and immunological risks of recombinant coagulation factors compared to their plasma counterparts [2].Introduction: the need for plasma-derived products is still there and growingOne point of agreement is the high costs of these products which have not significantly decreased much since their introduction to the market despite early promises and hopes.", [["plasma", "ANATOMY", 186, 192], ["plasma", "ANATOMY", 237, 243], ["recombinant coagulation factors", "GENE_OR_GENE_PRODUCT", 136, 167], ["plasma", "ORGANISM_SUBSTANCE", 186, 192], ["plasma", "ORGANISM_SUBSTANCE", 237, 243], ["recombinant coagulation factors", "PROTEIN", 136, 167], ["recombinant coagulation factors", "PROBLEM", 136, 167], ["plasma-derived products", "TREATMENT", 237, 260], ["high", "OBSERVATION_MODIFIER", 317, 321], ["significantly", "OBSERVATION_MODIFIER", 361, 374], ["decreased", "OBSERVATION", 375, 384]]], ["Recent technological advances show the feasibility of developing potentially safe modified recombinant products that exhibit improved functional characteristics including prolonged half-lives [3].", [["safe modified recombinant products", "TREATMENT", 77, 111]]], ["In spite of these important developments, there is a continuously increasing demand at the global level for fractionated plasma products, including immunoglobulin G (IgG), albumin, coagulation factors, anti-proteases, and fibrin sealants.", [["plasma", "ANATOMY", 121, 127], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 148, 164], ["IgG", "GENE_OR_GENE_PRODUCT", 166, 169], ["albumin", "GENE_OR_GENE_PRODUCT", 172, 179], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 181, 200], ["anti-proteases", "SIMPLE_CHEMICAL", 202, 216], ["fibrin", "GENE_OR_GENE_PRODUCT", 222, 228], ["fractionated plasma products", "PROTEIN", 108, 136], ["immunoglobulin G", "PROTEIN", 148, 164], ["IgG", "PROTEIN", 166, 169], ["albumin", "PROTEIN", 172, 179], ["coagulation factors", "PROTEIN", 181, 200], ["anti-proteases", "PROTEIN", 202, 216], ["a continuously increasing demand", "PROBLEM", 51, 83], ["fractionated plasma products", "TREATMENT", 108, 136], ["immunoglobulin G (IgG", "TEST", 148, 169], ["albumin", "TEST", 172, 179], ["coagulation factors", "PROBLEM", 181, 200], ["anti-proteases", "TREATMENT", 202, 216], ["fibrin sealants", "TREATMENT", 222, 237], ["fibrin sealants", "OBSERVATION", 222, 237]]], ["The development of plasma fractionation technologies has now expanded the range of plasma products to over 20 [4].Introduction: the need for plasma-derived products is still there and growingSupplies of plasma-derived products at the national level can be achieved by importation of products, fractionation of local plasma, or contract fractionation.", [["plasma", "ANATOMY", 19, 25], ["plasma", "ANATOMY", 83, 89], ["plasma", "ANATOMY", 141, 147], ["plasma", "ANATOMY", 203, 209], ["plasma", "ANATOMY", 316, 322], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["plasma", "ORGANISM_SUBSTANCE", 203, 209], ["plasma", "ORGANISM_SUBSTANCE", 316, 322], ["plasma fractionation technologies", "TEST", 19, 52], ["plasma products", "TREATMENT", 83, 98], ["plasma-derived products", "TREATMENT", 141, 164], ["plasma-derived products", "TREATMENT", 203, 226], ["local plasma", "TEST", 310, 322], ["plasma fractionation", "OBSERVATION", 19, 39]]], ["In terms of global demands, the volume of plasma fractionated has been steadily increasing in the last few years, and has now reached close to 35 million liters worldwide, compared to approximately 25 million liters some 10 years ago [5].Introduction: the need for plasma-derived products is still there and growingMost of the plasma is fractionated in advanced economies where professional fractionators and mature, well-balanced regulatory systems exist to ensure product quality and safety through rigorous licensing and post-marketing surveillance.", [["plasma", "ANATOMY", 42, 48], ["plasma", "ANATOMY", 265, 271], ["plasma", "ANATOMY", 327, 333], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["plasma", "ORGANISM_SUBSTANCE", 265, 271], ["plasma", "ORGANISM_SUBSTANCE", 327, 333], ["global demands", "PROBLEM", 12, 26], ["plasma fractionated", "PROBLEM", 42, 61], ["plasma-derived products", "TREATMENT", 265, 288], ["post-marketing surveillance", "TEST", 524, 551], ["global demands", "OBSERVATION", 12, 26], ["steadily", "OBSERVATION_MODIFIER", 71, 79], ["increasing", "OBSERVATION_MODIFIER", 80, 90]]], ["Approximately 80% of the plasma used for fractionation is obtained by apheresis procedures, most often collected from paid donors in the US and Europe, and the rest (approximately 8 million liters) is prepared from whole blood collected from volunteer, non-remunerated donors, in national blood collection systems that mostly target an appropriate supply of red blood cell concentrates [5].", [["plasma", "ANATOMY", 25, 31], ["whole blood", "ANATOMY", 215, 226], ["blood", "ANATOMY", 289, 294], ["red blood cell", "ANATOMY", 358, 372], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["donors", "ORGANISM", 269, 275], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["red blood cell", "CELL", 358, 372], ["fractionation", "TREATMENT", 41, 54], ["apheresis procedures", "TREATMENT", 70, 90], ["national blood collection systems", "TREATMENT", 280, 313], ["red blood cell concentrates", "TREATMENT", 358, 385]]], ["Most fractionated products are consumed in industrialized countries [6], where the plasma fractionation industry is consolidating to adjust to market forces [5].", [["plasma", "ANATOMY", 83, 89], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["Most fractionated products", "TREATMENT", 0, 26], ["the plasma fractionation industry", "TREATMENT", 79, 112]]], ["The developing world uses a small portion of the fractionated plasma products as a result of product shortages and/or a lack of purchasing power for these sophisticated medicinal products.Increasing volumes of recovered plasma are wasted: why?Whereas the number of units of whole blood collected is approximately 30 units/1000 people in high-income countries, in most low- and middle-income countries, this number still ranges 5~10 units/1000 people [7].", [["plasma", "ANATOMY", 62, 68], ["plasma", "ANATOMY", 220, 226], ["whole blood", "ANATOMY", 274, 285], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["plasma", "ORGANISM_SUBSTANCE", 220, 226], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["people", "SPECIES", 327, 333], ["people", "SPECIES", 443, 449], ["the fractionated plasma products", "TREATMENT", 45, 77], ["Increasing volumes of recovered plasma", "PROBLEM", 188, 226], ["whole blood", "TEST", 274, 285]]], ["As one estimates that the most essential need for red blood cells (to treat malaria-related anemia, fatal hemorrhage, and trauma) requires approximately 15 units/1000 inhabitants, the number of blood collections is expected to increase in those countries, generating additional plasma units.", [["red blood cells", "ANATOMY", 50, 65], ["blood", "ANATOMY", 194, 199], ["plasma", "ANATOMY", 278, 284], ["malaria", "DISEASE", 76, 83], ["anemia", "DISEASE", 92, 98], ["hemorrhage", "DISEASE", 106, 116], ["trauma", "DISEASE", 122, 128], ["red blood cells", "CELL", 50, 65], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["plasma", "ORGANISM_SUBSTANCE", 278, 284], ["red blood cells", "CELL_TYPE", 50, 65], ["red blood cells", "TREATMENT", 50, 65], ["malaria", "PROBLEM", 76, 83], ["anemia", "PROBLEM", 92, 98], ["fatal hemorrhage", "PROBLEM", 100, 116], ["trauma", "PROBLEM", 122, 128], ["blood collections", "PROBLEM", 194, 211], ["additional plasma units", "TREATMENT", 267, 290], ["fatal", "OBSERVATION_MODIFIER", 100, 105], ["hemorrhage", "OBSERVATION", 106, 116], ["blood", "ANATOMY", 194, 199], ["collections", "OBSERVATION", 200, 211], ["increase", "OBSERVATION_MODIFIER", 227, 235]]], ["Fig. 1illustrates what is taking place in many blood establishments of medium-income countries, e.g., in Asia and South America.", [["blood", "ANATOMY", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 47, 52]]], ["While in many low-income countries, whole blood is still mostly used for transfusion [8], in medium-income countries, the use of whole blood has decreased, and it is becoming standard practice to perform component therapy to prepare red blood cells, and to some extent platelet concentrates as well.", [["whole blood", "ANATOMY", 36, 47], ["whole blood", "ANATOMY", 129, 140], ["red blood cells", "ANATOMY", 233, 248], ["platelet", "ANATOMY", 269, 277], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["red blood cells", "CELL", 233, 248], ["platelet", "CELL", 269, 277], ["red blood cells", "CELL_TYPE", 233, 248], ["whole blood", "TEST", 36, 47], ["transfusion", "TREATMENT", 73, 84], ["whole blood", "PROBLEM", 129, 140], ["component therapy", "TREATMENT", 204, 221], ["red blood cells", "TEST", 233, 248], ["decreased", "OBSERVATION_MODIFIER", 145, 154], ["some extent", "OBSERVATION_MODIFIER", 257, 268], ["platelet concentrates", "OBSERVATION", 269, 290]]], ["This has gradually generated increasing volumes of recovered plasma.Increasing volumes of recovered plasma are wasted: why?Part of this plasma is used for direct transfusions to treat clinical situations where its use is justified, but also others where an infusion of albumin, colloids, and fractionated coagulation factors, if they were available and affordable, would represent better standards of clinical practice and patient care.", [["plasma", "ANATOMY", 61, 67], ["plasma", "ANATOMY", 100, 106], ["plasma", "ANATOMY", 136, 142], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["plasma", "ORGANISM_SUBSTANCE", 100, 106], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["albumin", "GENE_OR_GENE_PRODUCT", 269, 276], ["patient", "ORGANISM", 423, 430], ["fractionated coagulation factors", "PROTEIN", 292, 324], ["patient", "SPECIES", 423, 430], ["Increasing volumes of recovered plasma", "PROBLEM", 68, 106], ["direct transfusions", "TREATMENT", 155, 174], ["clinical situations", "PROBLEM", 184, 203], ["an infusion of albumin", "TREATMENT", 254, 276], ["colloids", "TREATMENT", 278, 286], ["fractionated coagulation factors", "TREATMENT", 292, 324], ["clinical practice and patient care", "TREATMENT", 401, 435], ["increasing", "OBSERVATION_MODIFIER", 29, 39], ["volumes", "OBSERVATION_MODIFIER", 40, 47]]], ["This plasma can be separated into cryoprecipitate to provide a slightly concentrated source of factor VIII, fibrinogen, Von Willebrand factor, and factor XIII.", [["plasma", "ANATOMY", 5, 11], ["plasma", "ORGANISM_SUBSTANCE", 5, 11], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 34, 49], ["factor VIII", "GENE_OR_GENE_PRODUCT", 95, 106], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 108, 118], ["Von Willebrand factor", "GENE_OR_GENE_PRODUCT", 120, 141], ["factor XIII", "GENE_OR_GENE_PRODUCT", 147, 158], ["factor VIII", "PROTEIN", 95, 106], ["fibrinogen", "PROTEIN", 108, 118], ["Von Willebrand factor", "PROTEIN", 120, 141], ["factor XIII", "PROTEIN", 147, 158], ["cryoprecipitate", "TREATMENT", 34, 49], ["factor VIII", "TEST", 95, 106], ["fibrinogen", "TEST", 108, 118], ["Von Willebrand factor", "TEST", 120, 141]]], ["As blood collection increases and the needs for red blood cells surpass that of clinical plasma or cryoprecipitate, this will generate a larger number of plasma units not used for transfusions.", [["blood", "ANATOMY", 3, 8], ["red blood cells", "ANATOMY", 48, 63], ["plasma", "ANATOMY", 89, 95], ["plasma", "ANATOMY", 154, 160], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["red blood cells", "CELL", 48, 63], ["plasma", "ORGANISM_SUBSTANCE", 89, 95], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 99, 114], ["plasma", "ORGANISM_SUBSTANCE", 154, 160], ["red blood cells", "CELL_TYPE", 48, 63], ["blood collection", "TEST", 3, 19], ["red blood cells surpass", "TREATMENT", 48, 71], ["cryoprecipitate", "TREATMENT", 99, 114], ["a larger number of plasma units", "TREATMENT", 135, 166], ["transfusions", "TREATMENT", 180, 192]]], ["In many situations, this plasma is destroyed.", [["plasma", "ANATOMY", 25, 31], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["destroyed", "OBSERVATION", 35, 44]]], ["It could be used for fractionation if it could meet several conditions that include compliance with quality specifications for fractionation as accepted by a fractionator and approved by national regulatory authorities (NRAs).Increasing volumes of recovered plasma are wasted: why?The volume of such wasted plasma was estimated at over 5~6 million liters 10 years ago at the global level, and more-recent surveys carried out through the World Health Organization (WHO; unpublished report), taking into account (a) the number of blood donations worldwide (currently estimated to be 103 million annually) [7], and (b) the use of recovered plasma for transfusions and (c) for fractionation, suggest that, actually, close to 9.3 million liters of recovered plasma may be currently wasted or discarded yearly.", [["plasma", "ANATOMY", 258, 264], ["plasma", "ANATOMY", 307, 313], ["blood", "ANATOMY", 528, 533], ["plasma", "ANATOMY", 637, 643], ["plasma", "ANATOMY", 753, 759], ["plasma", "ORGANISM_SUBSTANCE", 258, 264], ["plasma", "ORGANISM_SUBSTANCE", 307, 313], ["blood", "ORGANISM_SUBSTANCE", 528, 533], ["plasma", "ORGANISM_SUBSTANCE", 637, 643], ["plasma", "ORGANISM_SUBSTANCE", 753, 759], ["fractionation", "TREATMENT", 21, 34], ["fractionation", "TREATMENT", 127, 140], ["Increasing volumes of recovered plasma", "PROBLEM", 226, 264], ["such wasted plasma", "PROBLEM", 295, 313], ["transfusions", "TREATMENT", 648, 660], ["fractionation", "TREATMENT", 673, 686], ["plasma", "TREATMENT", 753, 759], ["volume", "OBSERVATION_MODIFIER", 285, 291]]], ["More countries are therefore becoming interested in fractionation programs that make use of such wasted plasma to improve access to plasma-derived products of assured quality.", [["plasma", "ANATOMY", 104, 110], ["plasma", "ANATOMY", 132, 138], ["plasma", "ORGANISM_SUBSTANCE", 104, 110], ["plasma", "ORGANISM_SUBSTANCE", 132, 138], ["fractionation programs", "TREATMENT", 52, 74], ["such wasted plasma", "TREATMENT", 92, 110]]], ["One major issue is that currently collected plasma in low- and medium-income countries typically does not meet specifications for fractionation and is therefore discarded.", [["plasma", "ANATOMY", 44, 50], ["plasma", "ORGANISM_SUBSTANCE", 44, 50]]], ["This situation may however gradually improve since the recent listing of blood components on the WHO Model List of Essential Medicines [9] that should contribute increasing government awareness on the need for well-organized blood services, and implementation of good manufacturing practice (GMP) principles in blood establishments for improved product quality, safety and supply.Complexity of plasma fractionation technologyThe production processes of all biological products (recombinant proteins, monoclonal antibodies, vaccines, antivenoms, and plasma products) are, together with the starting material, a very important factor in the quality and safety, explaining the high level of regulatory focus on manufacturing methods and process validation.", [["blood", "ANATOMY", 73, 78], ["blood", "ANATOMY", 225, 230], ["blood", "ANATOMY", 311, 316], ["plasma", "ANATOMY", 394, 400], ["plasma", "ANATOMY", 549, 555], ["GMP", "CHEMICAL", 292, 295], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["blood", "ORGANISM_SUBSTANCE", 311, 316], ["plasma", "ORGANISM_SUBSTANCE", 394, 400], ["plasma", "ORGANISM_SUBSTANCE", 549, 555], ["recombinant proteins", "PROTEIN", 478, 498], ["monoclonal antibodies", "PROTEIN", 500, 521], ["Essential Medicines", "TREATMENT", 115, 134], ["plasma fractionation technology", "TREATMENT", 394, 425], ["all biological products", "TREATMENT", 453, 476], ["recombinant proteins", "TREATMENT", 478, 498], ["monoclonal antibodies", "TREATMENT", 500, 521], ["vaccines", "TREATMENT", 523, 531], ["antivenoms", "TREATMENT", 533, 543], ["plasma products", "TREATMENT", 549, 564], ["manufacturing methods", "TREATMENT", 708, 729], ["plasma fractionation", "OBSERVATION", 394, 414]]], ["In plasma fractionation, product specification is linked to the manufacturing process, and product quality depends on both the plasma and the process.", [["plasma", "ANATOMY", 3, 9], ["plasma", "ANATOMY", 127, 133], ["plasma", "ORGANISM_SUBSTANCE", 3, 9], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["plasma fractionation", "TEST", 3, 23], ["plasma fractionation", "OBSERVATION", 3, 23]]], ["It is often not realized that, among all manufacturing industries of biological products, the plasma fractionation downstream technology has reached a high, if not the highest, level of sophistication.", [["plasma", "ANATOMY", 94, 100], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["biological products", "TREATMENT", 69, 88], ["the plasma fractionation downstream technology", "TEST", 90, 136]]], ["This complexity is frequently underestimated.Complexity of plasma fractionation technologyPlasma fractionation is unique in a way that it requires integrated downstream purification and viral-reduction processes of a level of complexity that is demultiplied by the number and biochemical diversity of protein products \u2013 usually more than four or five \u2013 made from each plasma batch.", [["plasma", "ANATOMY", 59, 65], ["plasma", "ANATOMY", 368, 374], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["Plasma", "ORGANISM_SUBSTANCE", 90, 96], ["plasma", "ORGANISM_SUBSTANCE", 368, 374], ["protein products", "PROTEIN", 301, 317], ["plasma fractionation technology", "TREATMENT", 59, 90], ["Plasma fractionation", "TEST", 90, 110], ["integrated downstream purification", "TREATMENT", 147, 181], ["viral-reduction processes", "TREATMENT", 186, 211], ["protein products", "TREATMENT", 301, 317], ["plasma batch", "TREATMENT", 368, 380], ["frequently", "OBSERVATION_MODIFIER", 19, 29], ["underestimated", "OBSERVATION_MODIFIER", 30, 44], ["plasma fractionation", "OBSERVATION", 59, 79], ["viral", "OBSERVATION_MODIFIER", 186, 191], ["reduction", "OBSERVATION_MODIFIER", 192, 201]]], ["Each product-extraction procedure includes several critical purification steps encompassing precipitation, chromatography, depth filtration, ultrafiltration, and sterile filtration that should be carefully validated, controlled, and monitored for implementation at a production scale.", [["extraction procedure", "TREATMENT", 13, 33], ["several critical purification steps", "TREATMENT", 43, 78], ["chromatography", "TEST", 107, 121], ["depth filtration", "TREATMENT", 123, 139], ["ultrafiltration", "TREATMENT", 141, 156], ["sterile filtration", "TREATMENT", 162, 180], ["a production scale", "TEST", 265, 283]]], ["Extraction processes should be mild to avoid the risks of alterations that could lead to protein antigenicity or activation, and associated side-effects, like hypotension, fever, and thromboembolic events.", [["hypotension", "DISEASE", 159, 170], ["fever", "DISEASE", 172, 177], ["thromboembolic", "DISEASE", 183, 197], ["Extraction processes", "TREATMENT", 0, 20], ["protein antigenicity", "PROBLEM", 89, 109], ["hypotension", "PROBLEM", 159, 170], ["fever", "PROBLEM", 172, 177], ["thromboembolic events", "PROBLEM", 183, 204], ["hypotension", "OBSERVATION", 159, 170], ["fever", "OBSERVATION", 172, 177], ["thromboembolic", "OBSERVATION", 183, 197]]], ["In addition, all products should typically go through two dedicated and complementary viral-reduction procedures, either two viral-inactivation steps, or one viral-reduction treatment followed by one viral-removal step.Complexity of plasma fractionation technologyExperimental studies should be done to show the capacity of the process to remove prions [10].", [["plasma", "ANATOMY", 233, 239], ["plasma", "ORGANISM_SUBSTANCE", 233, 239], ["complementary viral-reduction procedures", "TREATMENT", 72, 112], ["inactivation steps", "TREATMENT", 131, 149], ["one viral-reduction treatment", "TREATMENT", 154, 183], ["viral-removal step", "TREATMENT", 200, 218], ["plasma fractionation technology", "TREATMENT", 233, 264], ["Experimental studies", "TEST", 264, 284], ["plasma fractionation", "OBSERVATION", 233, 253]]], ["Fractionation plants should be designed with great care based on the core fractionation processes of all products, and working procedures should be strictly controlled and monitored to avoid risks of cross or downstream contamination.", [["Fractionation plants", "TREATMENT", 0, 20], ["the core fractionation processes", "TREATMENT", 65, 97], ["all products", "TREATMENT", 101, 113], ["working procedures", "TREATMENT", 119, 137], ["cross or downstream contamination", "PROBLEM", 200, 233]]], ["In addition, because human plasma is susceptible, if not continuously exposed, to threats of new, known and unknown, infectious agents, continuous vigilance is needed to safeguard safety.", [["plasma", "ANATOMY", 27, 33], ["human", "ORGANISM", 21, 26], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["infectious agents", "TREATMENT", 117, 134], ["infectious", "OBSERVATION", 117, 127]]], ["Finally, the level of sophistication and requirements of quality control tests are continually evolving as new clinical information from pharmacological surveillance of products is obtained, as was recently the case in relation to thromboembolic risks associated with immunoglobulins [11].Contract fractionation: a pragmatic way to goBecause of the technological challenges mentioned above, combined with economic considerations linked to the high capital investment needed for a domestic fractionation facility, a contract plasma fractionation phase is a reasonable approach to consider, at least for an interim period of time of no less than 5 years, before starting domestic production, if and when justified.", [["plasma", "ANATOMY", 524, 530], ["thromboembolic", "DISEASE", 231, 245], ["plasma", "ORGANISM_SUBSTANCE", 524, 530], ["immunoglobulins", "PROTEIN", 268, 283], ["quality control tests", "TEST", 57, 78], ["thromboembolic risks", "PROBLEM", 231, 251], ["immunoglobulins", "TEST", 268, 283], ["a domestic fractionation facility", "TREATMENT", 478, 511], ["a contract plasma fractionation phase", "TEST", 513, 550], ["thromboembolic", "OBSERVATION", 231, 245]]], ["In such a situation, plasma is sent to a licensed fractionator, and final products are returned to the plasma supplier for use in the country after licensing.", [["plasma", "ANATOMY", 21, 27], ["plasma", "ANATOMY", 103, 109], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["plasma", "ORGANISM_SUBSTANCE", 103, 109]]], ["Such a program can be implemented within a relatively short time (1~3 years) provided a sufficient plasma volume can meet the fractionator's and regulatory authority's requirements [12].", [["plasma", "ANATOMY", 99, 105], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["a sufficient plasma volume", "TREATMENT", 86, 112]]], ["This involves the signing of a contractual agreement between the plasma supplier and fractionator.", [["plasma", "ANATOMY", 65, 71], ["plasma", "ORGANISM_SUBSTANCE", 65, 71]]], ["Contract fractionation requires strict oversight from regulatory authorities of both the plasma suppliers and fractionators to ensure quality requirements of the plasma for fractionation and fractionated end-products.", [["plasma", "ANATOMY", 89, 95], ["plasma", "ANATOMY", 162, 168], ["plasma", "ORGANISM_SUBSTANCE", 89, 95], ["plasma", "ORGANISM_SUBSTANCE", 162, 168], ["Contract fractionation", "TREATMENT", 0, 22], ["the plasma", "TEST", 158, 168], ["fractionation", "TREATMENT", 173, 186], ["fractionated end-products", "TREATMENT", 191, 216], ["fractionation", "OBSERVATION", 9, 22]]], ["Invariably, blood establishments, subjected to inspections and audits, will have to improve their working methodologies, practices, and procedures to follow fractionation production criteria for plasma needed by fractionators and regulators [12].Contract fractionation: a pragmatic way to goExamples show that contract fractionation can be performed for yearly volumes of plasmas of as low as 10,000 L, although some fractionators would prefer a range of at least 30,000 to 50,000 L considering the regulatory work (e.g., blood plasma collection audits and product licensing) and logistics involved to ensure that the plasma meets quality specifications, and products can be licensed.", [["blood", "ANATOMY", 12, 17], ["plasma", "ANATOMY", 195, 201], ["blood plasma", "ANATOMY", 522, 534], ["plasma", "ANATOMY", 618, 624], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["plasma", "ORGANISM_SUBSTANCE", 195, 201], ["blood", "ORGANISM_SUBSTANCE", 522, 527], ["plasma", "ORGANISM_SUBSTANCE", 528, 534], ["plasma", "ORGANISM_SUBSTANCE", 618, 624], ["contract fractionation", "TREATMENT", 310, 332], ["plasmas", "TEST", 372, 379], ["some fractionators", "PROBLEM", 412, 430], ["blood plasma collection audits", "TEST", 522, 552]]], ["Existing contract fractionation agreements do not generally involve more than 200,000 L of plasma per year and per fractionator.", [["plasma", "ANATOMY", 91, 97], ["plasma", "ORGANISM_SUBSTANCE", 91, 97]]], ["Typically, products obtained from such contracts include factor VIII, albumin, IgG, prothrombin complex, and/or factor IX.Contract fractionation: a pragmatic way to goAlthough plasma fractionation activities may be expensive, some countries have reported substantial savings associated with implementing fractionation activities of normally discarded recovered plasma, provided a convenient product balance is achieved.", [["plasma", "ANATOMY", 176, 182], ["plasma", "ANATOMY", 361, 367], ["factor VIII", "GENE_OR_GENE_PRODUCT", 57, 68], ["albumin", "GENE_OR_GENE_PRODUCT", 70, 77], ["IgG", "GENE_OR_GENE_PRODUCT", 79, 82], ["prothrombin", "GENE_OR_GENE_PRODUCT", 84, 95], ["factor IX", "GENE_OR_GENE_PRODUCT", 112, 121], ["plasma", "ORGANISM_SUBSTANCE", 176, 182], ["plasma", "ORGANISM_SUBSTANCE", 361, 367], ["factor VIII", "PROTEIN", 57, 68], ["albumin", "PROTEIN", 70, 77], ["IgG", "PROTEIN", 79, 82], ["prothrombin complex", "PROTEIN", 84, 103], ["factor IX", "PROTEIN", 112, 121], ["factor VIII", "TREATMENT", 57, 68], ["albumin", "TREATMENT", 70, 77], ["IgG", "TREATMENT", 79, 82], ["prothrombin complex", "TREATMENT", 84, 103], ["plasma fractionation activities", "TEST", 176, 207], ["substantial savings", "PROBLEM", 255, 274]]], ["Beneficial impacts on the quality and safety of all blood components through the introduction of the concept of GMPs have also been observed [6], [13], [14], [15].Domestic fractionation: the hard way to go?Embarking on a domestic plasma fractionation program is challenging in technical, financial, and regulatory terms, as this industry is highly regulated at the global level.", [["blood", "ANATOMY", 52, 57], ["plasma", "ANATOMY", 230, 236], ["GMPs", "CHEMICAL", 112, 116], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["GMPs", "GENE_OR_GENE_PRODUCT", 112, 116], ["[13], [14]", "SIMPLE_CHEMICAL", 146, 156], ["[15]", "SIMPLE_CHEMICAL", 158, 162], ["plasma", "ORGANISM_SUBSTANCE", 230, 236], ["GMPs", "PROTEIN", 112, 116], ["all blood components", "TREATMENT", 48, 68], ["a domestic plasma fractionation program", "TREATMENT", 219, 258]]], ["Depending on the local market situation and the landscape of government support and commitment, domestic fractionation may be considered if reasonable prospects to generate at least approximately 300,000 L of quality plasma per year are objectively demonstrated [6].", [["plasma", "ANATOMY", 217, 223], ["plasma", "ORGANISM_SUBSTANCE", 217, 223], ["government support", "TREATMENT", 61, 79], ["domestic fractionation", "TREATMENT", 96, 118]]], ["This plasma can first be obtained as by-products of the preparation of cellular components from whole blood.", [["plasma", "ANATOMY", 5, 11], ["cellular", "ANATOMY", 71, 79], ["whole blood", "ANATOMY", 96, 107], ["plasma", "ORGANISM_SUBSTANCE", 5, 11], ["cellular", "CELL", 71, 79], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["cellular components", "PROBLEM", 71, 90], ["whole blood", "TEST", 96, 107], ["cellular components", "OBSERVATION", 71, 90]]], ["When demand for plasma products increases above the capacity that can be generated from recovered plasma, additional and dedicated collection of plasma by plasmapheresis should be considered.Domestic fractionation: the hard way to go?Apheresis collection can also be implemented at an early stage to prepare hyperimmune plasma for the production of specific immunoglobulins (hepatitis B, tetanus, rhesus, etc.), as some are essential therapeutic products on the WHO Model list of Essential Medicines.", [["plasma", "ANATOMY", 16, 22], ["plasma", "ANATOMY", 98, 104], ["plasma", "ANATOMY", 145, 151], ["plasma", "ANATOMY", 320, 326], ["hepatitis B", "DISEASE", 375, 386], ["tetanus", "DISEASE", 388, 395], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["plasma", "ORGANISM_SUBSTANCE", 98, 104], ["plasma", "ORGANISM_SUBSTANCE", 145, 151], ["hyperimmune", "ORGANISM", 308, 319], ["plasma", "ORGANISM_SUBSTANCE", 320, 326], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 358, 373], ["hepatitis B", "ORGANISM", 375, 386], ["tetanus", "ORGANISM", 388, 395], ["rhesus", "ORGANISM", 397, 403], ["immunoglobulins", "PROTEIN", 358, 373], ["plasma products", "TREATMENT", 16, 31], ["the capacity", "PROBLEM", 48, 60], ["plasmapheresis", "TREATMENT", 155, 169], ["Apheresis collection", "TREATMENT", 234, 254], ["hyperimmune plasma", "TREATMENT", 308, 326], ["specific immunoglobulins", "TREATMENT", 349, 373], ["hepatitis B", "TREATMENT", 375, 386], ["tetanus", "TREATMENT", 388, 395], ["Essential Medicines", "TREATMENT", 480, 499]]], ["Designing, building, qualifying, and validating a plasma fractionation facility is a very specialized activity that requires sharp expertise in many fields, including biological product manufacturing and engineering.", [["plasma", "ANATOMY", 50, 56], ["plasma", "ORGANISM_SUBSTANCE", 50, 56], ["biological product manufacturing", "TREATMENT", 167, 199]]], ["Experience shows that a partnership with an existing plasma fractionator, or a technology supplier with hands-on practical experience in plasma fractionation and proven success in licensing plasma products, appears preferable.", [["plasma", "ANATOMY", 53, 59], ["plasma", "ANATOMY", 137, 143], ["plasma", "ANATOMY", 190, 196], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["plasma", "ORGANISM_SUBSTANCE", 137, 143], ["plasma", "ORGANISM_SUBSTANCE", 190, 196], ["an existing plasma fractionator", "TREATMENT", 41, 72], ["plasma fractionation", "TREATMENT", 137, 157], ["licensing plasma products", "TREATMENT", 180, 205], ["plasma products", "OBSERVATION", 190, 205]]], ["The role of the engineering companies should not be underestimated as it is crucial.Domestic fractionation: the hard way to go?A skilled engineering company with an understanding of the manufacturing and regulatory requirements of biologicals is necessary.", [["the engineering companies", "TREATMENT", 12, 37], ["the manufacturing", "TREATMENT", 182, 199]]], ["Both the fractionator and engineering company are required to provide professional training of operators and powerful transmission of know-how to their forthcoming fractionation partner.Domestic fractionation: the hard way to go?It should be kept in mind that although several contract fractionation projects are ongoing, the world is still looking for actual completion of a successful technology transfer agreement between an existing fractionator and a partner in an emerging country.", [["fractionator", "OBSERVATION", 9, 21]]], ["Although this is certainly not the only possible model, a phasing process that allows progressive local production of plasma derivatives is seen as a reasonable way to implement a successful program.", [["plasma", "ANATOMY", 118, 124], ["plasma", "ORGANISM_SUBSTANCE", 118, 124], ["a phasing process", "PROBLEM", 56, 73], ["plasma derivatives", "PROBLEM", 118, 136], ["a successful program", "TREATMENT", 178, 198]]], ["Fig. 2illustrates such a phasing comprising a period where all products are manufactured abroad on a contractual basis (A), followed by preparation of intermediates at the local level and finishing steps abroad (B), preparation of a first finished product (such as albumin) locally while the finishing steps of the other products are still done abroad (C), and finally, complete manufacture of all products at the domestic level with assistance from the technology supplier (D).Domestic fractionation: the hard way to go?This phasing allows the gradual education of operators in production steps like plasma thawing and cryoprecipitation, ethanol fractionation technology, chromatographic purification, viral-inactivation and viral-removal processes, aseptic filling and freeze-drying, and production of production fluids, and their associated quality control and quality assurance requirements.", [["plasma", "ANATOMY", 601, 607], ["ethanol", "CHEMICAL", 639, 646], ["ethanol", "CHEMICAL", 639, 646], ["albumin", "GENE_OR_GENE_PRODUCT", 265, 272], ["plasma", "ORGANISM_SUBSTANCE", 601, 607], ["ethanol", "SIMPLE_CHEMICAL", 639, 646], ["a first finished product (such as albumin)", "TREATMENT", 231, 273], ["plasma thawing", "TREATMENT", 601, 615], ["cryoprecipitation", "TREATMENT", 620, 637], ["ethanol fractionation technology", "TREATMENT", 639, 671], ["chromatographic purification", "TREATMENT", 673, 701], ["viral-inactivation", "TREATMENT", 703, 721], ["viral-removal processes", "TREATMENT", 726, 749], ["aseptic filling", "PROBLEM", 751, 766], ["freeze-drying", "TREATMENT", 771, 784], ["production fluids", "TREATMENT", 804, 821], ["aseptic filling", "OBSERVATION", 751, 766]]], ["This also allows a phasing in of financial capital requirements.If \u201cgo\u201d, then which process?The experience gathered over the past few decades on the combination of ethanol fractionation with chromatography to produce a large range of plasma derivatives [4] makes this technological approach a serious contender for technology transfers to emerging countries.", [["plasma", "ANATOMY", 234, 240], ["ethanol", "CHEMICAL", 164, 171], ["ethanol", "CHEMICAL", 164, 171], ["ethanol", "SIMPLE_CHEMICAL", 164, 171], ["plasma", "ORGANISM_SUBSTANCE", 234, 240], ["ethanol fractionation", "TREATMENT", 164, 185], ["chromatography", "TREATMENT", 191, 205], ["plasma derivatives", "TREATMENT", 234, 252]]], ["Regulatory authorities in developed countries are familiar with it, even if each fractionator has its own know-how and specific combinations of production steps around a similar core fractionation process [4], [16].If \u201cgo\u201d, then which process?New technologies, however, are being evaluated in both developed and emerging economies that intend to provide either higher yields for current market drivers, higher flexibility to adjust to countries' needs, or ease of implementation [17].", [["production steps", "PROBLEM", 144, 160], ["a similar core fractionation process", "TREATMENT", 168, 204]]], ["They include fractionation processes based on multi-sequential purification processes using mimetic ligands [18], mixed mode, high-density, expanding bed adsorbents [19], large-scale preparative electrophoresis technology across membranes of controlled porosity [20], viral inactivation and mini-pool protein fractionation in closed-bag production systems [21], [22], and aqueous two-phase systems (ATPSs) using a mixture of polymer(s), salt, and water [23].", [["membranes", "ANATOMY", 229, 238], ["salt", "CHEMICAL", 437, 441], ["[22]", "SIMPLE_CHEMICAL", 362, 366], ["ATPSs", "SIMPLE_CHEMICAL", 399, 404], ["salt", "SIMPLE_CHEMICAL", 437, 441], ["fractionation processes", "TREATMENT", 13, 36], ["multi-sequential purification processes", "TREATMENT", 46, 85], ["mimetic ligands", "TREATMENT", 92, 107], ["expanding bed adsorbents", "TREATMENT", 140, 164], ["large-scale preparative electrophoresis technology", "TREATMENT", 171, 221], ["viral inactivation", "PROBLEM", 268, 286], ["mini-pool protein fractionation", "TREATMENT", 291, 322], ["closed-bag production systems", "TEST", 326, 355], ["fractionation processes", "OBSERVATION", 13, 36], ["high-density", "OBSERVATION_MODIFIER", 126, 138], ["large", "OBSERVATION_MODIFIER", 171, 176]]], ["These novel technologies should be proven to meet current quality, consistency, and safety standards.By the way, how are fractionation technologies coping with new infectious threats?As many new infectious agents are threatening particularly low- and medium-income economies, one critical question often being addressed is the capacity of current and newer plasma fractionation technologies to cope with the threats that these pathogens are specifically creating in these countries.", [["plasma", "ANATOMY", 357, 363], ["plasma", "ORGANISM_SUBSTANCE", 357, 363], ["new infectious threats", "PROBLEM", 160, 182], ["newer plasma fractionation technologies", "TREATMENT", 351, 390], ["these pathogens", "PROBLEM", 421, 436], ["new", "OBSERVATION_MODIFIER", 160, 163], ["infectious", "OBSERVATION", 164, 174], ["new", "OBSERVATION_MODIFIER", 191, 194], ["infectious", "OBSERVATION", 195, 205]]], ["Emerging viral agents that have impacted the blood supply in the last few years include, to name a few, West Nile virus (WNV), dengue virus (DENV), chikungunya virus, severe acute respiratory syndrome (SARS) virus, various avian flu viruses, Middle-East respiratory syndrome coronavirus (MERS-CoV), and hepatitis E virus (HEV) [24], [25].By the way, how are fractionation technologies coping with new infectious threats?There are concerns that viruses belonging to the Filoviridae family, particularly the Ebola virus, may enter the blood supply and affect the quality and safety of industrial plasma products.", [["blood", "ANATOMY", 45, 50], ["blood", "ANATOMY", 533, 538], ["plasma", "ANATOMY", 594, 600], ["West Nile virus (WNV), dengue virus (DENV), chikungunya virus", "DISEASE", 104, 165], ["acute respiratory syndrome (SARS) virus", "DISEASE", 174, 213], ["avian flu viruses", "DISEASE", 223, 240], ["Middle-East respiratory syndrome coronavirus", "DISEASE", 242, 286], ["hepatitis E", "DISEASE", 303, 314], ["Ebola virus", "DISEASE", 506, 517], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["West Nile virus", "ORGANISM", 104, 119], ["WNV", "ORGANISM", 121, 124], ["dengue virus", "ORGANISM", 127, 139], ["DENV", "ORGANISM", 141, 145], ["chikungunya virus", "ORGANISM", 148, 165], ["severe acute respiratory", "ORGANISM", 167, 191], ["avian flu viruses", "ORGANISM", 223, 240], ["Middle-East respiratory syndrome coronavirus", "ORGANISM", 242, 286], ["MERS-CoV", "ORGANISM", 288, 296], ["hepatitis E virus", "ORGANISM", 303, 320], ["HEV", "ORGANISM", 322, 325], ["Filoviridae", "GENE_OR_GENE_PRODUCT", 469, 480], ["Ebola virus", "ORGANISM", 506, 517], ["blood", "ORGANISM_SUBSTANCE", 533, 538], ["plasma", "ORGANISM_SUBSTANCE", 594, 600], ["West Nile virus", "SPECIES", 104, 119], ["dengue virus", "SPECIES", 127, 139], ["chikungunya virus", "SPECIES", 148, 165], ["avian flu viruses", "SPECIES", 223, 240], ["hepatitis E virus", "SPECIES", 303, 320], ["Ebola virus", "SPECIES", 506, 517], ["West Nile virus", "SPECIES", 104, 119], ["WNV", "SPECIES", 121, 124], ["dengue virus", "SPECIES", 127, 139], ["DENV", "SPECIES", 141, 145], ["chikungunya virus", "SPECIES", 148, 165], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 167, 213], ["avian flu viruses", "SPECIES", 223, 240], ["Middle-East respiratory syndrome coronavirus", "SPECIES", 242, 286], ["MERS-CoV", "SPECIES", 288, 296], ["hepatitis E virus", "SPECIES", 303, 320], ["HEV", "SPECIES", 322, 325], ["Ebola virus", "SPECIES", 506, 517], ["Emerging viral agents", "TREATMENT", 0, 21], ["West Nile virus (WNV", "PROBLEM", 104, 124], ["dengue virus (DENV", "PROBLEM", 127, 145], ["chikungunya virus", "PROBLEM", 148, 165], ["severe acute respiratory syndrome", "PROBLEM", 167, 200], ["SARS) virus", "PROBLEM", 202, 213], ["various avian flu viruses", "PROBLEM", 215, 240], ["Middle-East respiratory syndrome coronavirus", "PROBLEM", 242, 286], ["hepatitis E virus", "PROBLEM", 303, 320], ["new infectious threats", "PROBLEM", 397, 419], ["viruses", "PROBLEM", 444, 451], ["the Ebola virus", "PROBLEM", 502, 517], ["industrial plasma products", "TREATMENT", 583, 609], ["viral", "OBSERVATION", 9, 14], ["chikungunya virus", "OBSERVATION", 148, 165], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["acute", "OBSERVATION_MODIFIER", 174, 179], ["respiratory syndrome", "OBSERVATION", 180, 200], ["flu viruses", "OBSERVATION", 229, 240], ["Middle", "ANATOMY_MODIFIER", 242, 248], ["respiratory syndrome", "OBSERVATION", 254, 274], ["new", "OBSERVATION_MODIFIER", 397, 400], ["infectious", "OBSERVATION", 401, 411]]], ["The traditional tripod of safety of blood and plasma products for well-known blood-borne viruses [human immunodeficiency virus (HIV), hepatitis B virus (HBV), and C virus (HCV)] is, in addition to a well-structured blood collection organization [26], selection of donors, testing of blood donations, and viral-reduction treatments implemented during plasma product manufacture [27].", [["blood", "ANATOMY", 36, 41], ["plasma", "ANATOMY", 46, 52], ["blood", "ANATOMY", 77, 82], ["blood", "ANATOMY", 215, 220], ["blood", "ANATOMY", 283, 288], ["plasma", "ANATOMY", 350, 356], ["human immunodeficiency virus (HIV), hepatitis B", "DISEASE", 98, 145], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["blood-borne viruses", "ORGANISM", 77, 96], ["human immunodeficiency virus", "ORGANISM", 98, 126], ["HIV", "ORGANISM", 128, 131], ["hepatitis B virus", "ORGANISM", 134, 151], ["HBV", "ORGANISM", 153, 156], ["C virus", "ORGANISM", 163, 170], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["donors", "ORGANISM", 264, 270], ["blood", "ORGANISM_SUBSTANCE", 283, 288], ["plasma", "ORGANISM_SUBSTANCE", 350, 356], ["human", "SPECIES", 98, 103], ["immunodeficiency virus", "SPECIES", 104, 126], ["HIV", "SPECIES", 128, 131], ["hepatitis B virus", "SPECIES", 134, 151], ["C virus", "SPECIES", 163, 170], ["human immunodeficiency virus", "SPECIES", 98, 126], ["HIV", "SPECIES", 128, 131], ["hepatitis B virus", "SPECIES", 134, 151], ["HBV", "SPECIES", 153, 156], ["HCV", "SPECIES", 172, 175], ["blood and plasma products", "TREATMENT", 36, 61], ["known blood-borne viruses", "PROBLEM", 71, 96], ["human immunodeficiency virus (HIV)", "PROBLEM", 98, 132], ["hepatitis B virus (HBV)", "PROBLEM", 134, 157], ["C virus (HCV)", "PROBLEM", 163, 176], ["blood donations", "TEST", 283, 298], ["viral-reduction treatments", "TREATMENT", 304, 330], ["plasma product manufacture", "TREATMENT", 350, 376]]], ["In early phases of a new infection, selection of donors and testing of donations might not be effective or applicable if infective donors are asymptomatic or a test is unavailable.", [["infection", "DISEASE", 25, 34], ["donors", "ORGANISM", 49, 55], ["donors", "ORGANISM", 131, 137], ["a new infection", "PROBLEM", 19, 34], ["donors and testing of donations", "TEST", 49, 80], ["infective donors", "PROBLEM", 121, 137], ["asymptomatic", "PROBLEM", 142, 154], ["a test", "TEST", 158, 164], ["early phases", "OBSERVATION_MODIFIER", 3, 15], ["new", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34]]], ["In such situations, viral safety relies solely on the robustness of viral-reduction steps already in place in the manufacturing process of plasma products.", [["plasma", "ANATOMY", 139, 145], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["viral-reduction steps", "TREATMENT", 68, 89], ["plasma products", "TREATMENT", 139, 154], ["plasma products", "OBSERVATION", 139, 154]]], ["Over the years and following the identification of the transmission of HIV, HBV, and HCV enveloped viruses, and then non-enveloped parvovirus B19 and HAV viruses by plasma products, substantial progress has been made by the plasma fractionation industry, under close supervision of the main regulatory authorities, to develop, validate, and implement effective viral-inactivation treatments.", [["plasma", "ANATOMY", 165, 171], ["plasma", "ANATOMY", 224, 230], ["parvovirus B19", "DISEASE", 131, 145], ["HAV viruses", "DISEASE", 150, 161], ["HIV", "ORGANISM", 71, 74], ["HBV", "ORGANISM", 76, 79], ["HCV enveloped viruses", "ORGANISM", 85, 106], ["non-enveloped", "ORGANISM", 117, 130], ["parvovirus B19", "ORGANISM", 131, 145], ["HAV viruses", "ORGANISM", 150, 161], ["plasma", "ORGANISM_SUBSTANCE", 165, 171], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["HIV", "SPECIES", 71, 74], ["parvovirus B19", "SPECIES", 131, 145], ["HIV", "SPECIES", 71, 74], ["HBV", "SPECIES", 76, 79], ["HCV", "SPECIES", 85, 88], ["non-enveloped parvovirus B19", "SPECIES", 117, 145], ["HAV viruses", "SPECIES", 150, 161], ["HIV", "PROBLEM", 71, 74], ["HBV", "PROBLEM", 76, 79], ["HCV enveloped viruses", "PROBLEM", 85, 106], ["non-enveloped parvovirus B19", "PROBLEM", 117, 145], ["HAV viruses", "PROBLEM", 150, 161], ["plasma products", "TREATMENT", 165, 180], ["viral-inactivation treatments", "TREATMENT", 361, 390]]], ["For instance, a technology like solvent-detergent has been able to eliminate risks from lipid-enveloped viruses, including agents like WNV, DENV, SARS, avian influenza virus, and chikungunya when they entered the plasma supply and before the introduction of test procedures, if any, for viral markers [28], [29], [30].By the way, how are fractionation technologies coping with new infectious threats?It is expected that the robustness evidenced by this technology, and possibly other technologies against enveloped viruses like caprylic acid treatment, can safeguard plasma products from the risk of all lipid-enveloped infectious agents, including filoviruses.", [["plasma", "ANATOMY", 213, 219], ["plasma", "ANATOMY", 567, 573], ["SARS", "DISEASE", 146, 150], ["avian influenza virus", "DISEASE", 152, 173], ["chikungunya", "DISEASE", 179, 190], ["caprylic acid", "CHEMICAL", 528, 541], ["caprylic acid", "CHEMICAL", 528, 541], ["lipid", "SIMPLE_CHEMICAL", 88, 93], ["WNV", "ORGANISM", 135, 138], ["DENV", "ORGANISM", 140, 144], ["SARS", "ORGANISM", 146, 150], ["avian influenza virus", "ORGANISM", 152, 173], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["caprylic acid", "SIMPLE_CHEMICAL", 528, 541], ["plasma", "ORGANISM_SUBSTANCE", 567, 573], ["avian influenza virus", "SPECIES", 152, 173], ["WNV", "SPECIES", 135, 138], ["DENV", "SPECIES", 140, 144], ["avian influenza virus", "SPECIES", 152, 173], ["lipid", "TREATMENT", 88, 93], ["enveloped viruses", "PROBLEM", 94, 111], ["agents", "TREATMENT", 123, 129], ["WNV", "PROBLEM", 135, 138], ["DENV", "PROBLEM", 140, 144], ["SARS", "PROBLEM", 146, 150], ["avian influenza virus", "PROBLEM", 152, 173], ["chikungunya", "PROBLEM", 179, 190], ["test procedures", "TEST", 258, 273], ["viral markers", "TEST", 287, 300], ["new infectious threats", "PROBLEM", 377, 399], ["enveloped viruses", "PROBLEM", 505, 522], ["caprylic acid treatment", "TREATMENT", 528, 551], ["plasma products", "TREATMENT", 567, 582], ["all lipid", "TREATMENT", 600, 609], ["infectious agents", "TREATMENT", 620, 637], ["filoviruses", "PROBLEM", 649, 660], ["viruses", "OBSERVATION", 104, 111], ["new", "OBSERVATION_MODIFIER", 377, 380], ["infectious", "OBSERVATION", 381, 391], ["infectious", "OBSERVATION", 620, 630]]], ["To address the risks associated with non-enveloped (in addition to enveloped) viruses, a technology like nanofiltration provides generic and controlled removal of infectious agents based on a size-exclusion mechanism [31], while pasteurization has also demonstrated robustness against a large range of enveloped and non-enveloped viruses [27].", [["viruses", "PROBLEM", 78, 85], ["a technology like nanofiltration", "TREATMENT", 87, 119], ["generic and controlled removal", "TREATMENT", 129, 159], ["infectious agents", "TREATMENT", 163, 180], ["a large range of enveloped and non-enveloped viruses", "PROBLEM", 285, 337], ["infectious", "OBSERVATION", 163, 173], ["large", "OBSERVATION_MODIFIER", 287, 292], ["non-enveloped viruses", "OBSERVATION", 316, 337]]], ["Under the current state of viral-reduction technology implemented by plasma fractionators and multi-step purification procedures responsible for removing viruses, it seems scientifically reasonable to conclude that potential residual infectious risks for most plasma products would be restricted to emerging resistant small (<15~20 nm) non-enveloped viruses.ConclusionsGlobal needs for plasma products are still unmet.", [["plasma", "ANATOMY", 69, 75], ["plasma", "ANATOMY", 260, 266], ["plasma", "ANATOMY", 386, 392], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["plasma", "ORGANISM_SUBSTANCE", 260, 266], ["plasma", "ORGANISM_SUBSTANCE", 386, 392], ["viral-reduction technology", "TREATMENT", 27, 53], ["multi-step purification procedures", "TREATMENT", 94, 128], ["removing viruses", "PROBLEM", 145, 161], ["potential residual infectious risks", "PROBLEM", 215, 250], ["most plasma products", "TREATMENT", 255, 275], ["emerging resistant small (<15~20 nm) non-enveloped viruses", "PROBLEM", 299, 357], ["plasma products", "TREATMENT", 386, 401], ["residual", "OBSERVATION_MODIFIER", 225, 233], ["infectious", "OBSERVATION", 234, 244], ["viruses", "OBSERVATION", 350, 357]]], ["Recombinant coagulation factors, although available in increasing amounts and from more producers, are not expected to cover the needs in developing countries for several years to come.", [["Recombinant coagulation factors", "PROTEIN", 0, 31], ["Recombinant coagulation factors", "PROBLEM", 0, 31], ["coagulation", "OBSERVATION", 12, 23]]], ["Albumin, for cost reasons, and intravenous immunoglobulins, for technical and scientific reasons due to their biochemical diversity and multiple specificities, cannot easily be produced by recombinant technologies.", [["intravenous", "ANATOMY", 31, 42], ["Albumin", "CHEMICAL", 0, 7], ["Albumin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Albumin", "TREATMENT", 0, 7], ["intravenous immunoglobulins", "TREATMENT", 31, 58], ["their biochemical diversity", "PROBLEM", 104, 131]]], ["Many developing countries have an excess of plasma generated as a by-product of the production of red blood cell concentrates.ConclusionsThis plasma could be used as a source of fractionated plasma products.", [["plasma", "ANATOMY", 44, 50], ["red blood cell", "ANATOMY", 98, 112], ["plasma", "ANATOMY", 142, 148], ["plasma", "ANATOMY", 191, 197], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["red blood cell", "CELL", 98, 112], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["plasma", "ORGANISM_SUBSTANCE", 191, 197], ["red blood cell concentrates", "CELL_TYPE", 98, 125], ["red blood cell concentrates", "TREATMENT", 98, 125], ["fractionated plasma products", "TREATMENT", 178, 206], ["red blood cell concentrates", "OBSERVATION", 98, 125]]], ["In most situations, the quality of this plasma does not meet the requirements for fractionation.", [["plasma", "ANATOMY", 40, 46], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["fractionation", "TREATMENT", 82, 95]]], ["Discarded recovered plasma can be used for fractionation, as a raw material for the production of pooled plasma derivatives, only if quality and safety criteria and procedures used within blood establishments are improved and meet standards needed by fractionators and imposed by regulatory authorities [12].", [["plasma", "ANATOMY", 20, 26], ["plasma", "ANATOMY", 105, 111], ["blood", "ANATOMY", 188, 193], ["plasma", "ORGANISM_SUBSTANCE", 20, 26], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["blood", "ORGANISM_SUBSTANCE", 188, 193], ["fractionation", "TREATMENT", 43, 56], ["pooled plasma derivatives", "TREATMENT", 98, 123], ["procedures", "TEST", 165, 175], ["blood establishments", "TEST", 188, 208]]], ["Strong government support to enhance the quality of blood collection organizations is therefore required.", [["blood", "ANATOMY", 52, 57], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["Strong government support", "TREATMENT", 0, 25]]], ["Plasma meeting regulatory requirements for fractionation can be processed through contract agreements into various derivatives.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["fractionation", "TREATMENT", 43, 56], ["various derivatives", "TREATMENT", 107, 126]]], ["Regardless of which technologies are selected, it is important that both plasma collection and fractionation are performed following standards established at a global level to ensure end-product safety and ultimate improvements in healthcare systems.", [["plasma", "ANATOMY", 73, 79], ["plasma", "ORGANISM_SUBSTANCE", 73, 79]]]]}